United States Patent	7,776,521
Rota, et al.	August 17, 2010

Coronavirus isolated from humans

Abstract

Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.

Inventors:	Rota; Paul A. (Decatur, GA), Anderson; Larry J. (Atlanta, GA), Bellini; William J. (Lilburn, GA), Bowen; Michael
	D. (Decatur, GA), Burns; Cara Carthel (Avondale Estates, GA), Campagnoli; Raymond (Decatur, GA), Chen; Qi
	(Marietta, GA), Comer; James A. (Decatur, GA), Cook; Byron T. (Augusta, GA), Emery; Shannon L. (Lusaka,
	ZM), Erdman; Dean D. (Decatur, GA), Goldsmith; Cynthia S. (Lilburn, GA), Guarner; Jeanette (Decatur, GA),
	Humphrey; Charles D. (Lilburn, GA), Icenogle; Joseph P. (Atlanta, GA), Ksiazek; Thomas G. (Lilburn, GA),
	Meyer; Richard F. (Roswell, GA), Monroe; Stephan S. (Decatur, GA), Nix; William Allan (Bethlehem, GA),
	Oberste; M. Steven (Lilburn, GA), Paddock; Christopher D. (Atlanta, GA), Peret; Teresa C. T. (Atlanta, GA),
	Rollin; Pierre E. (Lilburn, GA), Pallansch; Mark A. (Lilburn, GA), Sanchez; Anthony (Lilburn, GA), Shieh; Wun-
	Ju (Norcross, GA), Tong; Suxiang (Alpharetta, GA), Zaki; Sherif R. (Atlanta, GA)
Assignee:	The United States of America as represented by the Secretary of the Department of Health and Human Services,
	Centers for Disease Control and Prevention (Washington, DC)
	N/A (N/A)
Family ID:	38049542
Appl. No.:	11/748,359
Filed:	May 14, 2007

Related U.S. Patent Documents

Application Number	<u>Filing Date</u>	<u>Patent Number</u>	<u>Issue Date</u>
10822904	May 22, 2007	7220852	
60465927	Apr 25, 2003		

Current U.S. Class:

435/5; 536/24.32; 536/24.33

Current CPC Class:	C12N 7/00 (20130101); C07K 14/005 (20130101); A61K
	39/12 (20130101); A61K 39/215 (20130101); C12N
	2770/20034 (20130101); C12N 2770/20021 (20130101);
	C12N 2770/20022 (20130101)
Current International	C12Q 1/70 (20060101); C07H 21/00 (20060101); C12N
Class:	15/50 (20060101)

References Cited [Referenced By]

U.S. Patent Documents

2005/0181357	August 2005	Peiris et al.

Foreign Patent Documents

WO 2004/092360	Oct 2004	WO

Other References

Ksiazek et al (New England Journal of Medicine 348:1953-1966, published online Apr. 10, 2003). cited by examiner .

Gut et al (Journal of Virological Methods 77:37-46, 1999). cited by examiner . Neilan et al (Nucleic Acids Research 25:2938-9, 1997). cited by examiner . Peiris et al (Lancet, 361:1319-1325, published online Apr. 8, 2003). cited by examiner .

Genbank Accession No. AY274119.1 GI:29826276 (Apr. 14, 2003). cited by examiner .

SARS-associated Coronavirus. Genomic Sequence Availability. [online] [retreived on Aug. 8, 2005]. Retreived from the Internet <URL: http://www.bcgsc.ca/bioinfo/SARS>. cited by examiner .

"Update: Outbreak of Severe Acute Respiratory Syndrome--Worldwide, 2003," MMWR Weekly 52:241-248, 2003. cited by other .

Emery et al., "Real-Time Reverse Transcription-Polymerase Chain Reaction Assay for SARS-Associated Coronavirus," Emerg. Infect. Diseases 10:311-316, 2004. cited by other .

Goldsmith et al., "Ultrastructural Characterization of SARS Coronavirus," Emerg. Infect. Diseases 10:320-326, 2004. cited by other .

Ksiazek et al., "A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome," N. Engl. J. Med. 348:1953-1966, 2003. cited by other .

Luo and Luo, "Initial SARS Coronavirus Genome Sequence Analysis Using a Bioinformatics Platform," 2.sup.nd Asia-Pacific Bioinformatics Conference (APBC2004), Dunedin, New Zealand, 2004. cited by other .

Marra et al., "The Genome Sequence of the SARS-Associated Coronavirus," Science 300:1393-1404, 2003. cited by other .

Supplementary Online Material for Marra et al., www.sciencemag.org/cgi/content/ full/1085953/DC1, (2003). cited by other .

Rota et al., "Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome," Science 300:1394-1399, 2003. cited by other .

Supplementary Online Material for Rota et al., www.sciencemag.org/cgi/content/ full/1085953/DC1, (2003). cited by other .

GenBank Accession No. AY274119, Apr. 14, 2003. cited by other .

GenBank Accession No. AY278741, Apr. 21, 2003. cited by other .

GenBank Accession No. AY278554.1, Apr. 18, 2003. cited by other .

GenBank Accession No. AY278491.1, Apr. 18, 2003. cited by other .

GenBank Accession No. AY278487, Apr. 21, 2003. cited by other.

Primary Examiner: Mosher; Mary E Attorney, Agent or Firm: Klarquist Sparkman, LLP

Government Interests

STATEMENT OF GOVERNMENT SUPPORT

This invention was made by the Centers for Disease Control and Prevention, an agency of the United States Government. Therefore, the U.S. Government has certain rights in this invention.

Parent Case Text

PRIORITY CLAIM

This is a division of co-pending U.S. patent application Ser. No. 10/822,904, filed Apr. 12, 2004, and issued as U.S. Pat. No. 7,220,852 on May 22, 2007, which in turn claims the benefit of U.S. Provisional Patent Application No. 60/465,927 filed Apr. 25, 2003. Both applications are incorporated herein by reference in their entirety.

Claims

The invention claimed is:

1. A method of detecting a severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in a sample comprising: contacting the sample with a pair of nucleic acid primers that hybridize to a SARS-CoV nucleic acid, wherein at least one primer is 5'-end labeled with a reporter dye, and wherein at least one of the primers comprises the sequence as set forth in any one of SEQ ID NOs: 13-15; amplifying the SARS-CoV nucleic acid or a fragment thereof from the sample utilizing the pair of nucleic acid primers; electrophoresing the amplified products; and detecting the 5'-end labeled reporter dye, thereby detecting a SARS-CoV.

2. The method of claim 1, wherein the amplification utilizes reverse transcriptase-polymerase chain reaction.

3. A method of detecting a severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in a sample, comprising: contacting the sample with a pair of nucleic acid primers that hybridize to a SARS-CoV nucleic acid, wherein at least one of the nucleic acid primers comprises the sequence as set forth in any one of SEQ ID NOs: 13-15; amplifying the SARS-CoV nucleic acid or a fragment thereof

from the sample utilizing the pair of nucleic acid primers; adding to the amplified SARS-CoV nucleic acid or the fragment thereof a SARS-CoV probe that hybridizes to the SARS-CoV nucleic acid, wherein the SARS-CoV probe is labeled with a 5'-reporter dye and a 3'-quencher dye; performing one or more additional rounds of amplification with Taq DNA polymerase; and detecting fluorescence of the 5'-reporter dye, thereby detecting a SARS-CoV.

4. A kit for detecting a severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in a sample, comprising a pair of nucleic acid primers that hybridize under stringent conditions to a SARS-CoV nucleic acid, wherein at least one of the primers comprises the sequence as set forth in any one of SEQ ID NOs: 13-15.

5. The kit of claim 4, wherein one primer is 5'-end labeled with a reporter dye.

6. The kit of claim 4, further comprising a SARS-CoV probe that hybridizes to the SARS-CoV nucleic acid amplified by the pair of primers, wherein the SARS-CoV probe is labeled with a 5'-reporter dye and a 3'-quencher dye.

7. The kit of claim 4, further comprising an isolated SARS-CoV organism.

Description

FIELD OF THE DISCLOSURE

This invention relates to a newly isolated human coronavirus. More particularly, it relates to an isolated coronavirus genome, isolated coronavirus proteins, and isolated nucleic acid molecules encoding the same. The disclosure further relates to methods of detecting a severe acute respiratory syndrome-associated coronavirus and compositions comprising immunogenic coronavirus compounds.

BACKGROUND

The coronaviruses (order Nidovirales, family Coronaviridae, genus Coronavirus) are a diverse group of large, enveloped, positive-stranded RNA viruses that cause respiratory and enteric diseases in humans and other animals. At approximately 30,000 nucleotides (nt), their genome is the largest found in any of the RNA viruses. Coronaviruses are spherical, 100-160 nm in diameter with 20-40 nm complex club shaped surface projections surrounding the periphery. Coronaviruses share common structural proteins including a spike protein (S), membrane protein (M), envelope protein (E), and, in a subset of coronaviruses, a hemagglutinin-esterase protein (HE). The S protein, a glycoprotein which protrudes from the virus membrane, is involved in host cell receptor binding and is a target for neutralizing antibodies. The E and M proteins are involved in virion formation and release from the host cell. Coronavirus particles are found within the cisternae of the rough endoplasmic reticulum and in vesicles of infected host cells where virions are assembled. The coronavirus genome consists of two open reading frames (ORF1a and ORF1b) yielding an RNA polymerase and a nested set of subgenomic

mRNAs encoding structural and nonstructural proteins, including the S, E, M, and nucleocapsid (N) proteins. The genus Coronavirus includes at least 13 species which have been subdivided into at least three groups (groups I, II, and III) on the basis of serological and genetic properties (deVries et al., Sem. Virol. 8:33-47, 1997; Fields et al. eds. Fields Virology, 3rd edition, Raven Press, Philadelphia, 1323-1341, 1996; Mahey and Collier eds. Microbiology and Microbial Infections, Volume 1 Virology, 9.sup.th edition, Oxford University Press, 463-479, 1998).

The three known groups of coronavirus are associated with a variety of diseases of humans and domestic animals (for example, cattle, pigs, cats, dogs, rodents, and birds), including gastroenteritis and upper and lower respiratory tract disease. Known coronaviruses include human Coronavirus 229E (HCoV-229E), canine coronavirus (CCoV), feline infectious peritonitis virus (FIPV), porcine transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), human coronavirus OC43 (HCoV-OC43), bovine coronavirus (BCoV), porcine hemagglutinating encephalomyelitis virus (HEV), rat sialodacryoadenitis virus (SDAV), mouse hepatitis virus (MHV), turkey coronavirus (TCoV), and avian infectious bronchitis virus (IBV-Avian) (Fields et al. eds. Fields Virology, 3rd edition, Raven Press, Philadelphia, 1323-1341, 1996; Mahey and Collier eds. Microbiology and Microbial Infections, Volume 1 Virology, 9.sup.th edition, Oxford University Press, 463-479, 1998).

Coronavirus infections are generally host specific with respect to infectivity and clinical symptoms. Coronaviruses further exhibit marked tissue tropism; infection in the incorrect host species or tissue type may result in an abortive infection, mutant virus production and altered virulence. Coronaviruses generally do not grow well in cell culture, and animal models for human coronavirus infection are lacking. Therefore, little is known about them (Fields et al. eds. Fields Virology, 3rd edition, Raven Press, Philadelphia, 1323-1341, 1996). The known human coronaviruses are notably fastidious in cell culture, preferring select cell lines, organ culture, or suckling mice for propagation. Coronaviruses grown in cell culture exhibit varying degrees of virulence and/or cytopathic effect (CPE) depending on the host cell type and culture conditions. The only human or animal coronavirus which has been shown to grow in Vero E6 cells is PEDV, and it requires the addition of trypsin to culture medium for growth in Vero E6 cells. Moreover, PEDV adapted to Vero E6 cell culture results in a strikingly different CPE, with cytoplasmic vacuoles and the formation of large syncytia (Hofmann and Wyler, J. Clin. Micro. 26:2235-39, 1988; Kusanagi et el., J. Vet. Med. Sci. 554:313-18, 1991).

Coronavirus have not previously been known to cause severe disease in humans, but have been identified as a major cause of upper respiratory tract illness, including the common cold. Repeat infections in humans are common within and across serotype, suggesting that immune response to coronavirus infection in humans is either incomplete or short lived. Coronavirus infection in animals can cause severe enteric or respiratory disease. Vaccination has been used successfully to prevent and control some coronavirus infections in animals. The ability of animal-specific coronaviruses to cause severe disease raises the possibility that coronavirus could also cause more severe disease in humans (Fields et al. eds. Fields Virology, 3rd edition, Raven Press, Philadelphia, 1323-1341, 1996; Mahey and Collier eds. Microbiology and Microbial Infections, Volume 1 Virology, 9.sup.th edition, Oxford University Press, 463-479, 1998).

In late 2002, cases of life-threatening respiratory disease with no identifiable etiology were reported from Guangdong Province, China, followed by reports from Vietnam, Canada, and Hong Kong of severe febrile respiratory illness that spread to household members and health care workers. The syndrome was designated "severe acute respiratory syndrome" (SARS) in February 2003 by the Centers for Disease Control and Prevention (MMWR, 52:241-48, 2003).

Past efforts to develop rapid diagnostics and vaccines for coronavirus infection in humans have been hampered by a lack of appropriate research models and the moderate course of disease in humans. Therefore, a need for rapid diagnostic tests and vaccines exists.

SUMMARY OF THE DISCLOSURE

A newly isolated human coronavirus has been identified as the causative agent of SARS, and is termed SARS-CoV. The nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames are provided herein.

This disclosure provides methods and compositions useful in detecting the presence of a SARS-CoV nucleic acid in a sample and/or diagnosing a SARS-CoV infection in a subject. Also provided are methods and compositions useful in detecting the presence of a SARS-CoV antigen or antibody in a sample and/or diagnosing a SARS-CoV infection in a subject.

The foregoing and other features and advantages will become more apparent from the following detailed description of several embodiments, which proceeds with reference to the accompanying figures.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A-B are photomicrographs illustrating typical early cytopathic effects seen with coronavirus isolates and serum from SARS patients. FIG. 1A is a photomicrograph of Vero E6 cells inoculated with an oropharyngeal specimen from a SARS patient (x40). FIG. 1B is a photomicrograph of infected Vero E6 cells reacting with the serum of a convalescent SARS patient in an indirect fluorescent antibody (IFA) assay (x400).

FIGS. 2A-B are electronmicrographs illustrating ultrastructural characteristics of the SARS-associated coronavirus (SARS-CoV). FIG. 2A is a thin-section electron-microscopical view of viral nucleocapsids aligned along the membrane of the rough endoplasmic reticulum (arrow) as particles bud into the cisternae. Enveloped virions have surface projections (arrowhead) and an electron-lucent center. Directly under the viral envelope lies a characteristic ring formed by the helical nucleocapsid, often seen in cross-section. FIG. 2B is a negative stain (methylamine tungstate) electronmicrograph showing stain-penetrated coronavirus particle with the typical internal helical nucleocapsid-like structure and club-shaped surface projections surrounding the periphery of the particle. Bars: 100 nm.

FIG. 3 is an estimated maximum parsimony tree illustrating putative phylogenetic relationships between SARS-CoV and other human and animal coronaviruses. Phylogenetic relationships are based

on sequence alignment of 405 nucleotides of the coronavirus polymerase gene ORF1b (nucleic acid 15,173 to 15,578 of SEQ ID NO: 1). The three major coronavirus antigenic groups (I, II and III), represented by HCoV-229E, CCoV, FIPV, TGEV, PEDV, HCoV-OC43, BCoV, HEV, SDAV, MHV, TCoV, and IBV-Avian, are shown shaded. Bootstrap values (100 replicates) obtained from a 50% majority rule consensus tree are plotted at the main internal branches of the phylogram. Branch lengths are proportionate to nucleotide differences.

FIG. 4 is a pictorial representation of neighbor joining trees illustrating putative phylogenetic relationships between SARS-CoV and other human and animal coronaviruses. Amino acid sequences of the indicated SARS-CoV proteins were compared with those from reference viruses representing each species in the three groups of coronaviruses for which complete genomic sequence information was available [group 1: HCoV-229E (AF304460); PEDV (AF353511); TGEV (AJ271965); group 2: BCoV (AF220295); MHV (AF201929); group 3: infectious bronchitis virus (M95169)]. Sequences for representative strains of other coronavirus species, for which partial sequence information was available, were included for some of the structural protein comparisons [group 1: CCoV (D13096); FCoV (AY204704); porcine respiratory coronavirus (Z24675); group 2: HCoV-OC43 (M76373, L14643, M93390); HEV (AY078417); rat coronavirus (AF207551)]. Sequence alignments and neighbor joining trees were generated by using Clustalx 1.83 with the Gonnet protein comparison matrix. The resulting trees were adjusted for final output using treetool 2.0.1.

FIGS. 5A-C are photomicrographs illustrating diffuse alveolar damage in a patient with SARS (FIGS. 5A-B), and immunohistochemical staining of SARS-CoV-infected Vero E6 cells (FIG. 5C). FIG. 5A is a photomicrograph of lung tissue from a SARS patient (x50). Diffuse alveolar damage, abundant foamy macrophages and multinucleated syncytial cells are present; hematoxylin and eosin stain was used. FIG. 5B is a higher magnification photomicrograph of lung tissue from the same SARS patient (x250). Syncytial cells show no conspicuous viral inclusions. FIG. 5C is a photomicrograph of immunohistochemically stained SARS-CoV-infected cells (x250). Membranous and cytoplasmic immunostaining of individual and syncytial Vero E6 cells was achieved using feline anti-FIPV-1 ascitic fluid. Immunoalkaline phosphatase with naphthol-fast red substrate and hematoxylin counter stain was used.

FIGS. 6A-B are electronmicrographs illustrating ultrastructural characteristics of a coronavirusinfected cell in bronchoalveolar lavage (BAL) from a SARS patient. FIG. 6A is an electron micrograph of a coronavirus-infected cell. Numerous intracellular and extracellular particles are present; virions are indicated by the arrowheads. FIG. 6B is a higher magnification electronmicrograph of the area seen at the arrow in FIG. 6A (rotated clockwise approximately) 90.degree.. Bars: FIG. 6A, 1 .mu.m; FIG. 6B, 100 nm.

FIGS. 7A-C illustrate the organization of the SARS-CoV genome. FIG. 7A is a diagram of the overall organization of the 29,727-nt SARS-CoV genomic RNA. The 72-nt leader sequence is represented as a small rectangle at the left-most end. ORFs1a and 1b, encoding the nonstructural polyproteins, and those ORFs encoding the S, E, M, and N structural proteins, are indicated. Vertical position of the boxes indicates the phase of the reading frame (phase 1 for proteins above the line, phase two for proteins on the line and phase three for proteins below the line). FIG. 7B is an expanded view of the structural

protein encoding region and predicted mRNA transcripts. Known structural protein encoding regions (dark grey boxes) and regions and reading frames for potential products X1-X5 (light gray boxes) are indicated. Lengths and map locations of the 3'-coterminal mRNAs expressed by the SARS-CoV are indicated, as predicted by identification of conserved transcriptional regulatory sequences. FIG. 7C is a digitized image of a nylon membrane showing Northern blot analysis of SARS-CoV mRNAs. Poly(A) + RNA from infected Vero E6 cells was separated on a formaldehyde-agarose gel, transferred to a nylon membrane, and hybridized with a digoxigenin-labeled riboprobe overlapping the 3'-untranslated region. Signals were visualized by chemiluminescence. Sizes of the SARS-CoV mRNAs were calculated by extrapolation from a log-linear fit of the molecular mass marker. Lane 1, SARS-CoV mRNA; lane 2, Vero E6 cell mRNA; lane 3, molecular mass marker, sizes in kB.

SEQUENCE LISTING

The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. In the accompanying sequence listing:

SEQ ID NO: 1 shows the nucleic acid sequence of the SARS-CoV genome.

SEQ ID NO: 2 shows the amino acid sequence of the SARS-CoV polyprotein 1a (encoded by nucleic acid 265 to nucleic acid 13,398 of SEQ ID NO: 1).

SEQ ID NO: 3 shows the amino acid sequence of the SARS-CoV polyprotein 1b (encoded by nucleic acid 13,398 to 21,482 of SEQ ID NO: 1).

SEQ ID NO: 4 shows the amino acid sequence of the SARS-CoV S protein (encoded by nucleic acid 21,492 to 25,256 of SEQ ID NO: 1).

SEQ ID NO: 5 shows the amino acid sequence of the SARS-CoV X1 protein (encoded by nucleic acid 25,268 to 26,089 of SEQ ID NO: 1).

SEQ ID NO: 6 shows the amino acid sequence of the SARS-CoV X2 protein (encoded by nucleic acid 25,689 to 26,150 of SEQ ID NO: 1).

SEQ ID NO: 7 shows the amino acid sequence of the SARS-CoV E protein (encoded by nucleic acid 26,117 to 26,344 of SEQ ID NO: 1).

SEQ ID NO: 8 shows the amino acid sequence of the SARS-CoV M protein (encoded by nucleic acid 26,398 to 27,060 of SEQ ID NO: 1).

SEQ ID NO: 9 shows the amino acid sequence of the SARS-CoV X3 protein (encoded by nucleic acid 27,074 to 27,262 of SEQ ID NO: 1).

SEQ ID NO: 10 shows the amino acid sequence of the SARS-CoV X4 protein (encoded by nucleic acid 27,273 to 27,638 of SEQ ID NO: 1).

SEQ ID NO: 11 shows the amino acid sequence of the SARS-CoV X5 protein (encoded by nucleic acid 27,864 to 28,115 of SEQ ID NO: 1).

SEQ ID NO: 12 shows the amino acid sequence of the SARS-CoV N protein (encoded by nucleic acid 28,120 to 29,385 of SEQ ID NO: 1).

SEQ ID NOs: 13-15 show the nucleic acid sequence of several SARS-CoV-specific oligonucleotide primers.

SEQ ID NOs: 16-33 show the nucleic acid sequence of several oligonucleotide primers/probes used for real-time reverse transcription-polymerase chain reaction (RT-PCR) SARS-CoV assays.

SEQ ID NOs: 34-35 show the nucleic acid sequence of two degenerate primers designed to anneal to sites encoding conserved coronavirus amino acid motifs.

SEQ ID NOs: 36-38 show the nucleic acid sequence of several oligonucleotide primers/probes used as controls in real-time RT-PCR assays.

DETAILED DESCRIPTION OF SEVERAL EMBODIMENTS

- I. Abbreviations
- BAL: bronchoalveolar lavage
- CPE: cytopathic effect
- E: coronavirus transmembrane protein
- ELISA: enzyme-linked immunosorbent assay
- HE: coronavirus hemagglutinin-esterase protein
- IFA: indirect fluorescent antibody
- M: coronavirus membrane protein
- N: coronavirus nucleoprotein
- ORF: open reading frame
- PCR polymerase chain reaction

RACE: 5' rapid amplification of cDNA ends

RT-PCR: reverse transcription-polymerase chain reaction

S: coronavirus spike protein

SARS: severe acute respiratory syndrome

SARS-CoV: severe acute respiratory syndrome-associated coronavirus

TRS: transcriptional regulatory sequence

II. Terms

Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology may be found in Benjamin Lewin, Genes VII, published by Oxford University Press, 2000 (ISBN 019879276X); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Publishers, 1994 (ISBN 0632021829); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by Wiley, John & Sons, Inc., 1995 (ISBN 0471186341); and other similar references.

As used herein, the singular terms "a," "an," and "the" include plural referents unless context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. Also, as used herein, the term "comprises" means "includes." Hence "comprising A or B" means including A, B, or A and B. It is further to be understood that all nucleotide sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

In order to facilitate review of the various embodiments of this disclosure, the following explanations of specific terms are provided:

Adjuvant: A substance that non-specifically enhances the immune response to an antigen. Development of vaccine adjuvants for use in humans is reviewed in Singh et al. (Nat. Biotechnol. 17:1075-1081, 1999), which discloses that, at the time of its publication, aluminum salts and the MF59 microemulsion are the only vaccine adjuvants approved for human use.

Amplification: Amplification of a nucleic acid molecule (e.g., a DNA or RNA molecule) refers to use of a laboratory technique that increases the number of copies of a nucleic acid molecule in a sample. An

example of amplification is the polymerase chain reaction (PCR), in which a sample is contacted with a pair of oligonucleotide primers under conditions that allow for the hybridization of the primers to a nucleic acid template in the sample. The primers are extended under suitable conditions, dissociated from the template, re-annealed, extended, and dissociated to amplify the number of copies of the nucleic acid. The product of amplification can be characterized by such techniques as electrophoresis, restriction endonuclease cleavage patterns, oligonucleotide hybridization or ligation, and/or nucleic acid sequencing.

Other examples of amplification methods include strand displacement amplification, as disclosed in U.S. Pat. No. 5,744,311; transcription-free isothermal amplification, as disclosed in U.S. Pat. No. 6,033,881; repair chain reaction amplification, as disclosed in WO 90/01069; ligase chain reaction amplification, as disclosed in EP-A-320,308; gap filling ligase chain reaction amplification, as disclosed in U.S. Pat. No. 5,427,930; and NASBA.TM. RNA transcription-free amplification, as disclosed in U.S. Pat. No. 6,025,134. An amplification method can be modified, including for example by additional steps or coupling the amplification with another protocol.

Animal: Living multi-cellular vertebrate organisms, a category that includes, for example, mammals and birds. The term mammal includes both human and non-human mammals. Similarly, the term "subject" includes both human and veterinary subjects, for example, humans, non-human primates, dogs, cats, horses, and cows.

Antibody: A protein (or protein complex) that includes one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

The basic immunoglobulin (antibody) structural unit is generally a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" (about 50-70 kDa) chain. The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms "variable light chain" (V.sub.L) and "variable heavy chain" (V.sub.H) refer, respectively, to these light and heavy chains

As used herein, the term "antibodies" includes intact immunoglobulins as well as a number of wellcharacterized fragments. For instance, Fabs, Fvs, and single-chain Fvs (SCFvs) that bind to target protein (or epitope within a protein or fusion protein) would also be specific binding agents for that protein (or epitope). These antibody fragments are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab', the fragment of an antibody molecule obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (3) (Fab').sub.2, the fragment of the antibody obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; (4) F(ab').sub.2, a dimer of two Fab' fragments held together by two disulfide bonds; (5) Fv, a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (6) single chain antibody, a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule. Methods of making these fragments are routine (see, for example, Harlow and Lane, Using Antibodies: A Laboratory Manual, CSHL, New York, 1999).

Antibodies for use in the methods and devices of this disclosure can be monoclonal or polyclonal. Merely by way of example, monoclonal antibodies can be prepared from murine hybridomas according to the classical method of Kohler and Milstein (Nature 256:495-97, 1975) or derivative methods thereof. Detailed procedures for monoclonal antibody production are described in Harlow and Lane, Using Antibodies: A Laboratory Manual, CSHL, New York, 1999.

Antigen: A compound, composition, or substance that can stimulate the production of antibodies or a Tcell response in an animal, including compositions that are injected or absorbed into an animal. An antigen reacts with the products of specific humoral or cellular immunity, including those induced by heterologous immunogens. In one embodiment, an antigen is a coronavirus antigen.

Binding or Stable Binding: An oligonucleotide binds or stably binds to a target nucleic acid if a sufficient amount of the oligonucleotide forms base pairs or is hybridized to its target nucleic acid, to permit detection of that binding. Binding can be detected by either physical or functional properties of the target:oligonucleotide complex. Binding between a target and an oligonucleotide can be detected by any procedure known to one skilled in the art, including functional or physical binding assays. Binding can be detected functionally by determining whether binding has an observable effect upon a biosynthetic process such as expression of a gene, DNA replication, transcription, translation, and the like.

Physical methods of detecting the binding of complementary strands of DNA or RNA are well known in the art, and include such methods as DNase I or chemical footprinting, gel shift and affinity cleavage assays, Northern blotting, Southern blotting, dot blotting, and light absorption detection procedures. For example, a method which is widely used, because it is so simple and reliable, involves observing a change in light absorption of a solution containing an oligonucleotide (or an analog) and a target nucleic acid at 220 to 300 nm as the temperature is slowly increased. If the oligonucleotide or analog has bound to its target, there is a sudden increase in absorption at a characteristic temperature as the oligonucleotide (or analog) and target dissociate or melt.

The binding between an oligomer and its target nucleic acid is frequently characterized by the temperature (T.sub.m) at which 50% of the oligomer is melted from its target. A higher T.sub.m means a stronger or more stable complex relative to a complex with a lower T.sub.m.

cDNA (complementary DNA): A piece of DNA lacking internal, non-coding segments (introns) and regulatory sequences that determine transcription. cDNA is synthesized in the laboratory by reverse transcription from messenger RNA extracted from cells.

Electrophoresis: Electrophoresis refers to the migration of charged solutes or particles in a liquid medium under the influence of an electric field. Electrophoretic separations are widely used for analysis of macromolecules. Of particular importance is the identification of proteins and nucleic acid sequences. Such separations can be based on differences in size and/or charge. Nucleotide sequences have a uniform charge and are therefore separated based on differences in size. Electrophoresis can be performed in an unsupported liquid medium (for example, capillary electrophoresis), but more commonly the liquid medium travels through a solid supporting medium. The most widely used supporting media are gels, for example, polyacrylamide and agarose gels.

Sieving gels (for example, agarose) impede the flow of molecules. The pore size of the gel determines the size of a molecule that can flow freely through the gel. The amount of time to travel through the gel increases as the size of the molecule increases. As a result, small molecules travel through the gel more quickly than large molecules and thus progress further from the sample application area than larger molecules, in a given time period. Such gels are used for size-based separations of nucleotide sequences.

Fragments of linear DNA migrate through agarose gels with a mobility that is inversely proportional to the log.sub.10 of their molecular weight. By using gels with different concentrations of agarose, different sizes of DNA fragments can be resolved. Higher concentrations of agarose facilitate separation of small DNAs, while low agarose concentrations allow resolution of larger DNAs.

Hybridization: Oligonucleotides and their analogs hybridize by hydrogen bonding, which includes Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary bases. Generally, nucleic acid consists of nitrogenous bases that are either pyrimidines (cytosine (C), uracil (U), and thymine (T)) or purines (adenine (A) and guanine (G)). These nitrogenous bases form hydrogen bonds between a pyrimidine and a purine, and the bonding of the pyrimidine to the purine is referred to as "base pairing." More specifically, A will hydrogen bond to T or U, and G will bond to C. "Complementary" refers to the base pairing that occurs between two distinct nucleic acid sequences or two distinct regions of the same nucleic acid sequence.

"Specifically hybridizable" and "specifically complementary" are terms that indicate a sufficient degree of complementarity such that stable and specific binding occurs between the oligonucleotide (or its analog) and the DNA or RNA target. The oligonucleotide or oligonucleotide analog need not be 100% complementary to its target sequence to be specifically hybridizable. An oligonucleotide or analog is specifically hybridizable when binding of the oligonucleotide or analog to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide or analog to non-target sequences under conditions where specific binding is desired, for example under physiological conditions in the case of in vivo assays or systems. Such binding is referred to as specific hybridization.

Hybridization conditions resulting in particular degrees of stringency will vary depending upon the nature of the hybridization method of choice and the composition and length of the hybridizing nucleic acid sequences. Generally, the temperature of hybridization and the ionic strength (especially the Na.sup.+ and/or Mg.sup.++ concentration) of the hybridization buffer will determine the stringency of hybridization, though wash times also influence stringency. Calculations regarding hybridization conditions required for attaining particular degrees of stringency are discussed by Sambrook et al. (ed.), Molecular Cloning: A Laboratory Manual, 2.sup.nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, chapters 9 and 11; and Ausubel et al. Short Protocols in Molecular Biology, 4.sup.th ed., John Wiley & Sons, Inc., 1999.

For purposes of the present disclosure, "stringent conditions" encompass conditions under which hybridization will only occur if there is less than 25% mismatch between the hybridization molecule and the target sequence. "Stringent conditions" may be broken down into particular levels of stringency for more precise definition. Thus, as used herein, "moderate stringency" conditions are those under which molecules with more than 25% sequence mismatch will not hybridize; conditions of "medium stringency" are those under which molecules with more than 15% mismatch will not hybridize, and conditions of "high stringency" are those under which sequences with more than 10% mismatch will not hybridize. Conditions of "very high stringency" are those under which sequences with more than 6% mismatch will not hybridize.

Immune Stimulatory Composition: A term used herein to mean a composition useful for stimulating or eliciting a specific immune response (or immunogenic response) in a vertebrate. In some embodiments, the immunogenic response is protective or provides protective immunity, in that it enables the vertebrate animal to better resist infection with or disease progression from the organism against which the vaccine is directed.

Without wishing to be bound by a specific theory, it is believed that an immunogenic response may arise from the generation of an antibody specific to one or more of the epitopes provided in the immune stimulatory composition. Alternatively, the response may comprise a T-helper or cytotoxic cell-based response to one or more of the epitopes provided in the immune stimulatory composition. All three of these responses may originate from naive or memory cells. One specific example of a type of immune stimulatory composition is a vaccine.

In some embodiments, an "effective amount" or "immune-stimulatory amount" of an immune stimulatory composition is an amount which, when administered to a subject, is sufficient to engender a detectable immune response. Such a response may comprise, for instance, generation of an antibody specific to one or more of the epitopes provided in the immune stimulatory composition. Alternatively, the response may comprise a T-helper or CTL-based response to one or more of the epitopes provided in the immune stimulatory composition. All three of these responses may originate from naive or memory cells. In other embodiments, a "protective effective amount" of an immune stimulatory composition is an amount which, when administered to a subject, is sufficient to confer protective immunity upon the subject.

Inhibiting or Treating a Disease: Inhibiting the full development of a disease or condition, for example, in a subject who is at risk for a disease such as SARS. "Treatment" refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop. As used herein, the term "ameliorating," with reference to a disease, pathological condition or symptom, refers to any observable beneficial effect of the treatment. The beneficial effect can be evidenced, for example, by a delayed onset of clinical symptoms of the disease in a susceptible subject, a reduction in severity of some or all clinical symptoms of the disease, a slower progression of the disease, a reduction in the number of relapses of the disease, an improvement in the overall health or well-being of the subject, or by other parameters well known in the art that are specific to the particular disease.

Isolated: An "isolated" microorganism (such as a virus, bacterium, fungus, or protozoan) has been substantially separated or purified away from microorganisms of different types, strains, or species. Microorganisms can be isolated by a variety of techniques, including serial dilution and culturing.

An "isolated" biological component (such as a nucleic acid molecule, protein or organelle) has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally occurs, such as other chromosomal and extra-chromosomal DNA and RNA, proteins, and organelles. Nucleic acids and proteins that have been "isolated" include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell, as well as chemically synthesized nucleic acids or proteins, or fragments thereof.

Label: A detectable compound or composition that is conjugated directly or indirectly to another molecule to facilitate detection of that molecule. Specific, non-limiting examples of labels include fluorescent tags, enzymatic linkages, and radioactive isotopes.

Nucleic Acid Molecule: A polymeric form of nucleotides, which may include both sense and anti-sense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. A nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide. A "nucleic acid molecule" as used herein is synonymous with "nucleic acid" and "polynucleotide." A nucleic acid molecule is usually at least 10 bases in length, unless otherwise specified. The term includes single- and double-stranded forms of DNA. A polynucleotide may include either or both naturally occurring and modified nucleotides linked together by naturally occurring and/or non-naturally occurring nucleotide linkages.

Oligonucleotide: A nucleic acid molecule generally comprising a length of 300 bases or fewer. The term often refers to single-stranded deoxyribonucleotides, but it can refer as well to single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs, among others. The term "oligonucleotide" also includes oligonucleosides (that is, an oligonucleotide minus the phosphate) and any other organic base polymer. In some examples, oligonucleotides are about 10 to about 90 bases in length, for example, 12, 13, 14, 15, 16, 17, 18, 19 or 20 bases in length. Other oligonucleotides are about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60 bases, about 65 bases, about 70 bases, about 75 bases or about 80 bases in length. Oligonucleotides may be single-stranded,

for example, for use as probes or primers, or may be double-stranded, for example, for use in the construction of a mutant gene. Oligonucleotides can be either sense or anti-sense oligonucleotides. An oligonucleotide can be modified as discussed above in reference to nucleic acid molecules. Oligonucleotides can be obtained from existing nucleic acid sources (for example, genomic or cDNA), but can also be synthetic (for example, produced by laboratory or in vitro oligonucleotide synthesis).

Open Reading Frame (ORF): A series of nucleotide triplets (codons) coding for amino acids without any internal termination codons. These sequences are usually translatable into a peptide/polypeptide/ protein/polyprotein.

Operably Linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in the same reading frame. If introns are present, the operably linked DNA sequences may not be contiguous.

Pharmaceutically Acceptable Carriers: The pharmaceutically acceptable carriers useful in this disclosure are conventional. Remington's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, Pa., 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of one or more therapeutic compounds or molecules, such as one or more SARS-CoV nucleic acid molecules, proteins or antibodies that bind these proteins, and additional pharmaceutical agents.

In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (for example, powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologicallyneutral carriers, pharmaceutical compositions to be administered can contain minor amounts of nontoxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.

Polypeptide: A polymer in which the monomers are amino acid residues which are joined together through amide bonds. When the amino acids are alpha-amino acids, either the L-optical isomer or the D-optical isomer can be used, the L-isomers being preferred. The terms "polypeptide" or "protein" as used herein are intended to encompass any amino acid sequence and include modified sequences such as glycoproteins. The term "polypeptide" is specifically intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically produced.

Conservative amino acid substitutions are those substitutions that, when made, least interfere with the properties of the original protein, that is, the structure and especially the function of the protein is

conserved and not significantly changed by such substitutions. Examples of conservative substitutions are shown below.

TABLE-US-00001 Original Residue Conservative Substitutions Ala Ser Arg Lys Asn Gln, His Asp Glu Cys Ser Gln Asn Glu Asp His Asn; Gln Ile Leu, Val Leu Ile; Val Lys Arg; Gln; Glu Met Leu; Ile Phe Met; Leu; Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp; Phe Val Ile; Leu

Conservative substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

The substitutions which in general are expected to produce the greatest changes in protein properties will be non-conservative, for instance changes in which (a) a hydrophilic residue, for example, seryl or threonyl, is substituted for (or by) a hydrophobic residue, for example, leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, for example, lysyl, arginyl, or histadyl, is substituted for (or by) an electronegative residue, for example, glutamyl or aspartyl; or (d) a residue having a bulky side chain, for example, phenylalanine, is substituted for (or by) one not having a side chain, for example, glycine.

Probes and Primers: A probe comprises an isolated nucleic acid attached to a detectable label or other reporter molecule. Typical labels include radioactive isotopes, enzyme substrates, co-factors, ligands, chemiluminescent or fluorescent agents, haptens, and enzymes. Methods for labeling and guidance in the choice of labels appropriate for various purposes are discussed, for example, in Sambrook et al. (ed.), Molecular Cloning: A Laboratory Manual, 2.sup.nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989 and Ausubel et al. Short Protocols in Molecular Biology, 4.sup.th ed., John Wiley & Sons, Inc., 1999.

Primers are short nucleic acid molecules, for instance DNA oligonucleotides 10 nucleotides or more in length, for example that hybridize to contiguous complementary nucleotides or a sequence to be amplified. Longer DNA oligonucleotides may be about 15, 20, 25, 30 or 50 nucleotides or more in length. Primers can be annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, and then the primer extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, for example, by the PCR or other nucleic-acid amplification methods known in the art, as described above.

Methods for preparing and using nucleic acid probes and primers are described, for example, in Sambrook et al. (ed.), Molecular Cloning: A Laboratory Manual, 2.sup.nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; Ausubel et al. Short Protocols in Molecular Biology, 4.sup.th ed., John Wiley & Sons, Inc., 1999; and Innis et al. PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc., San Diego, Calif., 1990. Amplification primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, .COPYRGT. 1991, Whitehead Institute for Biomedical Research, Cambridge, Mass.). One of ordinary skill in the art will appreciate that the specificity of a particular probe or primer increases with its length. Thus, in order to obtain greater specificity, probes and primers can be selected that comprise at least 20, 25, 30, 35, 40, 45, 50 or more consecutive nucleotides of a target nucleotide sequence.

Protein: A biological molecule, particularly a polypeptide, expressed by a gene and comprised of amino acids. A "polyprotein" is a protein that, after synthesis, is cleaved to produce several functionally distinct polypeptides.

Purified: The term "purified" does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified protein preparation is one in which the subject protein is more pure than in its natural environment within a cell. Generally, a protein preparation is purified such that the protein represents at least 50% of the total protein content of the preparation.

Recombinant Nucleic Acid: A sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, for example, by genetic engineering techniques such as those described in Sambrook et al. (ed.), Molecular Cloning: A Laboratory Manual, 2.sup.nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid.

Sample: A portion, piece, or segment that is representative of a whole. This term encompasses any material, including for instance samples obtained from an animal, a plant, or the environment.

An "environmental sample" includes a sample obtained from inanimate objects or reservoirs within an indoor or outdoor environment. Environmental samples include, but are not limited to: soil, water, dust, and air samples; bulk samples, including building materials, furniture, and landfill contents; and other reservoir samples, such as animal refuse, harvested grains, and foodstuffs.

A "biological sample" is a sample obtained from a plant or animal subject. As used herein, biological samples include all samples useful for detection of viral infection in subjects, including, but not limited to: cells, tissues, and bodily fluids, such as blood; derivatives and fractions of blood (such as serum); extracted galls; biopsied or surgically removed tissue, including tissues that are, for example, unfixed, frozen, fixed in formalin and/or embedded in paraffin; tears; milk; skin scrapes; surface washings; urine; sputum; cerebrospinal fluid; prostate fluid; pus; bone marrow aspirates; BAL; saliva; cervical swabs; vaginal swabs; and oropharyngeal wash.

Sequence Identity The similarity between two nucleic acid sequences, or two amino acid sequences, is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are.

Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith and Waterman (Adv. Appl. Math., 2:482, 1981); Needleman and Wunsch (J. Mol. Biol., 48:443, 1970); Pearson and Lipman (Proc. Natl. Acad. Sci., 85:2444, 1988); Higgins and Sharp (Gene, 73:237-44, 1988); Higgins and Sharp (CABIOS, 5:151-53, 1989); Corpet et al. (Nuc. Acids Res., 16:10881-90, 1988); Huang et al. (Comp. Appls Biosci., 8:155-65, 1992); and Pearson et al. (Meth. Mol. Biol., 24:307-31, 1994). Altschul et al. (Nature Genet., 6:119-29, 1994) presents a detailed consideration of sequence alignment methods and homology calculations.

The alignment tools ALIGN (Myers and Miller, CABIOS 4:11-17, 1989) or LFASTA (Pearson and Lipman, 1988) may be used to perform sequence comparisons (Internet Program.COPYRGT. 1996, W. R. Pearson and the University of Virginia, "fasta20u63" version 2.0u63, release date December 1996). ALIGN compares entire sequences against one another, while LFASTA compares regions of local similarity. These alignment tools and their respective tutorials are available on the Internet at the NCSA website. Alternatively, for comparisons of amino acid sequences of greater than about 30 amino acids, the "Blast 2 sequences" function can be employed using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per residue gap cost of 1). When aligning short peptides (fewer than around 30 amino acids), the alignment should be performed using the "Blast 2 sequences" function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). The BLAST sequence comparison system is available, for instance, from the NCBI web site; see also Altschul et al., J. Mol. Biol., 215:403-10, 1990; Gish and States, Nature Genet., 3:266-72, 1993; Madden et al., Meth. Enzymol., 266:131-41, 1996; Altschul et al., Nucleic Acids Res., 25:3389-402, 1997; and Zhang and Madden, Genome Res., 7:649-56, 1997.

Orthologs (equivalent to proteins of other species) of proteins are in some instances characterized by possession of greater than 75% sequence identity counted over the full-length alignment with the amino acid sequence of specific protein using ALIGN set to default parameters. Proteins with even greater similarity to a reference sequence will show increasing percentage identities when assessed by this method, such as at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, or at least 98% sequence identity. In addition, sequence identity can be compared over the full length of one or both binding domains of the disclosed fusion proteins.

When significantly less than the entire sequence is being compared for sequence identity, homologous sequences will typically possess at least 80% sequence identity over short windows of 10-20, and may possess sequence identities of at least 85%, at least 90%, at least 95%, or at least 99% depending on their similarity to the reference sequence. Sequence identity over such short windows can be determined using LFASTA; methods are described at the NCSA website. One of skill in the art will appreciate that these sequence identity ranges are provided for guidance only; it is entirely possible that strongly significant homologs could be obtained that fall outside of the ranges provided. Similar homology concepts apply for nucleic acids as are described for protein.

An alternative indication that two nucleic acid molecules are closely related is that the two molecules hybridize to each other under stringent conditions. Representative hybridization conditions are discussed above.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences, due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that each encode substantially the same protein.

Specific Binding Agent: An agent that binds substantially only to a defined target. Thus a proteinspecific binding agent binds substantially only the defined protein, or to a specific region within the protein. As used herein, a protein-specific binding agent includes antibodies and other agents that bind substantially to a specified polypeptide. The antibodies may be monoclonal or polyclonal antibodies that are specific for the polypeptide, as well as immunologically effective portions ("fragments") thereof.

The determination that a particular agent binds substantially only to a specific polypeptide may readily be made by using or adapting routine procedures. One suitable in vitro assay makes use of the Western blotting procedure (described in many standard texts, including Harlow and Lane, Using Antibodies: A Laboratory Manual, CSHL, New York, 1999).

Transformed: A "transformed" cell is a cell into which has been introduced a nucleic acid molecule by molecular biology techniques. The term encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration.

Vector: A nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. A vector may also include one or more selectable marker genes and other genetic elements known in the art.

Virus: Microscopic infectious organism that reproduces inside living cells. A virus typically consists essentially of a core of a single nucleic acid surrounded by a protein coat, and has the ability to replicate only inside a living cell. "Viral replication" is the production of additional virus by the occurrence of at least one viral life cycle. A virus may subvert the host cells' normal functions, causing the cell to behave in a manner determined by the virus. For example, a viral infection may result in a cell producing a cytokine, or responding to a cytokine, when the uninfected cell does not normally do so.

"Coronaviruses" are large, enveloped, RNA viruses that cause respiratory and enteric diseases in humans and other animals. Coronavirus genomes are non-segmented, single-stranded, positive-sense RNA, approximately 27-31 kb in length. Genomes have a 5' methylated cap and 3' poly-A tail, and function directly as mRNA. Host cell entry occurs via endocytosis and membrane fusion, and replication occurs in the cytoplasm. Initially, the 5' 20 kb of the positive-sense genome is translated to produce a viral polymerase, which then produces a full-length negative-sense strand used as a template

to produce subgenomic mRNA as a "nested set" of transcripts. Assembly occurs by budding into the golgi apparatus, and particles are transported to the surface of the cell and released.

III. Overview of Several Embodiments

A newly isolated human coronavirus (SARS-CoV) is disclosed herein. The entire genomic nucleic acid sequence of this virus is also provided herein. Also disclosed are the nucleic acid sequences of the SARS-CoV ORFs, and the polypeptide sequences encoded by these ORFs. Pharmaceutical and immune stimulatory compositions are also disclosed that include one or more SARS-CoV viral nucleic acids, polypeptides encoded by these viral nucleic acids and antibodies that bind to a SARS-CoV polypeptide fragment.

In one embodiment, a method is provided for detecting the presence of SARS-CoV in a sample. This method includes contacting the sample with a pair of nucleic acid primers that hybridize to a SARS-CoV nucleic acid, wherein at least one primer is 5'-end labeled with a reporter dye, amplifying the SARS-CoV nucleic acid or a fragment thereof from the sample utilizing the pair of nucleic acid primers, electrophoresing the amplified products, and detecting the 5'-end labeled reporter dye, thereby detecting a SARS-CoV. In a specific, non-limiting example, the amplification utilizes RT-PCR. In a further specific example of the provided method, at least one of the nucleic acid primers that hybridize to a SARS-CoV nucleic acid includes a sequence as set forth in any one of SEQ ID NOs: 13-15.

In another example of the provided method, detecting the presence of SARS-CoV in a sample includes contacting the sample with a pair of nucleic acid primers that hybridize to a SARS-CoV nucleic acid, amplifying the SARS-CoV nucleic acid or a fragment thereof from the sample utilizing the pair of nucleic acid primers, adding to the amplified SARS-CoV nucleic acid or the fragment thereof a TaqMan SARS-CoV probe that hybridizes to the SARS-CoV nucleic acid, wherein the TaqMan SARS-CoV probe is labeled with a 5'-reporter dye and a 3'-quencher dye, performing one or more additional rounds of amplification, and detecting fluorescence of the 5'-reporter dye, thereby detecting a SARS-CoV. In a specific, non-limiting example, the amplification utilizes RT-PCR. In a further specific example of the provided method, at least one of the nucleic acid primers that hybridize to a SARS-CoV nucleic acid and/or the TaqMan SARS-CoV probe that hybridizes to the SARS-CoV nucleic acid primers that hybridize to a SARS-CoV nucleic acid and/or the TaqMan SARS-CoV probe that hybridizes to the some additional section and some addition of the provided method, at least one of the nucleic acid primers that hybridize to a SARS-CoV nucleic acid and/or the TaqMan SARS-CoV probe that hybridizes to the SARS-CoV nucleic acid includes a sequence as set forth in any one of SEQ ID NOs: 16-33.

In another embodiment, a method is provided for detecting a SARS-CoV in a biological sample that contains antibodies. This method includes contacting the biological sample with a SARS-CoV-specific antigen, wherein the antigen includes a SARS-CoV organism and determining whether a binding reaction occurs between the SARS-CoV-specific antigen and an antibody in the biological sample if such is present, thereby detecting SARS-CoV.

In a further embodiment, a method is provided for detecting a SARS-CoV in a biological sample that contains polypeptides and/or fragments thereof. This method includes contacting the biological sample with a SARS-CoV-specific antibody and determining whether a binding reaction occurs between the SARS-CoV-specific antibody and a SARS-CoV polypeptide or fragment thereof in the biological sample if such is present, thereby detecting SARS-CoV. In a specific, non-limiting example,

determining whether a binding reaction occurs between the SARS-CoV-specific antibody and a SARS-CoV polypeptide or fragment thereof is carried out in situ or in a tissue sample. In a further specific example, determining whether a binding reaction occurs between the SARS-CoV-specific antibody and a SARS-CoV polypeptide or fragment thereof includes an immunohistochemical assay.

An additional embodiment includes a kit for detecting a SARS-CoV in a sample, including a pair of nucleic acid primers that hybridize under stringent conditions to a SARS-CoV nucleic acid, wherein one primer is 5'-end labeled with a reporter dye. In a specific, non-limiting example, at least one of the nucleic acid primers that hybridize to a SARS-CoV nucleic acid includes a sequence as set forth in any one of SEQ ID NOs: 13-15.

Another example of the provided kit includes a pair of nucleic acid primers that hybridize under high stringency conditions to a SARS-CoV nucleic acid and a TaqMan SARS-CoV probe that hybridizes to the SARS-CoV nucleic acid, wherein the TaqMan SARS-CoV probe is labeled with a 5'-reporter dye and a 3'-quencher dye. In a specific, non-limiting example, at least one of the nucleic acid primers that hybridize to a SARS-CoV nucleic acid and/or the TaqMan SARS-CoV probe that hybridizes to the SARS-CoV nucleic acid includes a sequence as set forth in any one of SEQ ID NOs: 16-33.

Also disclosed herein is a composition including an isolated SARS-CoV organism. In one embodiment, the isolated SARS-CoV organism is an inactive isolated SARS-CoV organism. In another embodiment, the composition includes at least one component selected from the group consisting of pharmaceutically acceptable carriers, adjuvants and combinations of two or more thereof. In yet another embodiment, the composition is introduced into a subject, thereby eliciting an immune response against a SARS-CoV antigenic epitope in a subject.

IV. SARS-CoV Nucleotide and Amino Acid Sequences

The current disclosure provides an isolated SARS-CoV genome, isolated SARS-CoV polypeptides, and isolated nucleic acid molecules encoding the same. In one embodiment, the isolated SARS-CoV genome has a sequence as shown in SEQ ID NO: 1 or an equivalent thereof. Polynucleotides encoding a SARS-CoV polypeptide (encoded by an ORF from within the genome) are also provided, and are termed SARS-CoV nucleic acid molecules. These nucleic acid molecules include DNA, cDNA and RNA sequences which encode a SARS-CoV polypeptide. Specific, non-limiting examples of a SARS-CoV nucleic acid molecule encoding an ORF are nucleic acid 265 to nucleic acid 13,398 of SEQ ID NO: 1 (encoding SARS-CoV 1a, SEQ ID NO: 2), nucleic acid 13,398 to 21,482 of SEQ ID NO: 1 (encoding SARS-CoV 1b, SEQ ID NO: 3), nucleic acid 21,492 to 25,256 of SEQ ID NO: 1 (encoding SARS-CoV S, SEQ ID NO: 4), nucleic acid 25,268 to 26,089 of SEQ ID NO: 1 (encoding SARS-CoV X1, SEQ ID NO: 5), nucleic acid 25,689 to 26,150 of SEQ ID NO: 1 (encoding SARS-CoV X2, SEQ ID NO: 6), nucleic acid 26,117 to 26,344 of SEQ ID NO: 1 (encoding SARS-CoV E, SEQ ID NO: 7), nucleic acid 26,398 to 27,060 of SEQ ID NO: 1 (encoding SARS-CoV M, SEQ ID NO: 8), nucleic acid 27,074 to 27,262 of SEQ ID NO: 1 (encoding SARS-CoV X3, SEQ ID NO: 9), nucleic acid 27,273 to 27,638 of SEQ ID NO: 1 (encoding SARS-CoV X4, SEQ ID NO: 10), nucleic acid 27,864 to 28,115 of SEQ ID NO: 1 (encoding SARS-CoV X5, SEQ ID NO: 11), and nucleic acid 28,120 to 29,385 of SEQ ID NO: 1 (encoding SARS-CoV N, SEQ ID NO: 12).

Oligonucleotide primers and probes derived from the SARS-CoV genome (SEQ ID NO: 1) are also encompassed within the scope of the present disclosure. Such oligonucleotide primers and probes may comprise a sequence of at least about 15 consecutive nucleotides of the SARS-CoV nucleic acid sequence, such as at least about 20, 25, 30, 35, 40, 45, or 50 or more consecutive nucleotides. These primers and probes may be obtained from any region of the disclosed SARS-CoV genome (SEQ ID NO: 1), including particularly from any of the ORFs disclosed herein. Specific, non-limiting examples of oligonucleotide primers derived from the SARS-CoV genome (SEQ ID NO: 1) include: Cor-p-F2 (SEQ ID NO: 13), Cor-p-F3 (SEQ ID NO: 14), Cor-p-R1 (SEQ ID NO: 15), SARS1-F (SEQ ID NO: 16), SARS1--R (SEQ ID NO: 17), SARS2-F (SEQ ID NO: 19), SARS2--R (SEQ ID NO: 20), SARS3-F (SEQ ID NO: 22), SARS3--R (SEQ ID NO: 23), N3-F (SEQ ID NO: 25), N3-R (SEQ ID NO: 26), 3'NTR-F (SEQ ID NO: 28), 3'NTR-R (SEQ ID NO: 29), M-F (SEQ ID NO: 31), and M-R (SEQ ID NO: 32). Specific, non-limiting examples of oligonucleotide probes derived from the SARS-CoV genome (SEQ ID NO: 1) include: SARS1-P (SEQ ID NO: 18), SARS2-P (SEQ ID NO: 21), SARS3-P (SEQ ID NO: 24), N3-P (SEQ ID NO: 27), 3'NTR-P (SEQ ID NO: 30), and M-P (SEQ ID NO: 33).

Nucleic acid molecules encoding a SARS-CoV polypeptide can be operatively linked to regulatory sequences or elements. Regulatory sequences or elements include, but are not limited to promoters, enhancers, transcription terminators, a start codon (for example, ATG), stop codons, and the like.

Additionally, nucleic acid molecules encoding a SARS-CoV polypeptide can be inserted into an expression vector. Specific, non-limiting examples of vectors include, plasmids, bacteriophages, cosmids, animal viruses and yeast artificial chromosomes (YACs) (Burke et al., Science 236:806-12, 1987). Such vectors may then be introduced into a variety of hosts including somatic cells, and simple or complex organisms, such as bacteria, fungi (Timberlake and Marshall, Science 244:1313-17, 1989), invertebrates, plants (Gasser et al., Plant Cell 1:15-24, 1989), and animals (Pursel et al., Science 244:1281-88, 1989).

Transformation of a host cell with an expression vector carrying a nucleic acid molecule encoding a SARS-CoV polypeptide may be carried out by conventional techniques, as are well known to those skilled in the art. By way of example, where the host is prokaryotic, such as E. coli, competent cells that are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCl.sub.2 method using procedures well known in the art. Alternatively, MgCl.sub.2 or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell if desired, or by electroporation.

When the host is a eukaryote, methods of transfection of DNA, such as calcium phosphate coprecipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors, may be used. Eukaryotic cells can also be cotransformed with SARS-CoV nucleic acid molecules, and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral vector, such as simian virus 40 or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein (see, for example, Eukaryotic Viral Vectors, Cold Spring Harbor Laboratory, Gluzman ed., 1982).

The SARS-CoV polypeptides of this disclosure include proteins encoded by any of the ORFs disclosed herein, and equivalents thereof. Specific, non-limiting examples of SARS-CoV proteins are provided in SEQ ID NOs: 2-12. Fusion proteins are also contemplated that include a heterologous amino acid sequence chemically linked to a SARS-CoV polypeptide. Exemplary heterologous sequences include short amino acid sequence tags (such as six histidine residues), as well as a fusion of other proteins (such as c-myc or green fluorescent protein fusions). Epitopes of the SARS-CoV proteins, that are recognized by an antibody or that bind the major histocompatibility complex, and can be used to induce a SARS-CoV-specific immune response, are also encompassed by this disclosure.

Methods for expressing large amounts of protein from a cloned gene introduced into E. coli may be utilized for the purification and functional analysis of proteins. For example, fusion proteins consisting of amino terminal peptides encoded by a portion of the E. coli lacZ or trpE gene linked to SARS-CoV proteins may be used to prepare polyclonal and monoclonal antibodies against these proteins.

Intact native protein may also be produced in E. coli in large amounts for functional studies. Methods and plasmid vectors for producing fusion proteins and intact native proteins in bacteria are described by Sambrook et al. (ed.), Molecular Cloning: A Laboratory Manual, 2.sup.nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989. Such fusion proteins may be made in large amounts, are easy to purify, and can be used to elicit antibody response. Native proteins can be produced in bacteria by placing a strong, regulated promoter and an efficient ribosome-binding site upstream of the cloned gene. If low levels of protein are produced, additional steps may be taken to increase protein production; if high levels of protein are produced, purification is relatively easy. Suitable methods are presented by Sambrook et al. (ed.), Molecular Cloning: A Laboratory Manual, 2.sup.nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, and are well known in the art. Often, proteins expressed at high levels are found in insoluble inclusion bodies. Methods for extracting proteins from these aggregates are described by Sambrook et al. (ed.), Molecular Cloning: A Laboratory Press, Cold Spring Harbor, N.Y., 1989.

Isolation and purification of recombinantly expressed proteins may be carried out by conventional means including preparative chromatography and immunological separations. Additionally, the proteins can be chemically synthesized by any of a number of manual or automated methods of synthesis known in the art.

V. Specific Binding Agents

The disclosure provides specific binding agents that bind to SARS-CoV polypeptides disclosed herein. The binding agent may be useful for purifying and detecting the polypeptides, as well as for detection and diagnosis of SARS-CoV. Examples of the binding agents are a polyclonal or monoclonal antibody, and fragments thereof, that bind to any of the SARS-CoV polypeptides disclosed herein.

Monoclonal or polyclonal antibodies may be raised to recognize a SARS-CoV polypeptide described herein, or a fragment or variant thereof. Optimally, antibodies raised against these polypeptides would

specifically detect the polypeptide with which the antibodies are generated. That is, antibodies raised against a specific SARS-CoV polypeptide will recognize and bind that polypeptide, and will not substantially recognize or bind to other polypeptides or antigens. The determination that an antibody specifically binds to a target polypeptide is made by any one of a number of standard immunoassay methods; for instance, the Western blotting technique (Sambrook et al. (ed.), Molecular Cloning: A Laboratory Manual, 2.sup.nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

Substantially pure SARS-CoV recombinant polypeptide antigens suitable for use as immunogen may be isolated from the transformed cells described above, using methods well known in the art. Monoclonal or polyclonal antibodies to the antigens may then be prepared.

Monoclonal antibodies to the polypeptides can be prepared from murine hybridomas according to the classic method of Kohler & Milstein (Nature 256:495-97, 1975), or a derivative method thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected protein immunogen (for example, a polypeptide comprising at least one SARS-CoV-specific epitope, a portion of a polypeptide comprising at least one SARS-CoV-specific epitope, or a synthetic peptide comprising at least one SARS-CoV-specific epitope) over a period of a few weeks. The mouse is then sacrificed, and the antibody-producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall (Meth. Enzymol., 70:419-39, 1980), or a derivative method thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Harlow and Lane, Using Antibodies: A Laboratory Manual, CSHL, New York, 1999.

Polyclonal antiserum containing antibodies can be prepared by immunizing suitable animals with a polypeptide comprising at least one SARS-CoV-specific epitope, a portion of a polypeptide comprising at least one SARS-CoV-specific epitope, or a synthetic peptide comprising at least one SARS-CoV-specific epitope, which can be unmodified or modified, to enhance immunogenicity.

Effective antibody production (whether monoclonal or polyclonal) is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than others and may require the use of carriers and adjuvant. Also, host animals vary in response to site of inoculations and dose, with either inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appear to be most reliable. An effective immunization protocol for rabbits can be found in Vaitukaitis et al. (J. Clin. Endocrinol. Metab., 33:988-91, 1971).

Booster injections can be given at regular intervals, and antiserum harvested when the antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against

known concentrations of the antigen, begins to fall. See, for example, Ouchterlony et al., Handbook of Experimental Immunology, Wier, D. (ed.), Chapter 19, Blackwell, 1973. A plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 .mu.M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher (Manual of Clinical Immunology, Ch. 42, 1980).

Antibody fragments may be used in place of whole antibodies and may be readily expressed in prokaryotic host cells. Methods of making and using immunologically effective portions of monoclonal antibodies, also referred to as "antibody fragments," are well known and include those described in Better & Horowitz, Methods Enzymol. 178:476-96, 1989; Glockshuber et al., Biochemistry 29:1362-67, 1990; and U.S. Pat. Nos. 5,648,237 (Expression of Functional Antibody Fragments); 4,946,778 (Single Polypeptide Chain Binding Molecules); and 5,455,030 (Immunotherapy Using Single Chain Polypeptide Binding Molecules), and references cited therein. Conditions whereby a polypeptide/binding agent complex can form, as well as assays for the detection of the formation of a polypeptide, are standard in the art. Such assays can include, but are not limited to, Western blotting, immunoprecipitation, immunofluorescence, immunocytochemistry, immunohistochemistry, fluorescence activated cell sorting (FACS), fluorescence in situ hybridization (FISH), immunomagnetic assays, ELISA, ELISPOT (Coligan et al., Current Protocols in Immunology, Wiley, NY, 1995), agglutination assays, flocculation assays, cell panning, and the like, as are well known to one of skill in the art.

Binding agents of this disclosure can be bound to a substrate (for example, beads, tubes, slides, plates, nitrocellulose sheets, and the like) or conjugated with a detectable moiety, or both bound and conjugated. The detectable moieties contemplated for the present disclosure can include, but are not limited to, an immunofluorescent moiety (for example, fluorescein, rhodamine), a radioactive moiety (for example, .sup.32P, .sup.125I, .sup.35S), an enzyme moiety (for example, horseradish peroxidase, alkaline phosphatase), a colloidal gold moiety, and a biotin moiety. Such conjugation techniques are standard in the art (for example, see Harlow and Lane, Using Antibodies: A Laboratory Manual, CSHL, New York, 1999; Yang et al., Nature, 382:319-24, 1996).

VI. Detection and Diagnosis of SARS-CoV

A. Nucleic Acid Based Methods of Detection and Diagnosis

A major application of the SARS-CoV sequence information presented herein is in the area of detection and diagnostic testing for SARS-CoV infection. Methods for screening a subject to determine if the subject has been or is currently infected with SARS-CoV are disclosed herein.

One such method includes providing a sample, which sample includes a nucleic acid such as DNA or RNA, and providing an assay for detecting in the sample the presence of a SARS-CoV nucleic acid molecule. Suitable samples include all biological samples useful for detection of viral infection in subjects, including, but not limited to, cells, tissues (for example, lung and kidney), bodily fluids (for example, blood, serum, urine, saliva, sputum, and cerebrospinal fluid), bone marrow aspirates, BAL,

and oropharyngeal wash. Additional suitable samples include all environmental samples useful for detection of viral presence in the environment, including, but not limited to, a sample obtained from inanimate objects or reservoirs within an indoor or outdoor environment. The detection in the sample of a SARS-CoV nucleic acid molecule may be performed by a number of methodologies, non-limiting examples of which are outlined below.

In one embodiment, detecting in the sample the presence of a SARS-CoV nucleic acid molecule includes the amplification of a SARS-CoV nucleic acid sequence (or a fragment thereof). Any nucleic acid amplification method can be used. In one specific, non-limiting example, PCR is used to amplify the SARS-CoV nucleic acid sequence(s). In another non-limiting example, RT-PCR can be used to amplify the SARS-CoV nucleic acid sequences. In an additional non-limiting example, transcription-mediated amplification can be used to amplify the SARS-CoV nucleic acid sequences.

In some embodiments, a pair of SARS-CoV-specific primers are utilized in the amplification reaction. One or both of the primers can be end-labeled (for example, radiolabeled, fluoresceinated, or biotinylated). In one specific, non-limiting example, at least one of the primers is 5'-end labeled with the reporter dye 6-carboxyfluorescein (6-FAM). The pair of primers includes an upstream primer (which binds 5' to the downstream primer) and a downstream primer (which binds 3' to the upstream primer). In one embodiment, either the upstream primer or the downstream primer is labeled. Specific, non-limiting examples of SARS-CoV-specific primers include, but are not limited to: Cor-p-F2 (SEQ ID NO: 13), Cor-p-F3 (SEQ ID NO: 14), Cor-p-R1 (SEQ ID NO: 15), SARS1-F (SEQ ID NO: 16), SARS1-R (SEQ ID NO: 17), SARS2-F (SEQ ID NO: 19), SARS2-R (SEQ ID NO: 20), SARS3-F (SEQ ID NO: 22), SARS3R (SEQ ID NO: 23), N3-F (SEQ ID NO: 25), N3-R (SEQ ID NO: 26), 3'NTR-F (SEQ ID NO: 28), 3'NTR-R (SEQ ID NO: 29), M-F (SEQ ID NO: 31), and M-R (SEQ ID NO: 32). Additional primer pairs can be generated, for instance, to amplify any of the specific ORFs described herein, using well known primer design principles and methods.

In one specific, non-limiting example, electrophoresis is used to detect amplified SARS-CoV-specific sequences. Electrophoresis can be automated using many methods well know in the art. In one embodiment, a genetic analyzer is used, such as an ABI 3100 Prism Genetic Analyzer (PE Applied Biosystems, Foster City, Calif.), wherein the bands are analyzed using GeneScan software (PE Applied Biosystems, Foster City, Calif.).

In another specific, non-limiting example, hybridization assays are used to detect amplified SARS-CoV-specific sequences using distinguishing oligonucleotide probes. Such probes include "TaqMan" probes. TaqMan probes consist of an oligonucleotide with a reporter at the 5'-end and a quencher at the 3'-end. In one specific, non-limiting example, the reporter is 6-FAM and the quencher is Blackhole Quencher (Biosearch Tech., Inc., Novato, Calif.). When the probe is intact, the proximity of the reporter to the quencher results in suppression of reporter fluorescence, primarily by fluorescence resonance energy transfer. If the target of interest is present, the TaqMan probe specifically hybridizes between the forward and reverse primer sites during the PCR annealing step. In the process of PCR elongation, the 5'-3' nucleolytic activity of the Taq DNA polymerase cleaves the hybridized probe between the reporter and the quencher. The probe fragments are then displaced from the target, and polymerization of the strand continues. Taq DNA polymerase does not cleave non-hybridized probe,

and cleaves the hybridized probe only during polymerization. The 3'-end of the probe is blocked to prevent extension of the probe during PCR. The 5'-3' nuclease cleavage of the hybridized probe occurs in every cycle and does not interfere with the exponential accumulation of PCR product. Accumulation of PCR products is detected directly by monitoring the increase in fluorescence of the released reporter. The increase in fluorescence signal is detected only if the target sequence is complementary to the probe and is amplified during PCR. Therefore, non-specific amplification is not detected. SARS-CoV-specific TaqMan probes of the present disclosure include, but are not limited to: SARS1-P (SEQ ID NO: 18), SARS2-P (SEQ ID NO: 21), SARS3-P (SEQ ID NO: 24), N3-P (SEQ ID NO: 27), 3'NTR-P (SEQ ID NO: 30), and M-P (SEQ ID NO: 33), and hybridization assays include, but are not limited to, a real-time RT-PCR assay.

B. Protein Based Methods of Detection and Diagnosis

The present disclosure further provides methods of detecting a SARS-CoV antigen in a sample, and/or diagnosing SARS-CoV infection in a subject by detecting a SARS-CoV antigen. Examples of such methods comprise contacting the sample with a SARS-CoV-specific binding agent under conditions whereby an antigen/binding agent complex can form; and detecting formation of the complex, thereby detecting SARS-CoV antigen in a sample and/or diagnosing SARS-CoV infection in a subject. It is contemplated that at least certain antigens will be on an intact SARS-CoV virion, will be a SARS-CoV-encoded protein displayed on the surface of a SARS-CoV-infected cell expressing the antigen, or will be a fragment of the antigen. Contemplated samples subject to analysis by these methods can comprise any sample, such as a clinical sample, useful for detection of viral infection in a subject.

Methods for detecting antigens in a sample are discussed, for example, in Ausubel et al. Short Protocols in Molecular Biology, 4.sup.th ed., John Wiley & Sons, Inc., 1999. Enzyme immunoassays such as IFA, ELISA and immunoblotting can be readily adapted to accomplish the detection of SARS-CoV antigens according to the methods of this disclosure. An ELISA method effective for the detection of soluble SARS-CoV antigens is the direct competitive ELISA. This method is most useful when a specific SARS-CoV antibody and purified SARS-CoV antigen are available. Briefly: 1) coat a substrate (for example, a microtiter plate) with a sample suspected of containing a SARS-CoV antigen; 2) contact the bound SARS-CoV antigen with a SARS-CoV-specific antibody bound to a detectable moiety (for example, horseradish peroxidase enzyme or alkaline phosphatase enzyme); 3) add purified inhibitor SARS-CoV antigen; 4) contact the above with the substrate for the enzyme; and 5) observe/ measure inhibition of color change or fluorescence and quantitate antigen concentration (for example, using a microtiter plate reader).

An additional ELISA method effective for the detection of soluble SARS-CoV antigens is the antibodysandwich ELISA. This method is frequently more sensitive in detecting antigen than the direct competitive ELISA method. Briefly: 1) coat a substrate (for example, a microtiter plate) with a SARS-CoV-specific antibody; 2) contact the bound SARS-CoV antibody with a sample suspected of containing a SARS-CoV antigen; 3) contact the above with SARS-CoV-specific antibody bound to a detectable moiety (for example, horseradish peroxidase enzyme or alkaline phosphatase enzyme); 4) contact the above with the substrate for the enzyme; and 5) observe/measure color change or fluorescence and quantitate antigen concentration (for example, using a microtiter plate reader). An ELISA method effective for the detection of cell-surface SARS-CoV antigens is the direct cellular ELISA. Briefly, cells suspected of exhibiting a cell-surface SARS-CoV antigen are fixed (for example, using glutaraldehyde) and incubated with a SARS-CoV-specific antibody bound to a detectable moiety (for example, horseradish peroxidase enzyme or alkaline phosphatase enzyme). Following a wash to remove unbound antibody, substrate for the enzyme is added and color change or fluorescence is observed/measured.

The present disclosure further provides methods of detecting a SARS-CoV-reactive antibody in a sample, and/or diagnosing SARS-CoV infection in a subject by detecting a SARS-CoV-reactive antibody. Examples of such methods comprise contacting the sample with a SARS-CoV polypeptide of this disclosure under conditions whereby a polypeptide/antibody complex can form; and detecting formation of the complex, thereby detecting SARS-CoV antibody in a sample and/or diagnosing SARS-CoV infection in a subject. Contemplated samples subject to analysis by these methods can comprise any sample, such as a clinical sample, as described herein as being useful for detection of viral infection in a subject.

Methods for detecting antibodies in a sample are discussed, for example, in Ausubel et al. Short Protocols in Molecular Biology, 4.sup.th ed., John Wiley & Sons, Inc., 1999. Enzyme immunoassays such as IFA, ELISA and immunoblotting can be readily adapted to accomplish the detection of SARS-CoV antibodies according to the methods of this disclosure. An ELISA method effective for the detection of specific SARS-CoV antibodies is the indirect ELISA method. Briefly: 1) bind a SARS-CoV polypeptide to a substrate (for example, a microtiter plate); 2) contact the bound polypeptide with a sample suspected of containing SARS-CoV antibody; 3) contact the above with a secondary antibody bound to a detectable moiety which is reactive with the bound antibody (for example, horseradish peroxidase enzyme or alkaline phosphatase enzyme); 4) contact the above with the substrate for the enzyme; and 5) observe/measure color change or fluorescence.

Another immunologic technique that can be useful in the detection of SARS-CoV antibodies uses monoclonal antibodies for detection of antibodies specifically reactive with SARS-CoV polypeptides in a competitive inhibition assay. Briefly, a sample suspected of containing SARS-CoV antibodies is contacted with a SARS-CoV polypeptide of this disclosure which is bound to a substrate (for example, a microtiter plate). Excess sample is thoroughly washed away. A labeled (for example, enzyme-linked, fluorescent, radioactive, and the like) monoclonal antibody specific for the SARS-CoV polypeptide is then contacted with any previously formed polypeptide-antibody complexes and the amount of monoclonal antibody binding is measured. The amount of inhibition of monoclonal antibody binding is measured relative to a control (no monoclonal antibody), allowing for detection and measurement of antibody in the sample. The degree of monoclonal antibody inhibition can be a very specific assay for detecting SARS-CoV. Monoclonal antibodies can also be used for direct detection of SARS-CoV in cells or tissue samples by, for example, IFA analysis according to standard methods.

As a further example, a micro-agglutination test can be used to detect the presence of SARS-CoV antibodies in a sample. Briefly, latex beads, red blood cells or other agglutinable particles are coated with a SARS-CoV polypeptide of this disclosure and mixed with a sample, such that antibodies in the

sample that are specifically reactive with the antigen crosslink with the antigen, causing agglutination. The agglutinated polypeptide-antibody complexes form a precipitate, visible with the naked eye or measurable by spectrophotometer. In a modification of the above test, SARS-CoV-specific antibodies of this disclosure can be bound to the agglutinable particles and SARS-CoV antigen in the sample thereby detected.

VII. Pharmaceutical and Immune Stimulatory Compositions and Uses Thereof

Pharmaceutical compositions including SARS-CoV nucleic acid sequences, SARS-CoV polypeptides, or antibodies that bind these polypeptides, are also encompassed by the present disclosure. These pharmaceutical compositions include a therapeutically effective amount of one or more SARS-CoV polypeptides, one or more nucleic acid molecules encoding a SARS-CoV polypeptide, or an antibody that binds a SARS-CoV polypeptide, in conjunction with a pharmaceutically acceptable carrier.

Disclosed herein are substances suitable for use as immune stimulatory compositions for the inhibition or treatment of SARS. Particular immune stimulatory compositions are directed against SARS-CoV, and include antigens obtained from SARS-CoV. In one embodiment, an immune stimulatory composition contains attenuated SARS-CoV. Methods of viral attenuation are well known in the art, and include, but are not limited to, high serial passage (for example, in susceptible host cells under specific environmental conditions to select for attenuated virions), exposure to a mutagenic agent (for example, a chemical mutagen or radiation), genetic engineering using recombinant DNA technology (for example, using gene replacement or gene knockout to disable one or more viral genes), or some combination thereof.

In another embodiment, the immune stimulatory composition contains inactivated SARS-CoV. Methods of viral inactivation are well known in the art, and include, but are not limited to, heat and chemicals (for example, formalin, .beta.-propiolactone, and ethylenimines).

In yet another embodiment, the immune stimulatory composition contains a nucleic acid vector that includes SARS-CoV nucleic acid molecules described herein, or that includes a nucleic acid sequence encoding an immunogenic polypeptide or polypeptide fragment of SARS-CoV or derived from SARS-CoV, such as a polypeptide that encodes a surface protein of SARS-CoV.

In a further embodiment, the immune stimulatory composition contains a SARS-CoV subunit, such as glycoprotein, major capsid protein, or other gene products found to elicit humoral and/or cell mediated immune responses.

The provided immune stimulatory SARS-CoV polypeptides, constructs or vectors encoding such polypeptides, are combined with a pharmaceutically acceptable carrier or vehicle for administration as an immune stimulatory composition to human or animal subjects. In some embodiments, more than one immune stimulatory SARS-CoV polypeptide may be combined to form a single preparation.

The immunogenic formulations may be conveniently presented in unit dosage form and prepared using conventional pharmaceutical techniques. Such techniques include the step of bringing into association

the active ingredient and the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets commonly used by one of ordinary skill in the art.

In certain embodiments, unit dosage formulations are those containing a dose or unit, or an appropriate fraction thereof, of the administered ingredient. It should be understood that in addition to the ingredients particularly mentioned above, formulations encompassed herein may include other agents commonly used by one of ordinary skill in the art.

The compositions provided herein, including those for use as immune stimulatory compositions, may be administered through different routes, such as oral, including buccal and sublingual, rectal, parenteral, aerosol, nasal, intramuscular, subcutaneous, intradermal, and topical. They may be administered in different forms, including but not limited to solutions, emulsions and suspensions, microspheres, particles, microparticles, nanoparticles, and liposomes.

The volume of administration will vary depending on the route of administration. By way of example, intramuscular injections may range from about 0.1 ml to about 1.0 ml. Those of ordinary skill in the art will know appropriate volumes for different routes of administration.

A relatively recent development in the field of immune stimulatory compounds (for example, vaccines) is the direct injection of nucleic acid molecules encoding peptide antigens (broadly described in Janeway & Travers, Immunobiology: The Immune System In Health and Disease, page 13.25, Garland Publishing, Inc., New York, 1997; and McDonnell & Askari, N. Engl. J. Med. 334:42-45, 1996). Vectors that include nucleic acid molecules described herein, or that include a nucleic acid sequence encoding an immunogenic SARS-CoV polypeptide may be utilized in such DNA vaccination methods.

Thus, the term "immune stimulatory composition" as used herein also includes nucleic acid vaccines in which a nucleic acid molecule encoding a SARS-CoV polypeptide is administered to a subject in a pharmaceutical composition. For genetic immunization, suitable delivery methods known to those skilled in the art include direct injection of plasmid DNA into muscles (Wolff et al., Hum. Mol. Genet. 1:363, 1992), delivery of DNA complexed with specific protein carriers (Wu et al., J. Biol. Chem. 264:16985, 1989), co-precipitation of DNA with calcium phosphate (Benvenisty and Reshef, Proc. Natl. Acad. Sci. 83:9551, 1986), encapsulation of DNA in liposomes (Kaneda et al., Science 243:375, 1989), particle bombardment (Tang et al., Nature 356:152, 1992; Eisenbraun et al., DNA Cell Biol. 12:791, 1993), and in vivo infection using cloned retroviral vectors (Seeger et al., Proc. Natl. Acad. Sci. 81:5849, 1984). Similarly, nucleic acid vaccine preparations can be administered via viral carrier.

The amount of immunostimulatory compound in each dose of an immune stimulatory composition is selected as an amount that induces an immunostimulatory or immunoprotective response without significant, adverse side effects. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Initial injections may range from about 1 .mu.g to about 1 mg, with some embodiments having a range of about 10 .mu.g to about 800 .mu.g, and still other embodiments a range of from about 25 .mu.g to about 500 .mu.g. Following an initial administration of the immune stimulatory composition, subjects may receive one or several booster administrations, adequately spaced. Booster administrations may range from about 1 .mu.g to about 1 mg, with other embodiments having a range of about 10 .mu.g, and still others a range of about 50 .mu.g to about 500 .mu.g. Periodic boosters at intervals of 1-5 years, for instance three years, may be desirable to maintain the desired levels of protective immunity.

It is also contemplated that the provided immunostimulatory molecules and compositions can be administered to a subject indirectly, by first stimulating a cell in vitro, which stimulated cell is thereafter administered to the subject to elicit an immune response. Additionally, the pharmaceutical or immune stimulatory compositions or methods of treatment may be administered in combination with other therapeutic treatments.

VIII. Kits

Also provided herein are kits useful in the detection and/or diagnosis of SARS-CoV. This includes kits for use with nucleic acid and protein detection methods, such as those disclosed herein.

The SARS-CoV-specific oligonucleotide primers and probes described herein can be supplied in the form of a kit for use in detection of SARS-CoV. In such a kit, an appropriate amount of one or more of the oligonucleotides is provided in one or more containers, or held on a substrate. An oligonucleotide primer or probe can be provided in an aqueous solution or as a freeze-dried or lyophilized powder, for instance. The container(s) in which the oligonucleotide(s) are supplied can be any conventional container that is capable of holding the supplied form, for instance, microfuge tubes, ampoules, or bottles. In some applications, pairs of primers are provided in pre-measured single use amounts in individual (typically disposable) tubes or equivalent containers. With such an arrangement, the sample to be tested for the presence of a SARS-CoV nucleic acid can be added to the individual tubes and amplification carried out directly.

The amount of each oligonucleotide supplied in the kit can be any appropriate amount, and can depend on the market to which the product is directed. For instance, if the kit is adapted for research or clinical use, the amount of each oligonucleotide primer provided would likely be an amount sufficient to prime several PCR amplification reactions. General guidelines for determining appropriate amounts can be found, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001; Ausubel et al. (eds.), Short Protocols in Molecular Biology, John Wiley and Sons, New York, N.Y., 1999; and Innis et al., PCR Applications, Protocols for Functional Genomics, Academic Press, Inc., San Diego, Calif., 1999. A kit can include more than two primers, in order to facilitate the amplification of a larger number of SARS-CoV nucleotide sequences. In some embodiments, kits also include one or more reagents necessary to carry out in vitro amplification reactions, including DNA sample preparation reagents, appropriate buffers (for example, polymerase buffer), salts (for example, magnesium chloride), and deoxyribonucleotides (dNTP5).

Kits can include either labeled or unlabeled oligonucleotide primers and/or probes for use in detection of SARS-CoV nucleotide sequences. The appropriate sequences for such a probe will be any sequence that falls between the annealing sites of the two provided oligonucleotide primers, such that the sequence that the probe is complementary to is amplified during the amplification reaction.

One or more control sequences for use in the amplification reactions also can be supplied in the kit. In other particular embodiments, the kit includes equipment, reagents, and instructions for extracting and/ or purifying nucleotides from a sample.

Kits for the detection of SARS-CoV antigen include for instance at least one SARS-CoV antigenspecific binding agent (for example, a polyclonal or monoclonal antibody or antibody fragment). The kits may also include means for detecting antigen:specific binding agent complexes, for instance the specific binding agent may be detectably labeled. If the specific binding agent is not labeled, it may be detected by second antibodies or protein A, for example, which may also be provided in some kits in one or more separate containers. Such techniques are well known.

Another example of an assay kit provided herein is a recombinant SARS-CoV-specific polypeptide (or fragment thereof) as an antigen and an enzyme-conjugated anti-human antibody as a second antibody. Examples of such kits also can include one or more enzymatic substrates. Such kits can be used to test if a sample from a subject contains antibodies against a SARS-CoV-specific protein.

The subject matter of the present disclosure is further illustrated by the following non-limiting Examples.

EXAMPLES

Example 1

Isolation and Characterization of SARS-CoV

Virus Isolation and Ultrastructural Characterization

This example describes the original isolation and characterization of a new human coronavirus from patients with SARS.

A variety of clinical specimens (blood, serum, material from oropharyngeal swabs or washings, material from nasopharyngeal swabs, and tissues of major organs collected at autopsy) from patients meeting the case definition of SARS were sent to the Centers for Disease Control and Prevention (CDC) as part of the etiologic investigation of SARS. These samples were inoculated onto a number of

continuous cell lines, including Vero E6, NCI-H292, MDCK, LLC-MK2, and B95-8 cells, and into suckling ICR mice by the intracranial and intraperitoneal routes. All cultures were observed daily for CPE. Maintenance medium was replenished at day seven, and cultures were terminated fourteen days after inoculation. Any cultures exhibiting identifiable CPE were subjected to several procedures to identify the cause of the effect. Suckling mice were observed daily for fourteen days, and any sick or dead mice were further tested by preparing a brain suspension that was filtered and subcultured. Mice that remained well after fourteen days were killed, and their test results were recorded as negative.

Two cell lines, Vero E6 cells and NCI-H292 cells, inoculated with oropharyngeal specimens from Patient 16 (a 46 year old male physician with an epidemiologic link to a hospital with multiple SARS patients) initially showed CPE (Table 1)

TABLE-US-00002 TABLE 1 Specimens from patients with SARS that were positive for SARS-CoV by one or more methods*. Exposure Findings Patient and on Chest Hospital- Serologic No Setting Age/ Sex Radiograph ization Results Specimen Isolation RT-PCR 1 Singapore, 53 yr/F Pneumonia Yes + Nasal, oropharyngeal - Not hospital swabs done 2.dagger. Hong Kong, 36 yr/F Pneumonia Yes + Nasal, swab - Not hotel done 3 Hong Kong, 22 yr/M Pneumonia Yes + Swab - - hotel 4.dagger. Hong Kong, 39 yr/M Pneumonia Yes + Nasal, pharyngeal swab - - hotel 5 Hong Kong, 49 Yr/M Pneumonia Yes Not Sputum + + hotel done 6.dagger-dbl. Hong Kong, 46 yr/M Pneumonia Yes + Kidney, lung, broncho-+.sctn. + hotel alveolar lavage 7 Vietnam, Adult/ Pneumonia Yes - Oropharyngeal wash + + hospital unknown 8 Vietnam, Adult/ Pneumonia Yes - Oropharyngeal wash - + hospital unknown 9 Vietnam, Adult/ Pneumonia Yes - Oropharyngeal wash - + hospital unknown 10 Vietnam, Adult/ Pneumonia Yes - Oropharyngeal wash - + hospital unknown 11 Vietnam, Adult/ Pneumonia Yes - Oropharyngeal wash - + hospital unknown 12 Vietnam, Adult/ Pneumonia Yes - Oropharyngeal wash - + hospital unknown 13 Vietnam, Adult/ Pneumonia Yes - Oropharyngeal wash + + hospital unknown 14 Vietnam, Adult/ Pneumonia Yes - Oropharyngeal wash - + hospital unknown 15 Vietnam, Adult/ Pneumonia Yes -Oropharyngeal wash - + hospital unknown 16 Vietnam, 46 yr/M Pneumonia Yes + Nasal, oropharyngeal + + hospital swabs 17 Canada, 43 yr/M Pneumonia Yes Not Lung, bone marrow family done 18 Taiwan, 51 yr/F Pneumonia Yes - Sputum - + family 19 Hong Kong, Adult/F Pneumonia Yes + Oropharyngeal wash - + hotel *Plus signs denote positive results, and minus signs negative results. The serologic and RT-PCR assays were not necessarily performed on samples obtained at the same time. .dagger. This was a late specimen, antibody positive at first sample. .daggerdbl.Travel included China, Hong Kong (hotel), and Hanoi (the patient was the index patient in the French Hospital). .sctn.Isolation was from the kidney only. Isolation was from the oropharyngeal only.

The CPE in the Vero E6 cells was first noted on the fifth day post-inoculation; it was focal, with cell rounding and a refractive appearance in the affected cells that was soon followed by cell detachment (FIG. 1A). The CPE spread quickly to involve the entire cell monolayer within 24 to 48 hours. Subculture of material after preparation of a master seed stock (used for subsequent antigen production) resulted in the rapid appearance of CPE, as noted above, and in complete destruction of the monolayer in the inoculated flasks within 48 hours. Similar CPE was also noted in four additional cultures: three cultures of respiratory specimens (two oropharyngeal washes and one sputum specimen) and one culture of a suspension of kidney tissue obtained at autopsy. In these specimens, the initial

CPE was observed between day two and day four and, as noted above, the CPE rapidly progressed to involve the entire cell monolayer.

Tissue culture samples showing CPE were prepared for electron-microscopical examination. Negativestain electron-microscopical specimens were prepared by drying culture supernatant, mixed 1:1 with 2.5% paraformaldehyde, onto Formvarcarbon-coated grids and staining with 2% methylamine tungstate. Thin-section electron-microscopical specimens were prepared by fixing a washed cell pellet with 2.5% glutaraldehyde and embedding the cell pellet in epoxy resin. In addition, a master seed stock was prepared from the remaining culture supernatant and cells by freeze-thawing the culture flask, clarifying the thawed contents by centrifugation at 1000.times.g, and dispensing the supernatant into aliquots stored in gas phase over liquid nitrogen. The master seed stock was subcultured into 850-cm.sup.2 roller bottles of Vero E6 cells for the preparation of formalin-fixed positive control cells for immunohistochemical analysis, mixed with normal Vero E6 cells, and gamma-irradiated for preparation of spot slides for IFA tests or extracted with detergent and gamma-irradiated for use as an ELISA antigen for antibody tests.

Examination of CPE-positive Vero E6 cells by thin-section electron microscopy revealed characteristic coronavirus particles within the cisternae of the rough endoplasmic reticulum and in vesicles (FIG. 2A) (Becker et al., J. Virol. 1:1019-27, 1967; Oshiro et al. J. Gen. Virol. 12:161-8, 1971). Extracellular particles were found in large clusters and adhering to the surface of the plasma membrane. Negative-stain electron microscopy identified coronavirus particles, 80 to 140 nm in diameter, with 20- to 40-nm complex surface projections surrounding the periphery (FIG. 2B). Hemagglutinin esterase-type glycoprotein projections were not seen.

The isolation and growth of a human-derived coronavirus in Vero E6 cells were unexpected. The previously known human coronaviruses are notably fastidious, preferring select cell lines, organ culture, or suckling mice for propagation. The only human or animal coronavirus which has been shown to grow in Vero E6 cells is PEDV, and it requires the addition of trypsin to culture medium for growth in the cells. Moreover, PEDV adapted to growth in Vero E6 cells results in a strikingly different CPE, with cytoplasmic vacuoles and the formation of large syncytia. Syncytial cells were only observed occasionally in monolayers of Vero E6 cells infected with the SARS-CoV; they clearly do not represent the dominant CPE.

Reverse Transcription-Polymerase Chain Reaction and Sequencing

For RT-PCR assays, cell-culture supernatants were placed in lysis buffer. RNA extracts were prepared from 100 .mu.l of each specimen (or culture supernatant) with the automated NucliSens extraction system (bioMerieux, Durham, N.C.). Initially, degenerate, inosine-containing primers IN-2 (+) 5'GGGTTGGGACTA TCCTAAGTGTGA3' (SEQ ID NO: 34) and IN-4(-) 5'TAACACACAACICCATCA TCA3' (SEQ ID NO: 35) were designed to anneal to sites encoding conserved amino acid motifs that were identified on the basis of alignments of available coronavirus ORF1a, ORF1b, S, HE, M, and N gene sequences. Additional, SARS-specific, primers Cor-p-F2 (+) 5'CTAACATGCTTAGGATAATGG3' (SEQ ID NO: 13), Cor-p-F3 (+) 5'GCCTCTTGTTCTTGCTCGC3' (SEQ ID NO: 14), and Cor-p-R1 (-) 5'

CAGGTAAGCGTAAAACTCATC3' (SEQ ID NO: 15) were designed as sequences were generated from RT-PCR products amplified with the degenerate primers. These SARS-specific primers were used to test patient specimens for SARS (see below). Primers used for specific amplification of human metapneumovirus have been described by Falsey et al. (J. Infect. Dis. 87:785-90, 2003).

For RT-PCR products of less than 3 kb, cDNA was synthesized in a 20 .mu.l reaction mixture containing 500 ng of RNA, 200 U of Superscript.TM. II reverse transcriptase (Invitrogen Life Technologies, Carlsbad, Calif.), 40 U of RNasin (Promega Corp., Madison, Wis.), 100 mM each dNTP (Roche Molecular Biochemicals, Indianapolis, Ind.), 4 .mu.l of 5.times. reaction buffer (Invitrogen Life Technologies, Carlsbad, Calif.), and 200 pmol of the reverse primer. The reaction mixture, except for the reverse transcriptase, was heated to 70.degree. C. for 2 minutes, cooled to 4.degree. C. for 5 minutes and then heated to 42.degree. C. in a thermocycler. The mixture was held at 42.degree. C. for 4 minutes, and then the reverse transcriptase was added, and the reactions were incubated at 42.degree. C. for 45 minutes. Two microliters of the cDNA reaction was used in a 50 .mu.l PCR reaction containing 67 mM Tris-HCl (pH 8.8), 1 mM each primer, 17 mM ammonium sulfate, 6 mM EDTA, 2 mM MgCl.sub.2, 200 mM each dNTP, and 2.5 U of Taq DNA polymerase (Roche Molecular Biochemicals, Indianapolis, Ind.). The thermocycler program for the PCR consisted of 40 cycles of denaturation at 95.degree. C. for 30 seconds, annealing at 42.degree. C. for 30 seconds, and extension at 65.degree. C. for 30 seconds. For SARS-CoV-specific primers, the annealing temperature was increased to 55.degree. C.

For amplification of fragments longer than 3 kb, regions of the genome between sections of known sequence were amplified by means of a long RT-PCR protocol and SARS-CoV-specific primers. Firststrand cDNA synthesis was performed at 42.degree. C. or 50.degree. C. using Superscript.TM. II RNase H reverse transcriptase (Invitrogen Life Technologies, Carlsbad, Calif.) according to the manufacturer's instructions with minor modifications. Coronavirus-specific primers (500 ng) and SARS-CoV RNA (350 ng) were combined with the PCR Nucleotide Mix (Roche Molecular Biochemicals, Indianapolis, Ind.), heated for 1 minute at 94.degree. C., and cooled to 4.degree. C. in a thermocycler. The 5.times. first-strand buffer, dithiothreitol (Invitrogen Life Technologies, Carlsbad, Calif.), and Protector RNase Inhibitor (Roche Molecular Biochemicals, Indianapolis, Ind.) were added, and the samples were incubated at 42.degree. C. or 50.degree. C. for 2 minutes. After reverse transcriptase (200 U) was added, the samples were incubated at 42.degree. C. or 50.degree. C. for 1.5 to 2 hours. Samples were inactivated at 70.degree. C. for 15 minutes and subsequently treated with 2 U of RNase H (Roche Molecular Biochemicals, Indianapolis, Ind.) at 37.degree. C. for 30 minutes. Long RT-PCR amplification of 5- to 8-kb fragments was performed using Taq Plus Precision (Stratagene, La Jolla, Calif.) and AmpliWax PCR Gem 100 beads (Applied Biosystems; Foster City, Calif.) for "hot start" PCR with the following thermocycling parameters: denaturation at 94.degree. C. for 1 minute followed by 35 cycles of 94.degree. C. for 30 seconds, 55.degree. C. for 30 seconds, an increase of 0.4 degrees per second up to 72.degree. C., and 72.degree. C. for 7 to 10 minutes, with a final extension at 72.degree. C. for 10 minutes. RT-PCR products were separated by electrophoresis on 0.9% agarose TAE gels and purified by use of a QIAquick Gel Extraction Kit (Qiagen, Inc., Santa Clarita, Calif.).

In all cases, the RT-PCR products were gel-isolated and purified for sequencing by means of a QIAquick Gel Extraction kit (Qiagen, Inc., Santa Clarita, Calif.). Both strands were sequenced by

automated methods, using fluorescent dideoxy-chain terminators (Applied Biosystems; Foster City, Calif.).

The sequence of the leader was obtained from the subgenomic mRNA coding for the N gene and from the 5' terminus of genomic RNA. The 5' rapid amplification of cDNA ends (RACE) technique (Harcourt et al., Virology 271:334-49, 2000) was used with reverse primers specific for the N gene or for the 5' untranslated region. RACE products were either sequenced directly or were cloned into a plasmid vector before sequencing. A primer that was specific for the leader of SARS-CoV was used to amplify the region between the 5'-terminus of the genome and known sequences in the rep gene. The 3'-terminus of the genome was amplified for sequencing by use of an oligo-(dT) primer and primers specific for the N gene.

Once the complete SARS-CoV genomic sequence had been determined, it was confirmed by sequencing a series of independently amplified RT-PCR products spanning the entire genome. Positiveand negative-sense sequencing primers, at intervals of approximately 300 nt, were used to generate a confirmatory sequence with an average redundancy of 9.1. The confirmatory sequence was identical to the original sequence. The genomic sequence (SEQ ID NO: 1) was published in the GenBank sequence database (Accession No. AY278741) on Apr. 21, 2003.

Sequence Analysis

Predicted amino acid sequences were compared with those from reference viruses representing each species for which complete genomic sequence information was available: group 1 representatives included human coronavirus 229E (GenBank Accession No. AF304460), porcine epidemic diarrhea virus (GenBank Accession No. AF353511), and transmissible gastroenteritis virus (GenBank Accession No. AF271965); group 2 representatives included bovine coronavirus (GenBank Accession No. AF220295) and mouse hepatitis virus (GenBank Accession No. AF201929); group 3 was represented by infectious bronchitis virus (GenBank Accession No. M95169). Sequences for representative strains of other coronavirus species for which partial sequence information was available were included for some of the structural protein comparisons: group 1 representative strains included canine coronavirus (GenBank Accession No. D13096), feline coronavirus (GenBank Accession No. AY204704), and porcine respiratory coronavirus (GenBank Accession No. Z24675); and group 2 representatives included three strains of human coronavirus OC43 (GenBank Accession Nos. M76373, L14643 and M93390), porcine hemagglutinating encephalomyelitis virus (GenBank Accession No. AY078417), and rat coronavirus (GenBank Accession No. AF207551).

Partial nucleotide sequences of the polymerase gene were aligned with published coronavirus sequences, using CLUSTAL W for Unix (version 1.7; Thompson et al., Nucleic Acids Res. 22:4673-80, 1994). Phylogenetic trees were computed by maximum parsimony, distance, and maximum likelihood-based criteria analysis with PAUP (version 4.0.d10; Swofford ed., Phylogenetic Analysis using Parsimony and other Methods, Sinauer Associates, Sunderland, Mass.). When compared with other human and animal coronaviruses, the nucleotide and deduced amino acid sequence from this region had similarity scores ranging from 0.56 to 0.63 and from 0.57 to 0.74, respectively. The highest sequence similarity was obtained with group II coronaviruses. The maximum-parsimony tree obtained

from the nucleotide-sequence alignment is shown in FIG. 3. Bootstrap analyses of the internal nodes at the internal branches of the tree provided strong evidence that the SARS-CoV is genetically distinct from other known coronaviruses.

Microarray analyses (using a long oligonucleotide DNA microarray with array elements derived from highly conserved regions within viral families) of samples from infected and uninfected cell cultures gave a positive signal for a group of eight oligonucleotides derived from two virus families: Coronaviridae and Astroviridae (Wang et al., PNAS 99:15687-92, 2002). All of the astroviruses and two of the coronavirus oligonucleotides share a consensus sequence motif that maps to the extreme 3'- end of astroviruses and two members of the coronavirus family: avian infectious bronchitis and turkey coronavirus (Jonassen et al., J. Gen. Virol. 79:715-8, 1998). Results were consistent with the identity of the isolate as a coronavirus.

Additional sequence alignments and neighbor-joining trees were generated by using ClustalX (Thompson et al., Nucleic Acids Res. 25:4876-82, 1997), version 1.83, with the Gonnet protein comparison matrix. The resulting trees were adjusted for final output by using treetool version 2.0.1. Uncorrected pairwise distances were calculated from the aligned sequences by using the Distances program from the Wisconsin Sequence Analysis Package, version 10.2 (Accelrys, Burlington, Mass.). Distances were converted to percent identity by subtracting from 100. The amino acid sequences for three well-defined enzymatic proteins encoded by the rep gene and the four major structural proteins of SARS-CoV were compared with those from representative viruses for each of the species of coronavirus for which complete genomic sequence information was available (FIG. 4, Table 2). The topologies of the resulting phylograms are remarkably similar (FIG. 4). For each protein analyzed, the species formed monophyletic clusters consistent with the established taxonomic groups. In all cases, SARS-CoV sequences segregated into a fourth, well-resolved branch. These clusters were supported by bootstrap values above 90% (1000 replicates). Consistent with pairwise comparisons between the previously characterized coronavirus species (Table 2), there was greater sequence conservation in the enzymatic proteins (3CL.sup.pro, polymerase (POL), and helicase (HEL)) than among the structural proteins (S, E, M, and N). These results indicate that SARS-CoV is not closely related to any of the previously characterized coronaviruses and forms a distinct group within the genus Coronavirus.

TABLE-US-00003 TABLE 2 Pairwise amino acid identities of coronavirus proteins. Group Virus 3CLPRO POL HEL S E M N Pairwise Amino Acid Identity (Percent) G1 HCoV-229E 40.1 58.8 59.7 23.9 22.7 28.8 23.0 PEDV 44.4 59.5 61.7 21.7 17.6 31.8 22.6 TGEV 44.0 59.4 61.2 20.6 22.4 30.0 25.6 G2 BCoV 48.8 66.3 68.3 27.1 20.0 39.7 31.9 MHV 49.2 66.5 67.3 26.5 21.1 39.0 33.0 G3 IBV 41.3 62.5 58.6 21.8 18.4 27.2 24.0 Predicted Protein Length (aa) SARS-CoV 306 932 601 1255 76 221 422 CoV Range 302-307 923-940 506-600 1173-1452 76-108 225-262 377-454

Example 2

Detection of SARS-CoV in a Subject

This example demonstrates the detection of SARS-CoV in patient specimens using SARS-CoV-specific primers.

The SARS-specific primers Cor-p-F2 (SEQ ID NO: 13), Cor-p-F3 (SEQ ID NO: 14) and Cor-p-R1 (SEQ ID NO: 15) were used to test patient specimens for SARS. One primer for each set was 5'-end-labeled with 6-FAM to facilitate GeneScan analysis. One-step amplification reactions were performed with the Access RT-PCR System (Promega, Madison, Wis.) as described by Falsey et al., J. Infect. Dis. 87:785-90, 2003. Positive and negative RT-PCR controls, containing standardized viral RNA extracts, and nuclease-free water were included in each run. Amplified 6-FAM-labeled products were analyzed by capillary electrophoresis on an ABI 3100 Prism Genetic Analyzer with GeneScan software (version 3.1.2; Applied Biosystems; Foster City, Calif.). Specimens were considered positive for SARS-CoV if the amplification products were within one nucleotide of the expected product size (368 nucleotides for Cor-p-F2 or Cor-p-R1 and 348 nucleotides for Cor-p-F3 or Cor-p-R1) for both specific primer sets, as confirmed by a second PCR reaction from another aliquot of RNA extract in a separate laboratory. Where DNA yield was sufficient, the amplified products were also sequenced. Additionally, as described above, microarray-based detection of SARS-CoV in patient specimens was carried out (Wang et al., PNAS 99:15687-92, 2002 and Bohlander et al., Genomics 13:1322-24, 1992).

Example 3

Immunohistochemical and Histopathological Analysis, and Electron-Microscopical Analysis of Bronchoalveolar Lavage Fluid

This example illustrates immunohistochemical, histopathological and electron-microscopical analysis of Vero E6 cells infected with the SARS-CoV and tissue samples from SARS patients.

Formalin-fixed, paraffin-embedded Vero E6 cells infected with the SARS-CoV and tissues obtained from patients with SARS were stained with hematoxylin and eosin and various immunohistochemical stains. Immunohistochemical assays were based on a method described previously for hantavirus (Zaki et al., Amer. J. Pathol. 146:552-79, 1995). Briefly, 4-.mu.m sections were deparaffinized, rehydrated, and digested in Proteinase K for 15 minutes. Slides were then incubated for 60 minutes at room temperature with monoclonal antibodies, polyclonal antiserum or ascitic fluids derived from animal species with reactivities to various known coronaviruses, and with a convalescent-phase serum specimen from a patient with SARS.

Optimal dilutions of the primary antibodies were determined by titration experiments with coronavirusinfected cells from patients with SARS and with noninfected cells or, when available, with concentrations recommended by the manufacturers. After sequential application of the appropriate biotinylated link antibody, avidin-alkaline phosphatase complex, and naphthol-fast red substrate, sections were counterstained in Mayer's hematoxylin and mounted with aqueous mounting medium. The following antibody and tissue controls were used: serum specimens from noninfected animals, various coronavirus-infected cell cultures and animal tissues, noninfected cell cultures, and normal human and animal tissues. Tissues from patients were also tested by immunohistochemical assays for various other viral and bacterial pulmonary pathogens. In addition, a BAL specimen was available from one patient for thin-section electron-microscopical evaluation.

Lung tissues were obtained from the autopsy of three patients and by open lung biopsy of one patient, 14-19 days following onset of SARS symptoms. Confirmatory laboratory evidence of infection with coronavirus was available for two patients (patients 6 and 17) and included PCR amplification of coronavirus nucleic acids from tissues, viral isolation from BAL fluid or detection of serum antibodies reactive with coronavirus (Table 1). For two patients, no samples were available for molecular, cell culture, or serological analysis; however, both patients met the CDC definition for probable SARS cases and had strong epidemiologic links with laboratory-confirmed SARS cases. Histopathologic evaluation of lung tissues of the four patients showed diffuse alveolar damage at various levels of progression and severity. Changes included hyaline membrane formation, interstitial mononuclear inflammatory infiltrates, and desquamation of pneumocytes in alveolar spaces (FIG. 5A). Other findings identified in some patients included focal intraalveolar hemorrhage, necrotic inflammatory debris in small airways, and organizing pneumonia. Multinucleated syncytial cells were identified in the intraalveolar spaces of two patients who died 14 and 17 days, respectively, after onset of illness. These cells contained abundant vacuolated cytoplasm with cleaved and convoluted nuclei. No obvious intranuclear or intracytoplasmic viral inclusions were identified (FIG. 5B), and electron-microscopical examination of a limited number of these syncytial cells revealed no coronavirus particles. No definitive immunostaining was identified in tissues from SARS patients with the use of a battery of immunohistochemical stains reactive with coronaviruses from antigenic groups I, II, and III. In addition, no staining of patient tissues was identified with the use of immunohistochemical stains for influenzaviruses A and B, adenoviruses, Hendra and Nipah viruses, human metapneumovirus, respiratory syncytial virus, measles virus, Mycoplasma pneumoniae, and Chlamydia pneumoniae.

Evaluation of Vero E6 cells infected with coronavirus isolated from a patient with SARS revealed viral CPE that included occasional multinucleated syncytial cells but no obvious viral inclusions (FIG. 5C). Immunohistochemical assays with various antibodies reactive with coronaviruses from antigenic group I, including HCoV-229E, FIPV and TGEV, and with an immune serum specimen from a patient with SARS, demonstrated strong cytoplasmic and membranous staining of infected cells (FIG. 5C and Table 3); however, cross-reactivity with the same immune human serum sample and FIPV antigen was not observed. No staining was identified with any of several monoclonal or polyclonal antibodies reactive with coronaviruses in antigenic group II (HCoV-OC43, BCoV and MHV) or group III (TCoV and IBV-Avian). Electron microscopical examination of a BAL fluid from one patient revealed many coronavirus-infected cells (FIGS. 6A-B).

TABLE-US-00004 TABLE 3 Immunohistochemical reactivities of various polyclonal group I anticoronavirus reference antiserum samples with a coronavirus isolated from a patient with SARS and with selected antigenic group I coronaviruses. Immunohistochemical reactivity of antiserum with coronavirus-infected culture cells HCoV-229E SARS-CoV (mouse 3T3- FIPV-1 Antiserum (Vero E6) hAPN) (BHK-fAPN) Convalescent- + + - phase SARS (patient 3) Guinea pig anti- + + - HCoV-229E Rabbit anti + + + HCoV-229E Feline anti-FIPV- + + + 1 Porcine anti- + - + TGEV

Example 4

SARS-CoV Serologic Analysis

This example illustrates representative methods of performing serological analysis of SARS-CoV.

Spot slides were prepared by applying 15 .mu.l of the suspension of gamma-irradiated mixed infected and noninfected cells onto 12-well Teflon-coated slides. Slides were allowed to air dry before being fixed in acetone. Slides were then stored at -70.degree. C. until used for IFA tests (Wulff and Lange, Bull. WHO 52:429-36, 1975). An ELISA antigen was prepared by detergent extraction and subsequent gamma irradiation of infected Vero E6 cells (Ksiazek et al., J. Infect. Dis. 179 (suppl. 1):S191-8, 1999). The optimal dilution (1:1000) for the use of this antigen was determined by checkerboard titration against SARS patient serum from the convalescent phase; a control antigen, similarly prepared from uninfected Vero E6 cells, was used to control for specific reactivity of tested sera. The conjugates used were goat antihuman IgG, IgA, and IgM conjugated to fluorescein isothiocyanate and horseradish peroxidase (Kirkegaard and Perry, Gaithersburg, Md.), for the IFA test and ELISA, respectively. Specificity and cross-reactivity of a variety of serum samples to the newly identified virus were evaluated by using the tests described herein. For this evaluation, serum from SARS patients in Singapore, Bangkok and Hong Kong was used, along with serum from healthy blood donors from the CDC serum bank and from persons infected with known human coronavirus (human coronaviruses OC43 and 229E) (samples provided by E. Walsh and A. Falsey, University of Rochester School of Medicine and Dentistry, Rochester, N.Y.).

Spot slides with infected cells reacted with serum from patients with probable SARS in the convalescent phase (FIG. 1B). Screening of a panel of serum from patients with suspected SARS from Hong Kong, Bangkok, Singapore as well as the United States showed a high level of specific reaction with infected cells, and conversion from negative to positive reactivity or diagnostic rises in the IFA test by a factor of four. Similarly, tests of these same serum samples with the ELISA antigen showed high specific signal in the convalescent-phase samples and conversion from negative to positive antibody reactivity or diagnostic increases in titer (Table 4).

TABLE-US-00005 TABLE 4 Results of serological testing with both IFA assay and ELISA in SARS patients tested against the newly isolated human coronavirus. Serum Days After Source No. Onset ELISA Titer* IFA Titer* Hong Kong 1.1 4 <100 <25 Hong Kong 1.2 13 .gtoreq.6400 1600 Hong Kong 2.1 11 400 100 Hong Kong 2.2 16 1600 200 Hong Kong 3.1 7 <100 <25 Hong Kong 3.2 17 .gtoreq. 6400 800 Hong Kong 4.1 8 <100 <25 Hong Kong 4.2 13 1600 50 Hong Kong 5.1 10 100 <25 Hong Kong 5.2 17 .gtoreq. 6400 1600 Hong Kong 6.1 12 1600 200 Hong Kong 6.2 20 .gtoreq.6400 6400 Hong Kong 7.1 17 400 50 Hong Kong 7.2 24 .gtoreq.6400 3200 Hong Kong 9.2 11 .gtoreq.6400 1600 Bangkok 1.1 2 <100 <25 Bangkok 1.2 4 <100 <25 Bangkok 1.3 7 <100 <25 Bangkok 1.4 15 1600 200 United States 1.1 2 <100 <25 United States 1.2 6 400 50 United States 1.3 13 .gtoreq.6400 800 Singapore 1.1 2 100 <25 Singapore 3.2 11 .gtoreq.6400 400 Singapore 4.1 5 100 <25 Singapore 4.2 16 1600 400 *Reciprocal of dilution

Information from the limited numbers of samples tested suggests that antibody is first detectable by IFA assay and ELISA between one and two weeks after the onset of symptoms in the patient. IFA testing and ELISA of a panel of 384 randomly selected serum samples (from U.S. blood donors) were negative

for antibodies to the new coronavirus, with the exception of one specimen that had minimal reactivity on ELISA. A panel of paired human serum samples with diagnostic increases (by a factor of four or more) in antibody (with very high titers to the homologous viral antigen in the convalescent-phase serum) to the two known human coronaviruses, OC43 (13 pairs) and 229E (14 pairs), showed no reactivity in either acute- or convalescent-phase serum with the newly isolated coronavirus by either the IFA test or the ELISA.

Example 5

Poly(A).sup.+RNA Isolation and Northern Hybridization

This example illustrates a representative method of Northern hybrididization to detect SARS-CoV messages in Vero E6 cells.

Total RNA from infected or uninfected Vero E6 cells was isolated with Trizol reagent (Invitrogen Life Technologies, Carlsbad, Calif.) used according to the manufacturer's recommendations. Poly(A).sup. +RNA was isolated from total RNA by use of the Oligotex Direct mRNA Kit (Qiagen, Inc., Santa Clarita, Calif.), following the instructions for the batch protocol, followed by ethanol precipitation. RNA isolated from 1 cm.sup.2 of cells was separated by electrophoresis on a 0.9% agarose gel containing 3.7% formaldehyde, followed by partial alkaline hydrolysis (Ausubel et al. eds. Current Protocols in Molecular Biology, vol. 1, John Wiley & Sons, Inc., NY, N.Y., Ch. 4.9, 1996). RNA was transferred to a nylon membrane (Roche Molecular Biochemicals, Indianapolis, Ind.) by vacuum blotting (Bio-Rad, Hercules, Calif.) and fixed by UV cross-linking. The DNA template for probe synthesis was generated by RT-PCR amplification of SARS-CoV nt 29,083 to 29,608 (SEQ ID NO: 1), by using a reverse primer containing a T7 RNA polymerase promoter to facilitate generation of a negative-sense riboprobe. In vitro transcription of the digoxigenin-labeled riboprobe, hybridization, and detection of the bands were carried out with the digoxigenin system by using manufacturer's recommended procedures (Roche Molecular Biochemicals, Indianapolis, Ind.). Signals were visualized by chemiluminescence and detected with x-ray film.

Example 6

SARS-CoV Genome Organization

This example illustrates the genomic organization of the SARS-CoV genome, including the location of SARS-CoV ORFs.

The genome of SARS-CoV is a 29,727-nucleotide, polyadenylated RNA, and 41% of the residues are G or C (range for published coronavirus complete genome sequences, 37% to 42%). The genomic organization is typical of coronaviruses, having the characteristic gene order [5'-replicase (rep), spike (S), envelope (E), membrane (M), nucleocapsid (N)-3'] and short untranslated regions at both termini (FIG. 7A, Table 5). The SARS-CoV rep gene, which comprises approximately two-thirds of the genome, encodes two polyproteins (encoded by ORF1a and ORF1b) that undergo co-translational proteolytic processing. There are four ORFs downstream of rep that encode the structural proteins, S,

E, M, and N, which are common to all known coronaviruses. The hemagglutinin-esterase gene, which is present between ORF1b and S in group 2 and some group 3 coronaviruses (Lai and Holmes, in Fields Virology, eds. Knipe and Howley, Lippincott Williams and Wilkins, New York, 4.sup.th edition, 2001, Ch. 35), was not found in SARS-CoV.

Coronaviruses also encode a number of non-structural proteins that are located between S and E, between M and N, or downstream of N. These non-structural proteins, which vary widely among the different coronavirus species, are of unknown function and are dispensable for virus replication (Lai and Holmes, in Fields Virology, eds. Knipe and Howley, Lippincott Williams and Wilkins, New York, 4.sup.th edition, 2001, Ch. 35). The genome of SARS-CoV contains ORFs for five non-structural proteins of greater than 50 amino acids (FIG. 7B, Table 5). Two overlapping ORFs encoding proteins of 274 and 154 amino acids (termed X1 (SEQ ID NO: 5) and X2 (SEQ ID NO: 6), respectively) are located between S (SEQ ID NO: 4) and E (SEQ ID NO: 7). Three additional non-structural genes, X3 (SEQ ID NO: 9), X4 (SEQ ID NO: 10), and X5 (SEQ ID NO: 11) (encoding proteins of 63, 122, and 84 amino acids, respectively), are located between M (SEQ ID NO: 8) and N (SEQ ID NO: 12). In addition to the five ORFs encoding the non-structural proteins described above, there are also two smaller ORFs between M and N, encoding proteins of less than 50 amino acids. Searches of the GenBank database (BLAST and FastA) indicated that there is no significant sequence similarity between these non-structural proteins of SARS-CoV and any other proteins.

The coronavirus rep gene products are translated from genomic RNA, but the remaining viral proteins are translated from subgenomic mRNAs that form a 3'-coterminal nested set, each with a 5'-end derived from the genomic 5'-leader sequence. The coronavirus subgenomic mRNAs are synthesized through a discontinuous transcription process, the mechanism of which has not been unequivocally established (Lai and Holmes, in Fields Virology, eds. Knipe and Howley, Lippincott Williams and Wilkins, New York, 4.sup.th edition, 2001, Ch. 35; Sawicki and Sawicki, Adv. Exp. Med. Biol. 440:215-19, 1998). The SARS-CoV leader sequence was mapped by comparing the sequence of 5'-RACE products synthesized from the N gene mRNA with those synthesized from genomic RNA. A sequence, AAACGAAC (nucleotides 65-72 of SEQ ID NO: 1), was identified immediately upstream of the site where the N gene mRNA and genomic sequences diverged. This sequence was also present upstream of ORF1a and immediately upstream of five other ORFs (Table 5), suggesting that it functions as the conserved core of the transcriptional regulatory sequence (TRS).

In addition to the site at the 5'-terminus of the genome, the TRS conserved core sequence appears six times in the remainder of the genome. The positions of the TRS in the genome of SARS-CoV predict that subgenomic mRNAs of 8.3, 4.5, 3.4, 2.5, 2.0, and 1.7 kb, not including the poly(A) tail, should be produced (FIGS. 7A-B, Table 5). At least five subgenomic mRNAs were detected by Northern hybridization of RNA from SARS-CoV-infected cells, using a probe derived from the 3'-untranslated region (FIG. 7C). The calculated sizes of the five predominant bands correspond to the sizes of five of the predicted subgenomic mRNAs of SARS-CoV; the possibility that other, low-abundance mRNAs are present cannot be excluded. By analogy with other coronaviruses (Lai and Holmes, in Fields Virology, eds. Knipe and Howley, Lippincott Williams and Wilkins, New York, 4.sup.th edition, 2001, Ch. 35), the 8.3-kb and 1.7-kb subgenomic mRNAs are monocistronic, directing translation of S and N, respectively, whereas multiple proteins are translated from the 4.5-kb (X1, X2, and E), 3.4-kb (M and

X3), and 2.5-kb (X4 and X5) mRNAs. A consensus TRS is not found directly upstream of the ORF encoding the predicted E protein, and a monocistronic mRNA that would be predicted to code for E could not be clearly identified by Northern blot analysis. It is possible that the 3.6-kb band contains more than one mRNA species or that the monocistronic mRNA for E is a low-abundance message.

TABLE-US-00006 TABLE 5 Locations of SARS-CoV ORFs and sizes of proteins and mRNAs Genome Location Predicted Size ORF TRS.sup.a ORF Start ORF End Protein (aa) mRNA (nt).sup.b 1a 72 265 13,398 4,378 29,727 1b 13,398 21,482 2,695 S 21,491 21,492 25,256 1,255 8,308.sup.c X1 25,265 25,268 26,089 274 4,534.sup.c X2 25,689 26,150 154 E 26,117 26,344 76 M 26,353 26,398 27,060 221 3,446.sup.c X3 27,074 27,262 63 X4 27,272 27,273 27,638 122 2,527.sup.c X5 27,778 27,864 28,115 84 2,021.sup.d N 28,111 28,120 29,385 422 1,688.sup.c .sup.aThe location is the 3'most nucleotide in the consensus TRS, AAACGAAC. .sup.bNot including poly(A). Predicted size is based on the position of the conserved TRS. .sup.cCorresponding mRNA detected by Northern blot analysis (FIG. 7C) .sup.dNo mRNA corresponding to utilization of this consensus TRS was detected by Northern blot analysis (FIG. 7C)

Example 7

Real-Time RT-PCR Assay for SARS-CoV Detection

This example demonstrates the use of SARS-CoV-specific primers and probes in a real-time RT-PCR assay to detect SARS-CoV in patient specimens.

A variant of the real-time format, based on TaqMan probe hydrolysis technology (Applied Biosystems, Foster City, Calif.), was used to analyze a total of 340 clinical specimens collected from 246 persons with confirmed or suspected SARS-CoV infection. Specimens included oro- and nasopharyngeal swabs (dry and in viral transport media), sputa, nasal aspirates and washes, BAL, and lung tissue specimens collected at autopsy.

Nucleic Acid Extraction

SARS-CoV nucleic acids were recovered from clinical specimens using the automated NucliSens extraction system (bioMerieux, Durham, N.C.). Following manufacturer's instructions, specimens received in NucliSens lysis buffer were incubated at 37.degree. C. for 30 min with intermittent mixing, and 50 .mu.L of silica suspension, provided in the extraction kit, was added and mixed. The contents of the tube were then transferred to a nucleic acid extraction cartridge and processed on an extractor workstation. Approximately 40-50 .mu.L of total nucleic acid eluate was recovered into nuclease-free vials and either tested immediately or stored at -70.degree. C.

Primers and Probes

Multiple primer and probe sets were designed from the SARS-CoV polymerase 1b (nucleic acid 13,398 to 21,482 of SEQ ID NO: 1) and nucleocapsid gene (nucleic acid 28,120 to 29,385 of SEQ ID NO: 1) sequences by using Primer Express software version 1.5 or 2.0.0 (Applied Biosystems, Foster City,

Calif.) with the following default settings: primer melting temperature (T.sub.M) set at 60.degree. C.; probe T.sub.M set at 10.degree. C. greater than the primers at approximately 70.degree. C.; and no guanidine residues permitted at the 5' probe termini. All primers and probes were synthesized by standard phosphoramidite chemistry techniques. TaqMan probes were labeled at the 5'-end with the reporter 6-FAM and at the 3'-end with the quencher Blackhole Quencher 1 (Biosearch Technologies, Inc., Novato, Calif.). Optimal primer and probe concentrations were determined by cross-titration of serial twofold dilutions of each primer against a constant amount of purified SARS-CoV RNA. Primer and probe concentrations that gave the highest amplification efficiencies were selected for further study (Table 6).

TABLE-US-00007 TABLE 6 Primers and probes used for real-time RT-PCR assays.sup.a Genomic Assay ID Primer/probe Sequence Region Primary diagnostic assay SARS1 F CATGTGTGGCGGCTCACTATAT (SEQ ID NO: 16) RNA Pol R GACACTATTAGCATAAGCAGTTGTAGCA (SEQ ID NO: 17) P TTAAACCAGGTGGAACATCATCCGGTG (SEQ ID NO: 18) SARS2 F GGAGCCTTGAATACACCCAAAG (SEQ ID NO: 19) Nucleocapsid R GCACGGTGGCAGCATTG (SEQ ID NO: 20) P CCACATTGGCACCCGCAATCC (SEQ ID NO: 21) SARS3 F CAAACATTGGCCGCAAATT (SEQ ID NO: 22) Nucleocapsid R CAATGCGTGACATTCCAAAGA (SEQ ID NO: 23) P CACAATTTGCTCCAAGTGCCTCTGCA (SEQ ID NO: 24) To confirm positive results N3 F GAAGTACCATCTGGGGGCTGAG (SEQ ID NO: 25) Nucleocapsid R CCGAAGAGCTACCCGACG (SEQ ID NO: 26) P CTCTTTCATTTTGCCGTCACCACCAC (SEQ ID NO: 27) 3'-NTR F AGCTCTCCCTAGCATTATTCACTG (SEQ ID NO: 28) 3'-NTR R CACCACATTTTCATCGAGGC (SEQ ID NO: 29) P TACCCTCGATCGTACTCCGCGT (SEQ ID NO: 30) M F TGTAGGCACTGATTCAGGTTTTG (SEQ ID NO: 31) M protein R CGGCGTGGTCTGTATTTAATTTA (SEQ ID NO: 32) P CTGCATACAACCGCTACCGTATTGGAA (SEQ ID NO: 33) .sup.aRT-PCR, reverse transcription-polymerase chain reaction; F, forward primer; R, reverse primer; P, probe; NTR, nontranslated region.

Real-Time RT-PCR Assay

The real-time RT-PCR assay was performed by using the Real-Time One-Step RT-PCR Master Mix (Applied Biosystems, Foster City, Calif.). Each 25-.mu.L reaction mixture contained 12.5 .mu.L of 2.times. Master Mix, 0.625 .mu.L of the 40.times. MultiScribe and RNase Inhibitor mix, 0.25 .mu.L of 10 .mu.M probe, 0.25 .mu.L each of 50 .mu.M forward and reverse primers, 6.125 .mu.L of nuclease-free water, and 5 .mu.L of nucleic acid extract. Amplification was carried out in 96-well plates on an iCycler iQ Real-Time Detection System (Bio-Rad, Hercules, Calif.). Thermocycling conditions consisted of 30 minutes at 48.degree. C. for reverse transcription, 10 minutes at 95.degree. C. for activation of the AmpliTaq Gold DNA polymerase, and 45 cycles of 15 seconds at 95.degree. C. and 1 minute at 60.degree. C. Each run included one SARS-CoV genomic template control and at least two no-template control for the PCR-amplification step. As a control for PCR inhibitors, and to monitor nucleic acid extraction efficiency, each sample was tested by real-time RT-PCR for the presence of the human ribonuclease (RNase) P gene (GenBank Accession No. NM.sub.--006413) by using the following primers and probe: forward primer 5'-AGATTTGGACCTGCGAGCG-3' (SEQ ID NO: 36);

reverse primer 5'-GAGCGGCTGTCTCCACAAGT-3' (SEQ ID NO: 37); probe 5'-TTCTGACC TGAAGGCTCTGCGCG-3' (SEQ ID NO: 38). The assay reaction was performed identically to that described above except that primer concentrations used were 30 .mu.M each. Fluorescence measurements were taken and the threshold cycle (C.sub.T) value for each sample was calculated by determining the point at which fluorescence exceeded a threshold limit set at the mean plus 10 standard deviations above the baseline. A test result was considered positive if two or more of the SARS genomic targets showed positive results (C.sub.T.ltoreq.45 cycles) and all positive and negative control reactions gave expected values.

While this disclosure has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations and equivalents of the preferred embodiments may be used and it is intended that the disclosure may be practiced otherwise than as specifically described herein. Accordingly, this disclosure includes all modifications encompassed within the spirit and scope of the disclosure as defined by the claims below.

SEQUENCE LISTINGS

1

38129727DNACoronavirusmisc_feature(265)..(13398)ORF 1a 1ttattaggtt tttacctacc caggaaaage caaccaacct cgatctcttg tagatctgtt 60ctctaaacga actttaaaat ctgtgtagct gtcgctcggc tgcatgccta gtgcacctac 120gcagtataaa caataataaa ttttactgtc gttgacaaga aacgagtaac tcgtccctct 180tctgcagact gcttacggtt tgccggtgt tgccggt catcagcata cctaggtttc 240gtccgggtgt gaccgaaagg taagatggag agecttgtte ttggtgteaa egagaaaaca 300eaegteeaae teagtttgee tgteetteag gttagagaeg tgetagtgeg tggetteggg 360gaetetgtgg aagaggeeet ateggaggea egtgaacaee teaaaaatgg eaettgtggt 420etagtagage tggaaaaagg cgtactgccc cagcttgaac agccctatgt gttcattaaa 480cgttctgatg ccttaagcac caatcacggc cacaaggtcg ttgagctggt tgcagaaatg 540gacggcattc agtacggtcg tagcggtata acactgggag tactcgtgcc acatgtggge 600gaaaccccaa ttgcataccg caatgttett ettegtaaga acggtaataa gggageeggt 660ggteataget atggeatega tetaaagtet tatgaettag gtgaegaget tggeaetgat 720eccattgaag attatgaaca aaaetggaae actaageatg geagtggtge acteegtgaa 780eteactegtg ageteaatgg aggtgeagte actegetatg tegacaacaa tttetgtgge 840ecagatgggt accetettga ttgeateaaa gatttteteg eaegeggg caagteaatg 900tgeactettt ccgaacaact tgattacatc gagtcgaaga gaggtgtcta ctgctgccgt 960gaccatgagc atgaaattgc ctggttcact gagcgctctg ataagagcta cgagcaccag 1020acaccettcg aaattaagag tgccaagaaa tttgacactt tcaaagggga atgcccaaag 1080tttgtgttte etettaaete aaaagtcaaa gteatteaae eaegtgttga aaagaaaaag 1140aetgagggtt teatggggeg tataegetet gtgtaeeetg ttgcatetee acaggagtgt 1200aacaatatge acttgtetae ettgatgaaa tgtaatcatt gegatgaagt tteatggeag 1260aegtgegaet ttetgaaage eacttgtgaa cattgtggea etgaaaattt agttattgaa 1320ggaeetaeta eatgtgggta eetaeetaet aatgetgtag tgaaaatgee atgteetgee 1380tgteaagaee cagagattgg acctgagcat agtgttgcag attatcacaa ccactcaaac 1440attgaaacte gactccgcaa gggaggtagg actagatgtt ttggaggctg tgtgtttgcc 1500tatgttggct gctataataa gcgtgcctac tgggttcctc gtgctagtgc tgatattggc 1560tcaggccata ctggcattac tggtgacaat gtggagacct tgaatgagga tctccttgag 1620atactgagtc gtgaacgtgt taacattaac attgttggcg attitcattt gaatgaagag 1680gttgccatca ttttggcatc tttctctgct tetacaagtg cetttattga cactataaag 1740agtettgatt acaagtettt caaaaccatt gttgagteet geggtaacta taaagttace 1800aagggaaage eegtaaaagg tgettggaac attggacaac agagateagt tttaacaeca 1860etgtgtggtt tteecteaca ggetgetggt gttateagat eaattittge gegeacaett 1920gatgeageaa accaeteaat teetgattig eaaagageag etgteaceat acttgatggt 1980attietgaae agteattaeg tettgtegae geeatggttt ataetteaga eegeeatgettt 2040aacagtgtca ttattatggc atatgtaact ggtggtcttg tacaacagac ttctcagtgg 2100ttgtctaatc ttttgggcac tactgttgaa aaactcaggc ctatctttga atggattgag 2160gcgaaactta ggcgggagt tgaatttctc aaggatgctt gggagattet caaattee 2220attacaggtg tittigacat egteaagggt caaatacagg tigetteaga taacateaag 2280gattgtgaa aatgetteat tgatgttgtt aacaaggeae tegaaatgtg eattgateaa 2340gteetateg etggegeaaa gttgcgatca ctcaacttag gtgaagtctt catcgctcaa 2400agcaagggac tttaccgtca gtgtatacgt ggcaaggagc agctgcaact actcatgcct 2460cttaaggcac caaaagaagt aacctttctt gaaggtgatt cacatgacac agtacttacc 2520tctgaggagg ttgttctcaa gaacggtgaa ctcgaagcac tcgagacgcc cgttgatagc 2580ttcacaaatg gagctatcgt tggcacacca gtctgtgtaa atggcctcat gctcttagag 2640attaaggaca aagaacaata ctgcgcattg tctcctggtt tactggctac aaacaatgtc 2700tttcgcttaa aagggggtgc accaattaaa ggtgtaacct ttggagaaga tactgtttgg 2760gaagttcaag gttacaagaa tgtgagaatc acatttgagc ttgatgaacg tgttgacaaa 2820gtgcttaatg aaaagtgctc tgtctacact gttgaatccg gtaccgaagt tactgagttt 2880gcatgtgttg tagcagaggc tgttgtgaag actitacaac cagtttctga tctccttacc 2940aacatgggta ttgatcttga tgagtggagt gtagctacat tctacttatt tgatgatgct 3000ggtgaagaaa acttiticate acgtatgtat tgiteettiti acceteeaga tgaggaagaa 3060gaggaegatg cagagtgtga ggaagaagaa attgatgaaa eetgtgaaca tgagtaeggt 3120acagaggatg attateaagg teteeetetg gaattiggtg cctcagctga aacagttcga 3180gttgaggaag aagaagagga agactggctg gatgatacta ctgagcaatc agagattgag 3240ccagaaccag aacctacacc tgaagaacca gttaatcagt ttactggtta tttaaaactt 3300actgacaatg ttgccatt algtgttgac atcgttaagg aggcacaaag tgctaatoct 3360atggtgattg taaatgctgc taacatacac ctgaaacatg gtggtggtgt agcaggtgca 3420ctcaacaagg caaccaatgg tgccatgcaa aaggagagtg atgattacat taagctaaat 3480ggccctctta cagtaggagg gtcttgtttg ctttctggac ataatcttgc taagaagtgt 3540ctgcatgttg ttggacctaa cctaaatgca ggtgaggaca tecagcttct taaggcagca 3600tatgaaaatt teaattcaca ggacatctta ettgcaccat tgttgtcage aggcatattt 3660ggtgctaaac cacttcagte tttacaagtg tgegtgcaga eggttegtae acaggtttat 3720attgeagtea atgacaaage tetttatgag caggttgtca tggattatet tgataacetg 3780aagecetagag tggaageace taaacaagag gagccaccaa acacagaaga ttocaaaact 3840gaggagaaat ctgtogtaca gaagcotgto gatgtgaago caaaaattaa ggootgcatt 3900gatgaggtta ccacaacact ggaagaaact aagtttotta ccaalaagtt actottgttt 3960gctgatatea atggtaaget ttaccatgat teteagaaca tgettagagg tgaagatatg 4020tetteettg agaaggatge acettacatg gtaggtgatg ttateactag tggtgatate 4080acttgtgttg taataceete caaaaagget ggtggeacta ctgagatgct ctcaagagct 4140ttgaagaaag tgccagttga tgagtatata accacgtacc ctggacaagg atgtgctggt 4200tatacacttg aggaagctaa gactgctctt aagaaatgca aatctgcatt ttatgtacta 4260ccttcagaag cacctaatgc taaggaagag attctaggaa ctgtatcctg gaatttgaga 4320gaaatgcttg ctcatgctga agagacaaga aaattaatgc ctatatgcat ggatgttaga 4380gccataatgg caaccatcca acgtaagtat aaaggaatta aaattcaaga gggcatcgtt 4440gactatggtg tccgattett ettitataet agtaaagage etgtagette tattattaeg 4500aagetgaaet etctaaatga geegettgte acaatgeeaa ttggttatgt gacacatggt 4560tttaatettg aagaggetge gegetgtatg egttetetta aageteetge egiagtigtea 4620gtateatea cagaigetgt factacatat aatggalace teactiegte ateaaagaca 4680tetgaggage actitigtaga aacagtitet tiggetgeet ettacagaga itggteetat 4740teaggacage gtacagagt aggtgttgaa tticttaage gtggtgacaa aattgtgtae 4800cacaetetgg agageeeegt egagtticat ettgaeggtg aggttettte acttgaeaaa 4860etaaagagte tettateeet gegggaggtt aagaetataa aagtgticae aaetgtggae 4920aacactaate tecacacaca gettgtggat atgtetatga catatggaca geagtttggt 4980ccaacataet tggatggtge tgatgttaca aaaattaaae etcatgtaaa teatgagggt 5040aagaetttet ttgtaetaee tagtgatgae acaetaegta gtgaagcttt cgagtactac 5100catactettg atgagagttt tettggtagg tacatgtetg etttaaacca cacaaagaaa 5160tggaaattte etcaagttgg tggtttaact teaattaaat gggetgataa caattgttat 5220ttgtetagtg ttttattage acticaacag citgaagtca aaticaatgc accagcacti 5280caagaggcti attatagagc ccgtgctggt gatgctgcta actititgtgc acteatacte 5340gcttacagta ataaaactgt tggcgagcti ggtgatgtca gagaaactat gacccatcti 5400ctacageatg claattigga atcigeaaag egagttetta atgiggigig taaacatig 5460ggteagaaaa etactacett aaegggigta gaagetgiga tgitatalggg taetetatet 5520tatgataate ttaagaeagg tgitteeatt eetatgigt gggtegtig tectacaca 5580tatchagtac aacaagagte ticttittet atagtgeca gatacata 5640ttacagecaa gatacatet atgtegaat gatacatet ggtacgtet gatacataca 5580tatchagtac aacaagagte ticttittet atagtgecagat actacataca 5580tatchagtac accaagagte ticttittet atagtgecagat gatacatat astegetaa ggagacecte tategtattg acggagetca cettacaaag 5760atgteagagt acaaaggaec agtgaetgat gttittetaca aggaaacate ttacaetaca 5820accateaage etgtgtegt tataacega gagttactt accaegagat tgaaccaaa 5880ttggatgggt attataaaaa ggataatgct tactatacag agcagcctat agaccttgta 5940ccaactcaac cattaccaaa tgcgagtttt gataattica aactcacatg ttctaacaca 6000aaattigctg atgatttaaa tcaaatgaca ggcttacaa agccagctta agaccaggtt agaccttgta cagagagcta 6060tctgtcacat tcttcccaga cttgaatggg gatgtagtgg ctattgacta tagacactat 6120tcagcgagtt tcaagaaagg tgctaaatta ctgcataagc caattgttt ggacattaa 6180caggctacaa ccaaggacaac ggttcaaaca aacacttggt gtttacgttg tctttggagt 6240acaaagccag tagatacttc aaattcattt gaagttotgg cagtgagag caaccaagga 6300atggacaatt tgcttgga aagtcaacaa cccacctctg agaaagtagt ggaaaatcct 6360accatacaga aggaagtcat agagtgtgac gtgaaaacta ccgaagttgt aggcaatgte 6420atacttaaac catcagatga aggtgttaaa gtaacacaag agttaggtca tgaggatctt 6480atggctgctt atgtggaaaa cacaagcatt accattaaga aacctaatga gettteacta 6540geettaggtt taaaaacaat tgeeacteat ggtattgetg eaattaatag tgtteettgg 6600agtaaaattt tggettatgt eaaaccatte ttaggacaag eageaattae aacateaaat 6660tgegetaaga gattageaca acgtgtgttt aacaattata tgccttatgt gtttacatta 6720ttgttccaat tgtgtacttt tactaaaagt accaattcta gaattagagc ttcactacct 6780acaactattg ctaaaaatag tgttgctaaat tatgtttgga tgccggcatt 6840aattatgtga agteaeceaa attitetaaa tigticaeaa tegetatgig getatigtig 6900ttaagtatti gettaggite tetaaleigi gtaaetgetg ettitggigt acteitatet 6960aattiiggig eteettetta tigtaatgge gitagagaat igtatettaa tiegtetaae 7020gttactacta tggatttctg tgaaggttct tttccttgca gcatttgttt aagtggatta 7080gactcccttg attcttatcc agctcttgaa accattcagg tgacgattte atcgtacaag 7140ctagacttga caattttagg tctggccgct gagtgggttt tggcatatat gttgttcaca 7200aaattctttt atttattagg tctttcagct ataatgcagg tgttctttgg ctattttgct 7260agtcatttca tcagcaattc ttggctcatg tggtttatca ttagtattgt acaaatggca 7320cccgtttctg caatggttag gatgtacatc ttctttgctt ctttetaeta eatatggaag 7380agetatgtte atateatgga tggttgeace tettegaett geatgatgtg etataagege 7440aategtgeea eaegegttga gtgtaeaaet attgttaatg geatgaagag atetttetat 7500gtetatgeaa atggaggeeg tggcttctgc aagactcaca attggaattg tctcaattgt 7560gacacatttt gcactggtag tacattcatt agtgatgaag ttgctcgtga tttgtcactc 7620cagtttaaaa gaccaatcaa ccctactgac cagtcatcgt atattgttga lagtgttgct 7680gtgaaaaatg gegegettea eetetaettt gacaaggetg gteaaaagae etatgagaga 7740eateegetet eecatttigt eaatttagae aatttgagag etaacaacae taaaggttea 7800etgeetatta atgteatagt tittgatgge aagteeaaat gcgacgagte tgcttctaag 7860tctgcttetg tgtactacag tegecaagtg tgccaaceta ttetgttget tgaceaagtt 7920ettgtateag acgttggaga lagtactgaa gttteegtta agatgtttga tgcttatgte 7980gacacettit eageaaetti tagtgiteet atggaaaaae ttaaggeaet tgitgetaea 8040geteaeageg agitageaaa gggtgtaget ttagatggtg teetitetae attegtgiea 8100getgeeegae aaggtgitgi tgataeegat gitgaeaeaa aggatgitat tgaatgiee

8160aaactttcac atcactetga cttagaagtg acaggtgaca gttgtaacaa tttcatgete 8220acctataata aggtgaaaa catgacgece agagatettg gegeatgtat tgactgtaat 8280gcaaggcata teaatgecea agtagcaaaa agteacaatg tttcactcat etggaatgta 8340aaagactaca tgtetttate tgaacagetg egtaaacaaa ttegtagtge tgecaagaag 8400aacaacatae ettttagaet aacttgtget acaactagae aggtgteaa tgteataaet 8460actaaaatet eacteaaggg tggtaagatt gttagtactt gttttaaact tatgcttaag 8520gccacattat tgtgcgttct tgctgcattg gtttgttata tcgttatgcc agtacataca 8580ttgtcaatcc atgatggtta cacaaatgaa atcattggt acaaagccat tcaggatggt 8640gtcactcgtg acatcattic tactgatgat tgttttgcaa ataaacatgc tggttttgac 8700gcatggttta gccagcgtgg tggttcatac aaaaatgaca aaagctgccc tgtagtagct 8760gctatcatta caagagagat tggtttcata gtgcctggct taccgggtac tgtgctgaga 8820gcaatcaatg gtgacttett gcatttteta eetegtgttt ttagtgetgt tggcaacatt 8880tgetacaee ettecaaaet eattgagtat agtgattttg etaeetege ttgegttett 8940getgetgagt gtacaatttt taaggatget atgggcaaae etgtgecata ttgttalgac 9000actaatttgc tagagggtte tatttettat agtgagette gecagacae tegttatgtg 9060ettatggatg gttecateat acagttteet aacaettaee tggagggtte tgttagagta 9120gtaacaaett ttgatgetga gtaetgtaga catggtacat gcgaaagtaggt 9180atttgcctat ctaccagtgg tagatgggt ettaataatg agcattacag agctctatca 9240ggagtttte gtggtgttg tgggtgata etcatageta acatetttae tectettgt 9300caacetgtgg gtgetttaga tgtgtetget teagtaggt getggtgat tattgeccata 9360ttggtgactt gtggtgecte teagtaget gtgetgetget gtggtggat tattgecata 9360ttggtgactt gtggtgete teagtaget 9420catgttgttg etgetaatge acttttgt ttgatgtett teagtaget teagtaget 9180atttgetaet etgetgetget 9180atttgetaet 9300caacetgtgg 9480ccagettaca getttetgee gggagtetae teagtetttt acttgtaett gacattetat 9540tteaceaatg atgttteatt ettggeteae etteaatggt ttgecatgtt tteeteatt 9600gtgeettttt ggataacage aatetatgta ttetgtattt etetgaagea ctgccattgg 9660ttctttaaca actatcttag gaaaagagte atgttaatg gagttacatt tagtacette 9720gaggaggetg etttgtgtae ettttgtgtae ettttgtgtae tagtacetaaa attgegtage 9780gagacactgt tgeccacttae acagtataae aggtatettg etetatataa caagtacaag 9840tattteagtg gageettaga taetaceage talegtgaag eagettgetg eecaettagea 9900aaggetetaa atgaetttag caaeteaggt getgatgtte tetaceaace aceaeagaea 9960teaateaett ctgctgttct gcagagtggt tttaggaaaa tggcattccc gtcaggcaaa 10020gttgaagggt gcatggtaca agtaacctgt ggaactacaa ctcttaatgg attgtggttg 10080gatgacacag tatactgtcc aagacatgtc atttgcacag cagaagacat gettaateet 10140aactatgaag atetgeteat tegeaaatee aaceataget ttettgttea ggetggeaat 10200gtteaaette gtgttattgg ceattetatg caaaattgte tgettagget taaagttgat 10260acttetaace etaagaeaee caagtataaa tttgtccgta tccaacetgg tcaaacattt 10320tcagttctag catgctacaa tggttcacca tctggtgttt atcagtgtgc catgagacct 10380aatcatacca ttaaaggtte tttccttaat ggatcatgtg gtagtgttgg ttttaacatt 10440gattatgatt gegtgtettt etgetatatg eateatatgg agetteeaa aggagtacae 10500getggtaetg aettagaagg taaattetat ggteeatttg ttgacagaea aaetgeacag 10560getgeaggta cagacacaae eataacatta aatgttttgg eatggetgta tgctgctgtt 10620atcaatggtg ataggtggtt tcttaataga ttcaccacta ctttgaatga ctttaacctt 10680gtggcaatga agtacaacta tgaacctttg acacaagatc atgttgacat attgggacct 10740ctttctgctc aaacaggaat tgccgtctta gatatgtgtg ctgctttgaa agagctgctg 10800cagaatggta tgaatggtcg tactatectt ggtageacta ttttagaaga tgagtttaca 10860ccatttgatg ttgttagaca atgetetggt gttacettee aaggtaagtt caagaaaatt 10920gttaagggca cicateating gatgettita actiteitga cateactait gattetigit 10980caaagtacae agtggteaet gtittietti gtitaegaga atgettiett gecatitaet 11040ettggtatia tggeaattge tgeatgiget atgetgett taageataa geaegeatte 11100ttgtgcttgt ttctgttacc ttctcttgca acagttgctt actttaatat ggtctacatg 11160cctgctagct gggtgatgcg tatcatgaca tggcttgaat tggctgacac tagcttgtct 11220ggttataggc ttaaggattg tgttatgtat gcttcagctt tagttttget tatteteat 11280acagetegea etgtttatga tgatgetget agaegtgttt ggacaetgat gaatgteatt 11340acaettgttt acaaagteta etatggtaat getttagate aagetattte eatgtgggee 11400ttagttattt etgtaaeete taactattet ggtgegtta egactateat gtttttaget 11460agagetatag tgtttggtgt tgttgagtat taeceattgt tatttattae tggeaacaee 11520ttaeagtgta teatgettgt ttattgttte ttaggetatt gttgetgetg etaetttgge 11580ettttetgtt tactcaaccg ttactcagg cttactctg gtgtttatga ctacttggtc 11640tctacacaag aatttaggta tatgaactcc caggggcttt tgcctcctaa gagtagtatt 11700gatgctttca agcttaacat taagttgttg ggtattggag gtaaaccatg tatcaaggt 11760gctactgtac agtctaaaat gtctgacgta aagtgcacat ctgtggtact gctctcggtt 11820cttcaacaac ttagagtaga gtcatcttct aaattgtggg cacaatgtgt acaactccac 11880aatgatatte ttettgcaaa agacacaact gaagettteg agaagatggt ttctcttttg 11940tctgttttgc tatccatgca gggtgctgta gacattaata ggttgtgcga ggaaatgctc 12000gataaccgtg ctactcttca ggctattgct tcagaattta gttctttacc atcatatgcc 12060gcttatgcca ctgcccagga ggcctatgag caggctgtag ctaatggtga ttctgaagte 12120gttctcaaaa agttaaagaa atctttgaat gtggctaaat ctgagtttga ccgtgatget 12180gccatgcaac gcaagttgga aaagatggca gatcaggcta tgacccaaat gtacaaacag 12240gcaagatetg aggacaagag ggcaaaagta actagtgeta tgeaaacaat getetteaet 12300atgettagga agettgataa tgatgeaett aacaacatta teaacaatge gegtgatggt 12360tgtgtteeae teaacateat accattgaet acagcageea aacteatggt tgttgteeet 12420gattatggta eetacaagaa eaettgtgat ggtaacaeet ttacatatge atetgeaete 12480tgggaaatee ageaagttgt tgatgeeggat ageaagattg tteaaettag tgaaattaae 12540atgggaaatt caccaaattt ggettggeet ettattgtta cagetetaag agecaactea 12600getgttaaae tacagaataa tgaactgagt ecagtageae tacgacagat gteetgtgeg 12660getggtaeea eacaaacage ttgtaetgat gaeaatgeae ttgeetaeta taacaatteg 12720aagggaggta ggtttgtget ggeattaeta teagaceaee aagateteaa atgggetaga 12780tteeetaaga gtgatggtae aggtaegatt taeaeagaae tggaaeeet tigtaggttt 12840gttaeagaee aceeaaaagg gcctaaagtg aaatacttgt acttcatcaa aggcttaaac 12900aacctaaata gaggtatggt gctgggcagt ttagctgcta cagtacgtct tcaggctgga 12960aatgctacag aagtacctgc caattcaact gtgctttcct tctgtgcttt tgcagtagac 13020cctgctaaag catataagga ttacctagca agtggaggac aaccaatcac caactgtgtg 13080aagatgttgt gtacacacac tggtacagga caggcaatta ctgtaacacc agaagctaac 13140atggaccaag agtcctttgg tggtgcttca tgttgtctgt attgtagatg ccacattgac 13200catccaaate ettgagett etgtgacttg aaaggtaagt acgtecaaat acetaccact 13260tgtgetaatg acecagtggg ttttacactt agaaacacag tetgtacegt etgeggaatg 13320tggaaaggtt atggetgtag ttgtgaccaa etcegegaac ecttgatgea gtetgeggat 13380geateaaegt ttttaaaegg gtttgeggt taagtgeage eegtettaa aagtigetg 13500gtittgeaaa giteetaaaa actaatiget giegeticea ggagaaggat gaggaaggat 13560attiattaga etettaetti gtagtaaga ggeataetat gietaacaa caacaagag 13620agaetattia taactiggit aaagatigte cageggitge tgiceatgae titticaagt 13680itagagtaga tggtgeacatg gtaecaeta tateaegtea gegetaacta aaataeaeaa 13740tggetgatti agteatget etagetatti tgatagaggg taatigtgat acattaaaag 13800aaataetegt cacatacaat tgetgtgatg atgattattt caataagaag gattggtatg 13860acttegtaga gaateetgac atettaegeg tatatgetaa ettaggtgag egtgtaegee 13920aateattatt aaagaetgta caattetgeg atgetatgeg tgatgeage attgtaggeg 13980tactgacatt agataatcag gatettaatg ggaactggta egattteggt gattteggt attgetae 14040aagtageaee aggetgeega gtteettattg tggatteata ttaeteattg etgatgeeea 14100teeteaettt gataggeea ttggetgetg agteeeatat ggatgetgat etegeaaaae 14160eaettattaa gtgggatttg etgaaatatg attttaegga agagagaett tgtetetteg 14220acegttattt taaatattgg gaeeagaeat aceateeeaa ttgtattaae tgtttggatg 14280ataggtgtat cetteattgt geaaacttta atgtgttatt ttetaetgtg ttteeaeeta 14340eaagtttgg accaetagta agaaaaatat ttgtagatgg tgtteetttt gttgttteaa 14400etggataeea ttttegtgag ttaggagteg taeataatea ggatgtaaae ttaeataget 14460cgcgteteag tttcaaggaa ettttagtgt atgetgetga tecagetatg eatgeagett 14520ctggeaattt attgetagat aaaegeacta eatgetttte agtagetgea etaaeaaaea 14580atgttgettt teaaaetgte aaaeeggaa attttaataa agaettttat gaetttgetg 14640tgeteaaagg tttetttaag gaaggaagtt etgttgaaet aaaaeaette ttetttgete 14700aggatggeaa egetgetate agtgattatg aetattateg ttataatetg teaaeaatgt 14760gtgatateag aeaaeteeta ttegtagttg aagttgttga taaataettt gattgttaeg 14820atggtggetg tattaatgee aaceaagtaa tegttaacaa tetggataaa teagetggtt 14880teeeatttaa taaatggggt aaggetagae tttattatga eteaatgagt tatgaggate 14940aagatgcact tttcgcgtat actaagcgta atgtcatccc tactataact caaatgaatc 15000ttaagtatgc

cattagtgca aagaatagag ctcgcaccgt agctggtgtc tctatctgta 15060gtactatgac aaatagacag tttcatcaga aattattgaa gtcaatagcc gccactagag 15120gagctactgt ggtaattgga acaagcaagt tttacggtgg ctggcataat algitaaaaa 15180ctgittacag lgatgiagaa acteeacaee ttatgggitg ggattateea aaalgigaca 15240gageeatgee taacatgett aggataatgg cetetetigt tetigetege aaacataaca 15300ettgetgaa ettateacae egittetaca ggttagctaa cgagtgtgcg caagtattaa 15360gtgagatggt catgtgtggc ggctcactat atgttaaacc aggtggaaca tcatccggtg 15420atgctacaac tgcttatgct aatagtgtct ttaacatttg tcaagctgtt acagccaatg 15480taaatgcact tettteaact gatggtaata agatagetga caagtatgte egeaatetae 15540aacacagget etatgagtgt etetatagaa atagggatgt tgateatgaa ttegtggatg 15600agttttaege ttaeetgegt aaacatttet ecatgatgat ettitetgat gatgeegttg 15660tgtgctataa cagtaactat gcggctcaag gtttagtagc tagcattaag aactttaagg 15720cagttcttta ttatcaaaat aatgtgttca tgtctgaggc aaaatgttgg actgagactg 15780accttactaa aggacctcac gaattttgct cacagcatac aatgetagtt aaacaaggag 15840atgattaegt gtaeetgeet taeceagate cateaagaat attaggegea ggetgtttig 15900tegatgatat tgteaaaaca gatggtaeae ttatgattga aaggttegtg teaetggeta 15960ttgatgetta eecaettaea aaacateeta ateaggagta tgetgatgte titeaetigt 16020attiacaata caltagaaag tiacatgatg agettaetgg ecacatgitg gacatgiatt 16080eegtaatget aactaatgat aacaeeteae ggtaetggga acetgagitt tatgaggeta 16140tgtacacacc acatacagtc ttgcaggctg taggtgcttg tgtattgtgc aattcacaga 16200cttcacttcg ttgcggtgcc tgtattagga gaccattcct atgttgcaag tgctgctatg 16260accatgtcat ttcaacatca cacaaattag tgttgtctgt taatcectat gtttgcaatg 16320ceccaggttg tgatgtcact gatgtgacae aactgtatet aggaggtatg agetattatt 16380geaagteaea taageeteee attagtttte cattatgtge taatggteag gtttttggtt 16440tataeaaaaa caeatgtgta ggcagtgaca atgtcactga cttcaatgcg atagcaacat 16500gtgattggac taatgctgcg gattacatac ttgccaacac ttgtactgag agactcaage 16560ttttcgcage agaaacgete aaagccactg aggaaacatt taagetgtca tatggtattg 16620ctactgtacg cgaagtactc tctgacagag aattgcatct ttcatgggag gttggaaaac 16680ctagaccacc attgaacaga aactatgtct ttactggta ccgtgtaact aaaaatagta 16740aagtacagat tggagagtac acctttgaaa aaggtgacta tggtgatget gttgtgtaca 16800gaggtactae gacataeaag ttgaatgttg gtgattaett tggttgaea teleacaetg 16860taatgeeaet tagtgeaeet aetetagtge eeeaagagea etatgtgaga attaetget 16920tgtaeeeaae acteaacate teagatgagt titelageaa tgitgeaaat tateaaaagg 16980teggeatgea aaagtactet acaeteeaag gaceacetgg taetggtaag agteatittig 17040ecateggaet tgetetetat taeceatetg etegeatagt gataeggea tgeteteatg 17100eagetgttga tgeeetatgt gaaaaggeat taaaatattt geeetagat aaatgtagta 17160gaateataee tgegegtgeg egegtagagt gttttgataa atteaaagtg aatteaaeae 17220tagaaeagta tgttttetge aetgtaaatg cattgccaga aacaactgct gacattgtag 17280tctttgatga aatctctatg gctactaatt atgacttgag tgttgtcaat gctagacttc 17340gtgcaaaaca ctacgtctat attggcgatc ctgctcaatt accagcccec cgcacattgc 17400tgactaaagg cacactagaa ccagaatatt ttaattcagt gtgcagactt atgaaaacaa 17460taggtccaga catgttcctt ggaacttgtc gccgttgtcc tgctgaaatt gttgacactg 17520tgagtgcttt agtttatgac aataagctaa aagcacacaa ggataagtca gctcaatgct 17580tcaaaatgtt ctacaaaggt gttattacac atgatgttte atctgcaatc aacagaccte 17640aaataggegt tgtaagagaa tttettacac gcaatcetge ttggagaaaa gctgttttta 17700tctcacetta taattcacag aacgetgtag cttcaaaaat cttaggattg cctacgcaga 17760ctgttgattc atcacagggt tctgaatatg actatgtcat attcacacaa actactgaaa 17820cagcacactc ttgtaatgtc aaccgcttca atgtggctat cacaagggca aaaattggca 17880ttttgtgcat aatgtetgat agagatetti atgacaaact geaatttaca agtetagaaa 17940taccaegteg eaatgtgget acattacaag eagaaaatgt aaetggaett tttaaggaet 18000gtagtaagat eattaetggt etteateeta eacaggeaee tacaecaecte agcgttgata 18060taaagttcaa gactgaagga ttatgtgttg acataccagg cataccaaag gacatgacct 18120accgtagact catctctatg atgggtttca aaatgaatta ccaagtcaat ggttacccta 18180atatgttat cacccgcgaa gaagctattc tagging billing billing to the second tgaatacct attatagga atgaactga ggttaattc gctgcagaa 18900aagtacaaca catggtigt aagtctgcat tgcttgcag taagttica gticticatg 18960acattggaaa tccaaaggct atcaagtgig tgcccaggc tgaagtagaa tggaagttct 19020acgatgctca gccatgtagt gacaaagect acaaaataga ggagctcttc tattcttatg 19080ctacaacac ggataaatt actgatggg tttgtttgttt ttggaattgt aacgttgac 19140gttacccag caatgcaatt gtgtgagg tigaaccaag agoctigtea aactigaact 19200taccagocig tgatgggtg agtigtata gaataagoa tgoattocae actocagoti 19260tegataaaag tgoattaca attaaago attagat tittaactaa tetgatagt 19320tagtgagte toatggaaga actiggaa toatgaaga tataataga tataataga 19380ctacgtgtat tacacgatgo aattaggt ggotgttig gagcaaccaa gaaaatgggt oggaattiga tatggtoca ctaaaatga tgattocgo tgaatga tataataga tgattocgo tgaattaga tataataga tgattocgo tgaatga tataataga tgattocgo tgaattaga tgaattaga tgattaga tataataga tgattocgo tgaattaga tgaattaga tgattaga tgaattaga tgaattagaa tgaattagaattaga tgaattagaattagaattagaattaga tgaattagaattagaattagaa ctatggattt 19500acaaacaatt tgatacttat aacctgtgga atacatttac caggttacag agtttagaaa 19560atgtggctta taatgttgtt aataaaggac actttgatgg acacgccgg gaagcacctg 19620tttccatcat taataatgct gttacacaa aggtagatgg tattgatgtg gagatctttg 19680aaaataagac aacacttcct gttaatgttg catttgatgtg cattgggctag cgtaacatta 19740aaccagtgcc agagattaag atactcaata atttgggtgt tgatatcgct gctaatactg 19800taatctggga ctacaaaaga gaageeeeag cacatgtate tacaataggt gtetgeacaa 19860tgactgacat tgecaagaaa eetactgaga gtgettgtte tteacttaet gtettgtttg 19920atggtagagt ggaaggacag gtagaeettt ttagaaaege eegtaatggt gttttaataa 19980cagaaggttc agtcaaaggt ctaacacctt caaagggacc agcacaagct agcgtcaatg 20040gagtcacatt aattggagaa tcagtaaaaa cacagtttaa ctactttaag aaagtagacg 20100gcattattca acagttgcct gaaacetact ttactcagag cagagactta gaggattta 20160agcecagate acaaatggaa actgactite tegagetege tatggatgaa tteatacage 20220gatataaget egagggetat geettegaac acategitta tggagattte agteatggae 20280aacttggcgg tcttcattta atgataggct tagccaaggg ctcacaaggt tcaccactta 20340aattagagga ttttatccct atggacagca cagtgaaaaa ttacttcata acagatgcgc 20400aaacaggttc atcaaaatgt gtgtgttctg tgattgatct tttacttgat gactttgtcg 20460agataataaa gtcacaagat ttgtcagtga tttcaaaagt ggtcaaggtt acaattgact 20520atgctgaaat ttcattcatg ctttggtgta aggatggaca tgttgaaace ttctacccaa 20580aactacaage aagtcaagge tggcaaccag gtgttgcgat gcctaacttg tacaagatgc 20640aaagaatgct tcttgaaaag tgtgaccttc agaattatgg tgaaaatgct gttataccaa 20700aaggaataat gatgaatgtc gcaaagtata ctcaactgtg tcaatactta aataccata 20760ctttagctgt accetacaac atgagagtta ticactttgg tgctggctct gataaaggag 20820ttgcaccagg tacagctgt ctcagacaat ggttgccaac tggcacacta cttgtcgatt 20880cagatcttaa tgacttcgtc tccgacgcag attetacttt aattggagac tgtgcaacag 20940tacatacggc taataaatgg gacettatta ttagegatat gtatgaceet aggaceaaae 21000atgtgacaaa agagaatgae tetaaagaag ggttttteae ttatetgtgt ggatttataa 21060ageaaaaaet ageeetgggt ggttetatag etgtaaagat aacagageat tettggaatg 21120etgacettta caagettatg ggecatttet eatggtggae agettttgtt acaaatgtaa 21180atgeateate ateggaagea tttttaattg gggetaaeta tettggeaag eegaaggaae ttattetett etggaaaaag 21420gtaggettat eattagagaa aacaacagag ttgtggttte aagtgatatt ettgtaaca 21480actaaaegaa eatgtttatt ttettattat ttettaetet eactagtggt agtgacettg 21540aeeggtgeae eaettttgat gatgttcaag ctcctaatta cactcaacat acttcatcta 216001gaggggggt ttactatcct gatgaaattt ttagatcaga cactctttat ttaactcagg 21660atttatttct tccatttat tctaatgtta cagggtttca tactattaat catacgttig 21720gcaaccctgt catacctttt aaggatggta tttatttige tgecacagag aaatcaaatg 21780ttgteegtgg ttgggttttt ggttetaeca tgaacaacaa gteacagteg gtgattatta 21840ttaacaatte taetaatgtt gttataegag eatgtaactt tgaattggt gacaaccett 21900tettgetgt ttetaaacce atgggtacae agacacatae tatgatatte gataatgeat 21960ttaattgeae tittegagtae atatetgatg eetitteget tgatgtttea gaaaagteag 22020gtaattttaa acaettaega gagttigtgt itaaaaataa agatgggtti cictatgtti 22080ataagggcta icaacctata gatgtagtic gigatciace tictggtitt aacactiiga 22140aacctattiit taagtiggeti cictaggtata acattacaaa itittagagee attettacag

22200ccttttcacc tgctcaagac atttggggca cgtcagctgc agcctatttt gttggctatt 22260taaagccaac tacatttatg ctcaagtatg atgaaaatgg tacaatcaca gatgctgttg 22320attgttctca aaatcactt gctgaactca aatgcctgt taagagettt gagaattgaca 22380aaggaattta ecagaeetet aattteaggg tigtteete aggagatgti gigagattee 22440etaalattae aaaettgigt eettittgag aggittitaa igetaetaaa tieeetteg 22500ietatgeatg ggagaaaaa aaaatticta attgigtige tgattactet gigetetaea 22560acteaaeatt titticaaee titaagtget atggegtite tgeeactaag tigaatgate 22620ttigettee caatgietat geagattett tigtagteaa gggagatgat gtaagaeaaa 23160attcactga ttcgttgg gatctaaaa catcgaaa attagacatt tcactgga gatcata ttagctgg 2250gtattee turbeaug gatattacaga ttgtaactga gatgacga gatcaga attagacat tcatggaaca atgattca gatgacat tcatggaaca atgattca gatgacat tcatggaaca atgattca gatgacat tcatggaaca atgattacaga gatgatta attagacat taggaaca atgattaca gatgatta atgatta at gtacaaaacc ccaactttga 23820aatattttgg tggttttaat ttitcacaaa tattacctga ccctctaaag ccaactaaga 23880ggtcttttat tgaggacttg ctctttaata aggtgacact cgctgatgct ggcttcatga 23940agcaatatgg cgaatggcta ggtgatatta atgctagaga tctcatttgt gcgcagaagt 24000tcaatggact tacagtgttg ccacctctgc tcactgatga tatgattgct gcctacactg 24060ctgctctagt tagtggtact gccactgctg gatggacatt tggtgctggc gctgctcttc 24120aaataccttt tgetatgeaa atggeatata ggtteaatgg eattggagtt acceaaaatg 24180ttetetatga gaaceaaaaa caaategeea aceaatttaa caaggegatt agteaaatte 24240aagaateaet tacaacaaaea teaaetgeat tgggeaaget gcaagacgtt gttaaccaga 24300atgctcaage attaaacaac acttgttaaac aacttagete taatttiggt gcaatticaa 24360gtgtgetaaa tgatateett tegegacttg ataaagtega ggeggaggta caaattgaca 24420ggttaattae aggeagactt caaageette aaacetatgt aacacaacaa etaatcaggg 24480etgetgaaat cagggettet getaatettg etgetactaa aatgtetgag tgtgttettg 24540gacaateaaa aagagttgae tittgtggaa agggetaeca eettatgtee tteecaeaag 24600cagcccccgca tggtgttgtc ttcctacatg tcacgtatgt gccatcccag gagaggaact 24660tcaccacage gccagcaatt tgtcatgaag gcaaagcata cttccctcgt gaaggtgttt 24720ttgtgtttaa tggcattct tggtttatta cacagaggaa cttcttttet ecacaaataa 24780ttactacaga caatacattt gtetcaggaa attgtgatgt egttattgge atcattaaca 24840acacagttta tgateetetg caacetgage tegaetcatt caaagaagag etggacaagt 24900acttcaaaaa teatacatca ccagatgttg atcttggcga catttcaggc attaacgctt 24960ctgtcgtcaa cattcaaaaa gaaattgacc gcctcaatga ggtcgctaaa aatttaaatg 25020aatcactcat tgaccttcaa gaattgggaa aatatgagca atatataaa tggccttggt 25080atgtttggct cggcttcatt gctggactaa ttgccatcgt catggttaca atcttgcttt 25140gttgcatgac tagttgttgc agttggctca agggtgcatg ctcttgtggt tcttggtgct cgg200agtttgatga ggatgactct gagccagttc tcaagggtgt caaattacat tacacataaa 25260cgaacttatg gatttgttta tgagattttt tactcttgga tcaattactg cacagccagt 25320aaaaattgac aatgcticte etgecaagtac tgtteatget acagecaaega tacegetaea 25380ageeteaete eettteggat ggettgttat tggegttgea tttettgetg ttttteagag 25440egetaceaaa ataattgege teaataaaag atggeageta gecetttata agggetteea 25500gtteattige aatttaetge tgetattigt taeeatetat teaeatetti tgettgtege 25560tgcaggtatg gaggcgcaat ttttgfacct ctatgccttg atatattttc tacaatgcat 25620caacgcatgt agaattatta tgagatgttg gctttgttgg aagtgcaaat ccaagaaccc 25680attactttat gatgccaact actitgtttg ctggcacaca cataactatg actactgtat 25740accatataac agtgtcacag atacaattgt cgttactgaa ggtgacggca tttcaacaec 25800aaaactcaaa gaagactacc aaattggtgg ttattctgag gataggcact caggtgttaa 25860agactatgtc gttgtacatg gctatttcac cgaagtttac taccagcttg agtctacaca 25920aattactaca gacactggta ttgaaaatgc tacattcttc atctttaaca agcttgttaa 25980agacccaccg aatgtgcaaa tacacacaat cgacggctct tcaggagttg ctaatccagc 26040aatggatcca attiatgatg agccgacgac gactactagc gtgcctttgt aagcacaaga 26100aagtgagtac gaacttatgt actcattcgt ttcggaagaa acaggtacgt taatagttaa 26160tagcgtactt cttttcttg ctttcgtggt attcttgcta gtcacactag ccatcettac 26220tgcgcttcga ttgtgtgcgt actgctgcaa tattgttaac gtgagtttag taaaaccaac 26280ggtttacgte tactegcgtg ttaaaaatet gaactettet gaaggagtte etgatettet 26340ggtetaaacg aactaactat tattattatt etgtttggaa etttaacatt gettateatg 26400geagacaaeg gtaetattae egttgaggag ettaaacaae teetggaaca atggaaceta 26460gtaataggtt teetatteet ageetggatt atgttaetae aatttgeeta tietaategg 26520aacaggtttt tgtacataat aaagcttgtt tteetetgge tettgtggee agtaacaett 26580gettgttttg tgettgetge tgtetacaga attaattggg tgaetggegg gattgegatt 26640geaatggett gtattgtagg ettgatgtgg ettagetaet tegtigetic eticaggetg 26700ttigetegia eccepticant gtegteatic aacceagaaa caaacattet teleaatgig 26760cetetecggg ggacaatigt gaccagaceg etcatggaaa gigaactigt cattggriget 26820gtgateatte gteggteactt gcgaatggcc ggacaccccc tagggcgctg tgacaitaag 26880gacctgccaa aagagatcac tgtggctaca tcacgaacgc tttettatta caaattagga 26940gcgtcgcagc gtgtaggcac tgattcaggt tttgetgeat acaaccgcta cogtattgga 27000aactataaat taaatacaga ccacgccggt agcaacgaca atattgettt getagtacag 27060taagtgacaa cagatgttte atettgttga ettecaggtt acaatagcag agatattgat 27120tateattatg aggaetttea ggattgetat ttggaatett gacgitataa taagticaat 27180agtgagacaa tatitaage cictaacaaga gacgitatat toggagtag algalaagag 27240acctalggag tagatate cataaacga acatgagaata tatictic cigacattag 27300tigtattac atcitaggag tagatagaa tatictic cigacattag 27300tigtattac atcitaggag tagatagaaga tatictic cigacattag 27300tigtattac atcitaggag tagatagaaga taticacat atcaggagtg tgttagaggt tgttagaggt acgacatga 27300tigtattac atcitageacat acgagggaa taticaccatti caccatti caccatti caccatti caccatti cacta atcaggagtg tgttagaggt acgacata actigcacta acagaga accttigecea tcaggaacat acgagggea tteaccatti caccatti caccatti caccatti caccatti caccatti caccatti caccatti caccatti cacta atcaggagtg tgttagaggta acgacata actigcacataaaaga accttigecea tcaggaacat acgagggeaa tteaccatti caccatti cactagaa tatatti tagaataa tattigcacataaaaga accttigecea tcaggaacat acgagggeaa tteaccatti caccatti cacc 27480gtactcgaca tacctatcag ctgcgtgcaa gatcagtttc accaaaaactt ttcatcagac 27540aagaggaggt tcaacaagag ctctactcgc cactttttct cattgttgct gctctagtat 27600ttttaatact ttgcttcacc attaagagaa agacagaatg aatgagctca ctttaattga 27660cttctatttg tgctttttag cctttctgct attccttgtt ttaataatgc ttattatatt 27720ttggttttca ctcgaaatcc aggatctaga agaacctgt accaaagtct aaacgaacat 27780gaaacttctc attgtttgg cttgtatttc tetatgeagt tgeatatgea etgtagtaea 27840gegetgtgea tetaataaae etcatgtget tgaagateet tgtaaggtae aacaetaggg 27900gtaataetta tageaetget tggettigtg etctaggaaa ggttttaeet ttteatagat 27960ggeaeaetat ggitcaaaca igcacaccia algitacial caacigicaa galccagcig 28020giggiggcgci lalagciagg igtiggiace itcaigaagg icaccaaaci gcigcaitta 28080gagacgiaci igtigtitta aalaaacgaa caaattaaaa igicigalaa tggaceccaa 28140tcaaaccaac gtagtgcccc cegeattaca tttggtggac ceacagatte aactgacaat 28200aaccagaatg gaggacgcaa tggggecgaagg ceaaaacage geegacecea aggtttaee 28260aataataetg egtettggtt cacagetete acteageatg geaaggagga acttagatte 28320eetegaggee agggegttee aateaacaee aatagtggte cagatgacea aattggetae 28380taecgaagg etaecegaeg agttegtggt ggtgaeggea aaatgaaaga getcagecee 28440agatggtact telattacet aggaactgge ecagaagett caetteeta eggegetaae 28500aaagaaggea tegtatgggt tgeaactgag ggageettga atacaeceaa agaeceaett 28560ggeaceegea ateetaataa caatgetgee acegtgetae aactteetea aggaacaaca 28620ttgeeaaaag gettetaege agagggaage agaggeggea gteaageete ttetegetee 28680teateaegta gtegeggtaa tteaagaaat teaaeteet g geageagtag gggaaattet 28740cctgctcgaa tggctagcgg aggtggtgaa actgccctcg cgctattgct gctagacaga 28800ttgaaccagc ttgagagcaa agtttctggt aaaggccaac aacaacaagg ccaaactgtc 28860actaagaaat ctgctgctga ggcatctaaa aageetegee aaaaaegtae tgeeaaaa 28920cagtacaaeg teacteaage attigggaga egtggteeag aacaaaeeea aggaaattte 28980ggggaceaag acetaateag acaaggaaet gattacaaae attiggeegea aattgeeega 29040ttigeteeaa gigeetetge attettigga algteaegea tiggeatgga agteaeaeet 29100tegggaaeat ggetgaetta teatggagee attaaattgg atgaeaaaga teeaeaatte 29160aaagaeaaeg teataetget gaacaageae attgacgeat acaaaacait eccaccaaca 29220gagectaaaa aggacaaaaa gaaaaagact gatgaagete agectittgee geagagacaa 29280aagaagee ecactgtgae tettetteet gegetgaca tggatgatit etceagacaa 29340cttcaaaatt ccatgagtgg agcttctgct gattcaacte aggcataaac actcatgatg 29400accacacaag gcagatgggc tatgtaaacg ttttcgcaat tccgtttacg atacatagtc 29460tactcttgtg cagaatgaat tctcgtaact aaacagcaca agtaggttta gttaacttta 29520atctcacata gcaatcttta atcaatgtgt aacattaggg aggacttgaa agagccacca 29580cattttcatc gagggccacge ggagtacgat cgagggtaca gtgaataatg ctaggggagg 29640ctgcctatat ggaagageee taatgtgtaa aattaatttt agtagtgeta teeecatgtg 29700attttaatag ettettagga gaatgae 2972724382PRTCoronavirus 2Met Glu Ser Leu Val Leu Gly Val Asn Glu Lys Thr His Val Gln Leu 1 5 10 15Ser Leu Pro Val Leu Gln Val Arg Asp Val Leu Val Arg Gly Phe Gly 20 25 30Asp Ser Val Glu Glu Ala Leu Ser Glu Ala Arg Glu His Leu Lys Asn 35 40

45Gly Thr Cys Gly Leu Val Glu Leu Glu Lys Gly Val Leu Pro Gln Leu 50 55 60Glu Gln Pro Tyr Val Phe Ile Lys Arg Ser Asp Ala Leu Ser Thr Asn65 70 75 80His Gly His Lys Val Val Glu Leu Val Ala Glu Met Asp Gly Ile Gln 85 90 95Tyr Gly Arg Ser Gly Ile Thr Leu Gly Val Leu Val Pro His Val Gly 100 105 110Glu Thr Pro Ile Ala Tyr Arg Asn Val Leu Arg Lys Asn Gly Asn 115 120 125Lys Gly Ala Gly Gly His Ser Tyr Gly Ile Asp Leu Lys Ser Tyr Asp 130 135 140Leu Gly Asp Glu Leu Gly Thr Asp Pro Ile Glu Asp Tyr Glu Gln Asn145 150 155 160Trp Asn Thr Lys His Gly Ser Gly Ala Leu Arg Glu Leu Thr Arg Glu 165 170 175Leu Asn Gly Gly Ala Val Thr Arg Tyr Val Asp Asn Asn Phe Cys Gly 180 185 190Pro Asp Gly Tyr Pro Leu Asp Cys Ile Lys Asp Phe Leu Ala Arg Ala 195 200 205Gly Lys Ser Met Cys Thr Leu Ser Glu Gln Leu Asp Tyr Ile Glu Ser 210 215 220Lys Arg Gly Val Tyr Cys Cys Arg Asp His Glu His Glu Ile Ala Trp225 230 235 240Phe Thr Glu Arg Ser Asp Lys Ser Tyr Glu His Gln Thr Pro Phe Glu 245 250 2551le Lys Ser Ala Lys Lys Phe Asp Thr Phe Lys Gly Glu Cys Pro Lys 260 265 270Phe Val Phe Pro Leu Asn Ser Lys Val Lys Val Ile Gln Pro Arg Val 275 280 285Glu Lys Lys Lys Thr Glu Gly Phe Met Gly Arg Ile Arg Ser Val Tyr 290 295 300Pro Val Ala Ser Pro Gln Glu Cys Asn Asn Met His Leu Ser Thr Leu305 310 315 320Met Lys Cys Asn His Cys Asp Glu Val Ser Trp Gln Thr Cys Asp Phe 325 330 335Leu Lys Ala Thr Cys Glu His Cys Gly Thr Glu Asn Leu Val Ile Glu 340 345 350Gly Pro Thr Thr Cys Gly Tyr Leu Pro Thr Asn Ala Val Val Lys Met 355 360 365Pro Cys Pro Ala Cys Gln Asp Pro Glu Ile Gly Pro Glu His Ser Val 370 375 380Ala Asp Tyr His Asn His Ser Asn Ile Glu Thr Arg Leu Arg Lys Gly385 390 395 400Gly Arg Thr Arg Cys Phe Gly Gly Cys Val Phe Ala Tyr Val Gly Cys 405 410 415Tyr Asn Lys Arg Ala Tyr Trp Val Pro Árg Ala Ser Ala Asp Ile Gly 420 425 430Ser Gly His Thr Gly Ile Thr Gly Asp Asn Val Glu Thr Leu Asn Glu 435 440 445Asp Leu Leu Glu Ile Leu Ser Arg Glu Arg Val Asn Ile Asn Ile Val 450 455 460Gly Asp Phe His Leu Asn Glu Glu Val Ala Ile Ile Leu Ala Ser Phe465 470 475 480Ser Ala Ser Thr Ser Ala Phe Ile Asp Thr Ile Lys Ser Leu Asp Tyr 485 490 495Lys Ser Phe Lys Thr Ile Val Glu Ser Cys Gly Asn Tyr Lys Val Thr 500 505 510Lys Gly Lys Pro Val Lys Gly Ala Trp Asn Ile Gly Gln Gln Arg Ser 515 520 525Val Leu Thr Pro Leu Cys Gly Phe Pro Ser Gln Ala Ala Gly Val Ile 530 535 540Arg Ser Ile Phe Ala Arg Thr Leu Asp Ala Ala Asn His Ser Ile Pro545 550 555 560Asp Leu Gln Arg Ala Ala Val Thr Ile Leu Asp Gly Ile Ser Glu Gln 565 570 575Ser Leu Arg Leu Val Asp Ala Met Val Tyr Thr Ser Asp Leu Leu Thr 580 585 590Asn Ser Val Ile Ile Met Ala Tyr Val Thr Gly Gly Leu Val Gln Gln 595 600 605Thr Ser Gln Trp Leu Ser Asn Leu Leu Gly Thr Thr Val Glu Lys Leu 610 615 620Arg Pro Ile Phe Glu Trp Ile Glu Ala Lys Leu Ser Ala Gly Val Glu625 630 635 640Phe Leu Lys Asp Ala Trp Glu Ile Leu Lys Phe Leu Ile Thr Gly Val 645 650 655Phe Asp Lie Val Lys Gly Gln IE GIn Val Ala Ser Asp Asn Ile Lys 660 665 670Asp Cys Val Lys Cys Phe Ile Asp Val Val Asn Lys Ala Leu Glu Met 675 680 685Cys Ile Asp Gln Val Thr Ile Ala Gly Ala Lys Leu Arg Ser Leu Asn 690 695 700Leu Gly Glu Val Phe Ile Ala Gln Ser Lys Gly Leu Tyr Arg Gln Cys705 710 715 720Ile Arg Gly Lys Glu Gln Leu Glu Met Pro Leu Lys Ala Pro 725 730 735Lys Glu Val Thr Phe Leu Glu Gly Asp Ser His Asp Thr Val Leu Thr 740 745 750Ser Glu Glu Val Val Leu Lys Asn Gly Glu Leu Glu Ala Leu Glu Thr 755 760 765Pro Val Asp Ser Leu Leu Lys Ala Ala Tyr 1100 1105 1110Glu Asn Phe Asn Ser Gln Asp Ile Leu Leu Ala Pro Leu Leu Ser 1115 1120 1125Ala Gly Ile Phe Gly Ala Lys Pro Leu Gln Ser Leu Gln Val Cys 1130 1135 1140 Val Gin Thr Val Arg Thr Gin Val Tyr Ile Ala Val Asn Asp Lys 1145 1150 1155 Ala Leu Tyr Glu Gin Val Val Met Asp Tyr Leu Asp Asn Leu Lys 1160 1165 1170 Pro Arg Val Glu Ala Pro Lys Gln Glu Glu Pro Pro Asn Thr Glu 1175 1180 1185Asp Ser Lys Thr Glu Glu Lys Ser Val Val Gln Lys Pro Val Asp 1190 1195 1200Val Lys Pro Lys Ile Lys Ala Cys Ile Asp Glu Val Thr Thr Thr 1205 1210 1215Leu Glu Glu Thr Lys Phe Leu Thr Asn Lys Leu Leu Leu Phe Ala 1220 1225 1230Asp Ile Asn Gly Lys Leu Tyr His Asp Ser Gin Asn Met Leu Arg 1235 1240 1245Gly Glu Asp Met Ser Phe Leu Glu Lys Asp Ala Pro Tyr Met Val 1250 1255 1260Gly Asp Val Ile Thr Ser Gly Asp Ile Thr Cys Val Val Ile Pro 1265 1270 1275Ser Lys Lys Ala Gly Gly Thr Thr Glu Met Leu Ser Arg Ala Leu 1280 1285 1290Lys Lys Val Pro Val Asp Glu Tyr Ile Thr Tyr Pro Gly Gln 1295 1300 1305Gly Cys Ala Gly Tyr Thr Leu Glu Glu Ala Lys Thr Ala Leu Lys 1310 1315 1320Lys Cys Lys Ser Ala Phe Tyr Val Leu Pro Ser Glu Ala Pro Asn 1325 1330 1335Ala Lys Glu Glu Ile Leu Gly Thr Val Ser Trp Asn Leu Arg Glu 1340 1345 1350Met Leu Ala His Ala Glu Glu Thr Arg Lys Leu Met Pro Ile Cys 1355 1360 1365Met Asp Val Arg Ala Ile Met Ala Thr Ile Gln Arg Lys Tyr Lys 1370 1375 1380Gly Ile Lys Ile Gln Glu Gly Ile Val Asp Tyr Gly Val Arg Phe 1385 1390 1395Phe Phe Tyr Thr Ser Lys Glu Pro Val Ala Ser Ile Ile Thr Lys 1400 1405 1410Leu Asn Ser Leu Asn Glu Pro Leu Val Thr Met Pro Ile Gly Tyr 1415 1420 1425Val Thr His Gly Phe Asn Leu Glu Glu Ala Ala Arg Cys Met Arg 1430 1435 1440Ser Leu Lys Ala Pro Ala Val Val Ser Val Ser Pro Asp Ala 1445 1450 1455 Val Thr Thr Tyr Asn Gly Tyr Leu Thr Ser Ser Ser Lys Thr Ser 1460 1465 1470Glu Glu His Phe Val Glu Thr Val Ser Leu Ala Gly Ser Tyr Arg 1475 1480 1485Asp Trp Ser Tyr Ser Gly Gln Arg Thr Glu Leu Gly Val Glu Phe 1490 1495

1500Leu Lys Arg Gly Asp Lys Ile Val Tyr His Thr Leu Glu Ser Pro 1505 1510 1515Val Glu Phe His Leu Asp Gly Glu Val Leu Ser Leu Asp Lys Leu 1520 1525 1530Lys Ser Leu Leu Ser Leu Arg Glu Val Lys Thr Ile Lys Val Phe 1535 1540 1545Thr Thr Val Asp Asn Thr Asn Leu His Thr Gln Leu Val Asp Met 1550 1555 1560Ser Met Thr Tyr Gly Gln Gln Phe Gly Pro Thr Tyr Leu Asp Gly 1565 1570 1575 Åla Asp Val Thr Lys Ile Lys Pro His Val Asn His Glu Gly Lys 1580 1585 1590 Thr Phe Phe Val Leu Pro Ser Asp Asp Thr Leu Arg Ser Glu Ala 1595 1600 1605Phe Glu Tyr Tyr His Thr Leu Asp Glu Ser Phe Leu Gly Arg Tyr 1610 1615 1620Met Ser Ala Leu Asn His Thr Lys Lys Trp Lys Phe Pro Gln Val 1625 1630 1635Gly Gly Leu Thr Ser Ile Lys Trp Ala Asp Asn Asn Cys Tyr Leu 1640 1645 1650Ser Ser Val Leu Leu Ala Leu Gln Gln Leu Glu Val Lys Phe Asn 1655 1660 1665Ala Pro Ala Leu Gln Glu Ala Tyr Tyr Arg Ala Arg Ala Gly Asp 1670 1675 1680Ala Ala Asn Phe Cys Ala Leu Ile Leu Ala Tyr Ser Asn Lys Thr 1685 1690 1695Val Gly Glu Leu Gly Asp Val Arg Glu Thr Met Thr His Leu Leu 1700 1705 1710Gln His Ala Asn Leu Glu Ser Ala Lys Arg Val Leu Asn Val Val 1715 1720 1725Cys Lys His Cys Gly Gln Lys Thr Thr Thr Leu Thr Gly Val Glu 1730 1735 1740Ala Val Met Tyr Met Gly Thr Leu Ser Tyr Asp Asn Leu Lys Thr 1745 1750 1755Gly Val Ser Ile Pro Cys Val Cys Gly Arg Asp Ala Thr Gln Tyr 1760 1765 1770Leu Val Gln Gln Gln Glu Ser Ser Phe Val Met Met Ser Ala Pro Pro 1775 1780 1785Ala Glu Tyr Lys Leu Gln Gln Gln Gln Gly Thr Phe Leu Cys Ala Asn Glu 1790 1795 1800Tyr Thr Gly Asn Tyr Gln Cys Gly His Tyr Thr His Ile Thr Ala 1805 1810 1815Lys Glu Thr Leu Tyr Arg Ile Asp Gly Ala His Leu Thr Lys Met 1820 1825 1830Ser Glu Tyr Lys Gly Pro Val Thr Asp Val Phe Tyr Lys Glu Thr 1835 1840 1845Ser Tyr Thr Thr Thr Ile Lys Pro Val Ser Tyr Lys Leu Asp Gly 1850 1855 1860Val Thr Tyr Thr Glu Ile Glu Pro Lys Leu Asp Gly Tyr Tyr Lys 1865 1870 1875Lys Asp Asn Ala Tyr Tyr Thr Glu Gln Pro Ile Asp Leu Val Pro 1880 1885 1890Thr Gln Pro Leu Pro Asn Ala Ser Phe Asp Asn Phe Lys Leu Thr 1895 1900 1905Cys Ser Asn Thr Lys Phe Ala Asp Asp Leu Asn Gln Met Thr Gly 1910 1915 1920Phe Thr Lys Pro Ala Ser Arg Glu Leu Ser Val Thr Phe Phe Pro 1925 1930 1935Asp Leu Asn Gly Asp Val Val Ala Ile Asp Tyr Arg His Tyr Ser 1940 1945 1950Ala Ser Phe Lys Lys Gly Ala Lys Leu Leu His Lys Pro Ile Val 1955 1960 1965Trp His Ile Asn Gln Ala Thr Thr Lys Thr Thr Phe Lys Pro Asn 1970 1975 1980Thr Trp Cys Leu Arg Cys Leu Trp Ser Thr Lys Pro Val Asp Thr 1985 1990 1995Ser Asn Ser Phe Glu Val Leu Ala Val Glu Asp Thr Gln Gly Met 2000 2005 2010Asp Asn Leu Ala Cys Glu Ser Gln Gln Pro Thr Ser Glu Glu Val 2015 2020 2025Val Glu Asn Pro Thr Ile Gln Lys Glu Val Ile Glu Cys Asp Val 2030 2035 2040Lys Thr Thr Glu Val Val Gly Asn Val Ile Leu Lys Pro Ser Asp 2045 2050 2055Glu Gly Val Lys Val Thr Gln Glu Leu Gly His Glu Asp Leu Met 2060 2065 2070Ala Ala Tyr Val Glu Asn Thr Ser Ile Thr Ile Lys Lys Pro Asn 2075 2080 2085Glu Leu Ser Leu Ala Leu Gly Leu Lys Thr Ile Ala Thr His Gly 2090 2095 2100Ile Ala Ala Ile Asn Ser Val Pro Trp Ser Lys Ile Leu Ala Tyr 2105 2110 2115Val Lys Pro Phe Leu Gly Gln Ala Ala Ile Thr Thr Ser Asn Cys 2120 2125 2130Ala Lys Arg Leu Ala Gln Arg Val Phe Asn Asn Tyr Met Pro Tyr 2135 2140 2145Val Phe Thr Leu Leu Phe Gln Leu Cys Thr Phe Thr Lys Ser Thr 2150 2155 2160Asn Ser Arg Ile Arg Ala Ser Leu Pro Thr Thr Ile Ala Lys Asn 2165 2170 2175Ser Val Lys Ser Val Ala Lys Leu Cys Leu Asp Ala Gly Ile Asn 2180 2185 2190Tyr Val Lys Ser Pro Lys Phe Ser Lys Leu Phe Thr Ile Ala Met 2195 2200 2205Trp Leu Leu Leu Leu Ser Ile Cys Leu Gly Ser Leu Ile Cys Val 2210 2215 2220Thr Ala Ala Phe Gly Val Leu Leu Ser Asn Phe Gly Ala Pro Ser 2225 2230 2235Tyr Cys Asn Gly Val Arg Glu Leu Tyr Leu Asn Ser Ser Asn Val 2240 2245 2250Thr Thr Met Asp Phe Cys Glu Gly Ser Phe Pro Cys Ser Ile Cys 2255 2260 2265Leu Ser Gly Leu Asp Ser Leu Asp Ser Tyr Pro Ala Leu Glu Thr 2270 2275 2280Ile Gln Val Thr Ile Ser Ser Tyr Lys Leu Asp Leu Thr Ile Leu 2285 2290 2295Gly Leu Ala Ala Glu Trp Val Leu Ala Tyr Met Leu Phe Thr Lys 2300 2305 2310Phe Phe Tyr Leu Leu Gly Leu Ser Ala Ile Met Gln Val Phe Phe 2315 2320 2325Gly Tyr Phe Ala Ser His Phe Ile Ser Asn Ser Trp Leu Met Trp 2330 2335 2340Phe Ile Ile Ser Ile Val Gln Met Ala Pro Val Ser Ala Met Val 2345 2350 2355Arg Met Tyr Ile Phe Phe Ala Ser Phe Tyr Tyr Ile Trp Lys Ser 2360 2365 2370Tyr Val His Ile Met Asp Gly Cys Thr Ser Ser Thr Cys Met Met 2375 2380 2385Cys Tyr Lys Arg Asn Arg Ala Thr Arg Val Glu Cys Thr Thr Ile 2390 2395 2400Val Asn Gly Met Lys Arg Ser Phe Tyr Val Tyr Ala Asn Gly Gly 2405 2410 2415 Arg Gly Phe Cys Lys Thr His Asn Trp Asn Cys Leu Asn Cys Asp 2420 2425 2430 Thr Phe Cys Thr Gly Ser Thr Phe Ile Ser Asp Glu Val Ala Arg 2435 2440 2445Asp Leu Ser Leu Gin Phe Lys Arg Pro Ile Asn Pro Thr Asp Gin 2450 2455 2460Ser Ser Tyr Ile Val Asp Ser Val Ala Val Lys Asn Gly Ala Leu 2465 2470 2475His Leu Tyr Phe Asp Lys Ala Gly Gln Lys Thr Tyr Glu Arg His 2480 2485 2490Pro Leu Ser His Phe Val

Asn Leu Asp Asn Leu Arg Ala Asn Asn 2495 2500 2505Thr Lys Gly Ser Leu Pro Ile Asn Val Ile Val Phe Asp Gly Lys 2510 2515 2520Ser Lys Cys Asp Glu Ser Ala Ser Lys Ser Ala Ser Val Tyr Tyr 2525 2530 2535Ser Gln Leu Met Cys Gln Pro Ile Leu Leu Leu Asp Gln Val Leu 2540 2545 2550Val Ser Asp Val Gly Asp Ser Thr Glu Val Ser Val Lys Met Phe 2555 2560 2565Asp Ala Tyr Val Asp Thr Phe Ser Ala Thr Phe Ser Val Pro Met 2570 2575 2580Glu Lys Leu Lys Ala Leu Val Ala Thr Ala His Ser Glu Leu Ala 2585 2590 2595Lys Gly Val Ala Leu Asp Gly Val Leu Ser Thr Phe Val Ser Ala 2600 2605 2610Ala Arg Gln Gly Val Val Asp Thr Asp Val Asp Thr Lys Asp Val 2615 2620 2625Ile Glu Cys Leu Lys Leu Ser His His Ser Asp Leu Glu Val Thr 2630 2635 2640Gly Asp Ser Cys Asn Asn Phe Met Leu Thr Tyr Asn Lys Val Glu 2645 2650 2655Asn Met Thr Pro Arg Asp Leu Gly Ala Cys Ile Asp Cys Asn Ala 2660 2665 2670Arg His Ile Asn Ala Gln Val Ala Lys Ser His Asn Val Ser Leu 2675 2680 268511e Trp Asn Val Lys Asp Tyr Met Ser Leu Ser Glu Gln Leu Arg 2690 2695 2700Lys Gln 11e Arg Ser Ala Ala Lys Lys Asn Asn 11e Pro Phe Arg 2705 2710 2715Leu Thr Cys Ala Thr Thr Arg Gln Val Val Asn Val Ile Thr Thr 2720 2725 2730Lys Ile Ser Leu Lys Gly Gly Lys Ile Val Ser Thr Cys Phe Lys 2735 2740 2745Leu Met Leu Lys Ala Thr Leu Leu Cys Val Leu Ala Ala Leu Val 2750 2755 2760Cys Tyr Ile Val Met Pro Val His Thr Leu Ser Ile His Asp Gly 2765 2770 2775 Tyr Thr Asn Glu Ile Ile Gly Tyr Lys Ala Ile Gln Asp Gly Val 2780 2785 2790Thr Arg Asp Ile Ile Ser Thr Asp Asp Cys Phe Ala Asn Lys His 2795 2800 2805Ala Gly Phe Asp Ala Trp Phe Ser Gln Arg Gly Gly Ser Tyr Lys 2810 2815 2820Asn Asp Lys Ser Cys Pro Val Val Ala Ala Ile Ile Thr Arg Glu 2825 2830 2835Ile Gly Phe Ile Val Pro Gly Leu Pro Gly Thr Val Leu Arg Ala 2840 2845 2850Ile Asn Gly Asp Phe Leu His Phe Leu Pro Arg Val Phe Ser Ala 2855 2860 2865Val Gly Asn Ile Cys Tyr Thr Pro Ser Lys Leu Ile Glu Tyr Ser 2870 2875 2880Asp Phe Ala Thr Ser Ala Cys Val Leu Ala Ala Glu Cys Thr Ile 2885 2890 2895Phe Lys Asp Ala Met Gly Lys Pro Val Pro Tyr Cys Tyr Asp Thr 2900 2905 2910Asn Leu Leu Glu Gly Ser Ile Ser Tyr Ser Glu Leu Arg Pro Asp 2915 2920 2925Thr Arg Tyr Val Leu Met Asp Gly Ser Ile Ile Gln Phe Pro Asn 2930 2935 2940Thr Tyr Leu Glu Gly Ser Val Arg Val Val Thr Thr Phe Asp Ala 2945 2950 2955Glu Tyr Cys Arg His Gly Thr Cys Glu Arg Ser Glu Val Gly Ile 2960 2965 2970Cys Leu Ser Thr Ser Gly Arg Trp Val Leu Asn Glu His Tyr 2975 2980 2985Arg Ala Leu Ser Gly Val Asp Ala Met Asn Leu 2990 2995 3000lle Ala Asn Ile Phe Thr Pro Leu Val Gln Pro Val Gly Ala Leu 3005 3010 3015Asp Val Ser Ala Ser Val Val Ala Gly Gly Ile Ile Ala Ile Leu 3020 3025 3030Val Thr Cys Ala Ala Tyr Tyr Phe Met Lys Phe Arg Arg Val Phe 3035 3040 3045Gly Glu Tyr Asn His Val Val Ala Ala Asn Ala Leu Leu Phe Leu 3050 3055 3060Met Ser Phe Thr Ile Leu Cys Leu Val Pro Ala Tyr Ser Phe Leu 3065 3070 3075Pro Gly Val Tyr Ser Val Phe Tyr Leu Tyr Leu Tyr Leu Thr Phe 3080 3085 3090Thr Asn Asp Val Ser Phe Leu Ala His Leu Gln Trp Phe Ala Met 3095 3100 3105Phe Ser Pro Ile Val Pro Phe Trp Ile Thr Ala Ile Tyr Val Phe 3110 3115 3120Cys Ile Ser Leu Lys His Cys His Trp Phe Phe Asn Asn Tyr Leu 3125 3130 3135Arg Lys Arg Val Met Phe Asn Gly Val Thr Phe Ser Thr Phe Glu 3140 3145 3150Glu Ala Ala Leu Cys Thr Phe Leu Leu Asn Lys Glu Met Tyr Leu 3155 3160 3165Lys Leu Arg Ser Glu Thr Leu Leu Pro Leu Thr Gln Tyr Asn Arg 3170 3175 3180Tyr Leu Ala Leu Tyr Asn Lys Tyr Lys Tyr Phe Ser Gly Ala Leu 3185 3190 3195Asp Thr Thr Ser Tyr Arg Glu Ala Ala Cys Cys His Leu Ala Lys 3200 3205 3210Ala Leu Asn Asp Phe Ser Asn Ser Gly Ala Asp Val Leu Tyr Gln 3215 3220 3225Pro Pro Gln Thr Ser Ile Thr Ser Ala Val Leu Gln Ser Gly Phe 3230 3235 3240Arg Lys Met Ala Phe Pro Ser Gly Lys Val Glu Gly Cys Met Val 3245 3250 3255Gln Val Thr Cys Gly Thr Thr Leu Asn Gly Leu Trp Leu Asp 3260 3265 3270Asp Thr Val Tyr Cys Pro Arg His Val Ile Cys Thr Ala Glu Asp 3275 3280 3285Met Leu Asn Pro Asn Tyr Glu Asp Leu Leu Ile Arg Lys Ser Asn 3290 3295 3300His Ser Phe Leu Val Gln Ala Gly Asn Val Gln Leu Arg Val Ile 3305 3310 3315Gly His Ser Met Gln Asn Cys Leu Leu Arg Leu Lys Val Asp Thr 3320 3325 3330Ser Asn Pro Lys Thr Pro Lys Tyr Lys Phe Val Arg Ile Gln Pro 3335 3340 3345Gly Gln Thr Phe Ser Val Leu Ala Cys Tyr Asn Gly Ser Pro Ser 3350 3355 3360Gly Val Tyr Gln Cys Ala Met Arg Pro Asn His Thr Ile Lys Gly 3365 3370 3375Ser Phe Leu Asn Gly Ser Cys Gly Ser Val Gly Phe Asn Ile Asp 3380 3385 3390Tyr Asp Cys Val Ser Phe Cys Tyr Met His His Met Glu Leu Pro 3395 3400 3405Thr Gly Val His Ala Gly Thr Asp Leu Glu Gly Lys Phe Tyr Gly 3410 3415 3420Pro Phe Val Asp Arg Gln Thr Ala Gln Ala Ala Gly Thr Asp Thr 3425 3430 3435Thr Ile Thr Leu Asn Val Leu Ala Trp Leu Tyr Ala Ala Val Ile 3440 3445 3450Asn Gly Asp Arg Trp Phe Leu Asn Arg Phe Thr Thr Thr Leu Asn 3455 3460 3465Asp Phe Asn Leu Val Ala Met Lys Tyr Asn Tyr Glu Pro Leu Thr 3470 3475 3480Gln Asp His Val Asp Hie Leu Gly Pro Leu Ser Ala Gln Thr Gly 3485 3490 3495Ile Ala Val Leu Asp Met Cys Ala Ala Leu Lys Glu Leu Leu Glu 3500 3505 3510Asn Gly Met Asn Gly Arg Thr Ile Leu Gly Ser Thr Ile Leu Glu 3515 3520 3525Asp Glu Phe Thr Pro Phe Asp Val Val Arg Gln Cys Ser Gly Val 3530 3535 3540Thr Phe Gln Gly Lys Phe Lys Lys Ile Val Lys Gly Thr His His 3545 3550 3555Trp Met Leu Leu Thr Phe Leu Thr Ser Leu Leu Ile Leu Val Gln 3560 3565 3570Ser Thr Gln Trp Ser Leu Phe Phe Val Tyr Glu Asn Ala Phe 3575 3580 3585Leu Pro Phe Thr Leu Gly Ile Met Ala Ile Ala Ala Cys Ala Met 3590 3595 3600Leu Leu Val Lys His Lys His Ala Phe Leu Cys Leu Phe Leu Leu 3605 3610 3615Pro Ser Leu Ala Thr Val Ala Tyr Phe Asn Met Val Tyr Met Pro 3620 3625 3630Ala Ser Trp Val Met Arg Ile Met Thr Trp Leu Glu Leu Ala Asp 3635 3640 3645Thr Ser Leu Ser Gly Tyr Arg Leu Lys Asp Cys Val Met Tyr Ala 3650 3655 3660Ser Ala Leu Val Leu Leu Ile Leu Met Thr Ala Arg Thr Val Tyr 3665 3670 3675Asp Asp Ala Ala Arg Arg Val Trp Thr Leu Met Asn Val Ile Thr 3680 3685 3690Leu Val Tyr Lys Val Tyr Tyr Gly Asn Ala Leu Asp Gln Ala Ile 3695 3700 3705Ser Met Trp Ala Leu Val Ile Ser Val Thr Ser Asn Tyr Ser Gly 3710 3715 3720Val Val Thr Thr Ile Met Phe Leu Ala Arg Ala Ile Val Phe Val 3725 3730 3735Cys Val Glu Tyr Tyr Pro Leu Leu Phe Ile Thr Gly Asn Thr Leu 3740 3745 3750Gln Cys Ile Met Leu Val Tyr Cys Phe Leu Gly Tyr Cys Cys 3755 3760 3765Cys Tyr Phe Gly Leu Phe Cys Leu Leu Asn Arg Tyr Phe Arg Leu 3770 3775 3780Thr Leu Gly Val Tyr Asp Tyr Leu Val Ser Thr Gln Glu Phe Arg 3785 3790 3795Tyr Met Asn Ser Gln Gly Leu Leu Pro Pro Lys Ser Ser Île Asp 3800 3805 3810Ala Phe Lys Leu Asn Ile Lys Leu Leu Gly Île Gly Gly Lys Pro 3815 3820 3825Cys Ile Lys Val Ala Thr Val Gin Ser Lys Met Ser Asp Val Lys 3830 3835 3840Cys Thr Ser Val Val Leu Leu Ser Val Leu Gin Gin Leu Arg Val 3845 3850 3855Giu Ser Ser Lys Leu Trp Ala Gin Cys Val Gin Leu His Asn 3860 3865 3870Asp Ile Leu Leu Ala Lys Asp Thr Thr Glu Ala Phe Glu Lys Met 3875 3880 3885Val Ser Leu Leu Ser Val Leu Leu Ser Met Gln Gly Ala Val Asp 3890 3895 3900Ile Asn Arg Leu Cys Glu Glu Met Leu Asp Asn Arg Ala Thr Leu 3905 3910 3915Gin Ala Ile Ala Ser Glu Phe Ser Ser Leu Pro Ser Tyr Ala Ala 3920 3925 3930Tyr Ala Thr Ala Gin Glu Ala Tyr Glu Gln Ala Val Ala Asn Gly 3935 3940 3945Asp Ser Glu Val Val Leu Lys Lys Leu Lys Lys Ser Leu Asn Val 3950 3955 3960Ala Lys Ser Glu Phe Asp Arg Asp Ala Ala Met Gln Arg Lys Leu 3965 3970 3975Glu Lys Met Ala Asp Gln Ala Met Thr Gln Met Tyr Lys Gln Ala 3980 3985 3990Arg Ser Glu Asp Lys Arg Ala Lys Val Thr Ser Ala Met Gln Thr 3995 4000 4005Met Leu Phe Thr Met Leu Arg Lys Leu Asp Asp Asp Asp Ala Leu Asp 4010 4015 4020Asp Ile Ile Asp Asp Ala Arg Asp Gly Cys Val Pro Leu Asp Ile 4025 4030 4035Ile Pro Leu Thr Thr Ala Ala Lys Leu Met Val Val Val Pro Asp 4040 4045 4050Tyr Gly Thr Tyr Lys Asn Thr Cys Asp Gly Asn Thr Phe Thr Tyr 4055 4060 4065Ala Ser Ala Leu Trp Glu Ile Gln Gln Val Val Asp Ala Asp Ser 4070 4075 4080Lys Ile Val All Leu Arg Gln 4115 4120 4125Met Ser Cys Ala Ala Gly Thr Thr Gln Thr Ala Cys Thr Asp Asp 4130 4135 4140Asn Ala Leu Ala Tyr Tyr Asn Asn Ser Lys Gly Gly Arg Phe Val 4145 4150 Gin Pro Ile Thr Asn Cys Val Lys Met Leu Cys Thr His 4265 4270 4275Thr Gly Thr Gly Gin Ala Ile Thr Val Thr Pro Glu Ala Asn Met 4280 4285 4290Asp Gin Glu Ser Phe Gly Gly Ala Ser Cys Cys Leu Tyr Cys Arg 4295 4300 4305Cys His Ile Asp His Pro Asn Pro Lys Gly Phe Cys Asp Leu Lys 4310 4315 4320Gly Lys Tyr Val Gln Ile Pro Thr Thr Cys Ala Asn Asp Pro Val 4325 4330 4335Gly Phe Thr Leu Arg Asn Thr Val Cys Thr Val Cys Gly Met Trp 4340 4345 4350Lys Gly Tyr Gly Cys Ser Cys Asp Gln Leu Arg Glu Pro Leu Met 4355 4360 4365Gln Ser Ala Asp Ala Ser Thr Phe Leu Asn Gly Phe Ala Val 4370 4375 438032695PRTCoronavirus 3Arg Val Cys Gly Val Ser Ala Ala Arg Leu Thr Pro Cys Gly Thr Gly 1 5 10 15Thr Ser Thr Asp Val Val Tyr Arg Ala Phe Asp Ile Tyr Asn Glu Lys 20 25 30Val Ala Gly Phe Ala Lys Phe Leu Lys Thr Asn Cys Cys Arg Phe Gln 35 40 45Glu Lys Asp Glu Gly Asn Leu Leu Asp Ser Tyr Phe Val Val Lys 50 55 60Arg His Thr Met Ser Asn Tyr Gln His Glu Glu Thr Ile Tyr Asn Leu65 70 75 80Val Lys Asp Cys Pro Ala Val Ala Val His Asp Phe Phe Lys Phe Arg 85 90 95Val Asp Gly Asp Met Val Pro His Ile Ser Arg Gln Arg Leu Thr Lys 100 105 110Tyr Thr Met Ala Asp Leu Val Tyr Ala Leu Arg His Phe Asp Glu Gly 115 120 125Asn Cys Asp Thr Leu Lys Glu Ile Leu Val Thr Tyr Asn Cys Cys Asp 130 135 140Asp Asp Tyr Phe Asn Lys Lys Asp Trp Tyr Asp Phe Val Glu Asn Pro145 150 155 160Asp Ile Leu Arg Val Tyr Ala Asn Leu Gly Glu Arg Val Arg Gln Ser 165 170 175Leu Leu Lys Thr Val Gln Phe Cys Asp Ala Met Arg Asp Ala Gly Ile 180 185 190Val Gly Val Leu Thr Leu Asp Asn Gln Asp Leu Asn Gly Asn Trp Tyr 195 200 205Asp Phe Gly Asp Phe Val Gln Val Ala Pro Gly Cys Gly Val Pro Ile 210 215 220 Val Asp Ser Tyr Tyr Ser Leu Leu Met Pro Ile Leu Thr Leu Thr Arg225 230 235 240 Ala Leu Ala Ala Glu Ser His Met Asp Ala Asp Leu Ala Lys Pro Leu 245 250 2551le Lys Trp Asp Leu Leu Lys Tyr Asp Phe Thr Glu Glu Arg Leu Cys 260 265 270Leu Phe Asp Arg Tyr Phe Lys Tyr Trp Asp Gln Thr Tyr His Pro Asn 275 280 285Cys Ile Asn

Cys Leu Asp Asp Arg Cys Ile Leu His Cys Ala Asn Phe 290 295 300Asn Val Leu Phe Ser Thr Val Phe Pro Pro Thr Ser Phe Gly Pro Leu305 310 315 320Val Arg Lys Ile Phe Val Asp Gly Val Pro Phe Val Val Ser Thr Gly 325 330 335Tyr His Phe Arg Glu Leu Gly Val Val His Asn Gln Asp Val Asn Leu 340 345 350His Ser Ser Arg Leu Ser Phe Lys Glu Leu Leu Val Tyr Ala Ala Asp 355 360 365Pro Ala Met His Ala Ala Ser Gly Asn Leu Leu Leu Asp Lys Arg Thr 370 375 380Thr Cys Phe Ser Val Ala Ala Leu Thr Asn Asn Val Ala Phe Gln Thr385 390 395 400Val Lys Pro Gly Asn Phe Asn Lys Asp Phe Tyr Asp Phe Ala Val Ser 405 410 415Lys Gly Phe Phe Lys Glu Gly Ser Ser Val Glu Leu Lys His Phe Phe 420 425 430Phe Ala Gln Asp Gly Asn Ala Ala Ile Ser Asp Tyr Asp Tyr Tyr Arg 435 440 445Tyr Asn Leu Pro Thr Met Cys Asp Ile Arg Gln Leu Leu Phe Val Val 450 455 460Glu Val Ala Asp Lys Tyr Phe Asp Cys Tyr Asp Gly Gly Cys Ile Asn465 470 475 480Ala Asn Gln Val Ile Val Asn Asn Leu Asp Lys Ser Ala Gly Phe Pro 485 490 495Phe Asn Lys Trp Gly Lys Ala Arg Leu Tyr Tyr Asp Ser Met Ser Tyr 500 505 510Glu Asp Gln Asp Her Yr Asp Ser Mat Gly Val Phe Ala Gln Yas Cys Thr Met Thr Asn Arg 545 550 555

560Gln Phe His Gln Lys Leu Leu Lys Ser Ile Ala Ala Thr Arg Gly Ala 565 570 575Thr Val Val Ile Gly Thr Ser Lys Phe Tyr Gly Gly Trp His Asn Met 580 585 590Leu Lys Thr Val Tyr Ser Asp Val Glu Thr Pro His Leu Met Gly Trp 595 600 605Asp Tyr Pro Lys Cys Asp Arg Ala Met Pro Asn Met Leu Arg Ile Met 610 615 620Ala Ser Leu Val Leu Ala Arg Lys His Asn Thr Cys Cys Asn Leu Ser625 630 635 640His Arg Phe Tyr Arg Leu Ala Asn Glu Cys Ala Gln Val Leu Ser Glu 645 650 655Met Val Met Cys Gly Gly Ser Leu Tyr Val Lys Pro Gly Gly Thr Ser 660 665 670Ser Gly Asp Ala Thr Thr Ala Tyr Ala Asn Ser Val Phe Asn Ile Cys 675 680 685Gln Ala Val Thr Ala Asn Val Asn Ala Leu Leu Ser Thr Asp Gly Asn 690 695 700Lys Ile Ala Asp Lys Tyr Val Arg Asn Leu Gin His Arg Leu Tyr Glu705 710 715 720Cys Leu Tyr Arg Asn Arg Asp Val Asp His Glu Phe Val Asp Glu Phe 725 730 735Tyr Ala Tyr Leu Arg Lys His Phe Ser Met Met Ile Leu Ser Asp Asp 740 745 750Ala Val Val Cys Tyr Asn Ser Asn Tyr Ala Ala Gln Gly Leu Val Ala 755 760 765Ser Ile Lys Asn Phe Lys Ala Val Leu Tyr Tyr Gln Asn Asn Val Phe 770 775 780Met Ser Glu Ala Lys Cys Trp Thr Glu Thr Asp Leu Thr Lys Gly Pro785 790 795 800His Glu Phe Cys Ser Gln His Thr Met Leu Val Lys Gln Gly Asp Asp 805 810 815Tyr Val Tyr Leu Pro Tyr Pro Asp Pro Ser Arg Ile Leu Gly Ala Gly 820 825 830Cys Phe Val Asp Asp Ile Val Lys Thr Asp Gly Thr Leu Met Ile Glu 835 840 845Arg Phe Val Ser Leu Ala Ile Asp Ala Tyr Pro Leu Thr Lys His Pro 850 855 860Asn Gln Glu Tyr Ala Asp Val Phe His Leu Tyr Leu Gln Tyr Ile Arg865 870 875 880Lys Leu His Asp Glu Leu Thr Gly His Met Leu Asp Met Tyr Ser Val 885 890 895Met Leu Thr Asn Asp Asn Thr Ser Arg Tyr Trp Glu Pro Glu Phe Tyr 900 905 910Glu Ala Met Tyr Thr Pro His Thr Val Leu Gln Ala Val Gly Ala Cys 915 920 925Val Leu Cys Asn Ser Gln Thr Ser Leu Arg Cys Gly Ala Cys Ile Arg 930 935 940 Arg Pro Phe Leu Cys Cys Lys Cys Cys Tyr Asp His Val Ile Ser Thr945 950 955 960 Ser His Lys Leu Val Leu Ser Val Asn Pro Tyr Val Cys Asn Ala Pro 965 970 975Gly Cys Asp Val Thr Asp Val Thr Gln Leu Tyr Leu Gly Gly Met Ser 980 985 990Tyr Tyr Cys Lys Ser His Lys Pro Pro Ile Ser Phe Pro Leu Cys Ala 995 1000 1005Asn Gly Gln Val Phe Gly Leu Tyr Lys Asn Thr Cys Val Gly Ser 1010 1015 1020Asp Asn Val Thr Asp Phe Asn Ala Ile Ala Thr Cys Asp Trp Thr 1025 1030 1035Asn Ala Gly Asp Tyr Ile Leu Ala Asn Thr Cys Thr Glu Arg Leu 1040 1045 1050Lys Leu Phe Ala Ala Glu Thr Leu Lys Ala Thr Glu Glu Thr Phe 1055 1060 1065Lys Leu Ser Tyr Gly Ile Ala Thr Val Arg Glu Val Leu Ser Asp 1070 1075 1080Arg Glu Leu His Leu Ser Trp Glu Val Gly Lys Pro Arg Pro Pro 1085 1090 1095Leu Asn Arg Asn Tyr Val Phe Thr Gly Tyr Arg Val Thr Lys Asn 1100 1105 1110Ser Lys Val Gln Ile Gly Glu Tyr Thr Phe Glu Lys Gly Asp Tyr 1115 1120 1125Gly Asp Ala Val Val Tyr Arg Gly Thr Thr Thr Tyr Lys Leu Asn 1130 1135 1140Val Gly Asp Tyr Phe Val Leu Thr Ser His Thr Val Met Pro Leu 1145 1150 1155Ser Ala Pro Thr Leu Val Pro Gln Glu His Tyr Val Arg Ile Thr 1160 1165 1170Gly Leu Tyr Pro Thr Leu Asn Ile Ser Asp Glu Phe Ser Ser Asn 1175 1180 1185Val Ala Asn Tyr Gln Lys Val Gly Met Gln Lys Tyr Ser Thr Leu 1190 1195 1200Gln Gly Pro Pro Gly Thr Gly Lys Ser His Phe Ala Ile Gly Leu 1205 1210 1215Ala Leu Tyr Tyr Pro Ser Ala Arg Ile Val Tyr Thr Ala Cys Ser 1220 1225 1230His Ala Ala Val Asp Ala Leu Cys Glu Lys Ala Leu Lys Tyr Leu 1235 1240 1245Pro Ile Asp Lys Cys Ser Arg Ile Ile Pro Ala Arg Ala Arg Val 1250 1255 1260Glu Cys Phe Asp Lys Phe Lys Val Asn Ser Thr Leu Glu Gln Tyr 1265 1270 1275 Val Phe Cys Thr Val Asn Ala Leu Pro Glu Thr Thr Ala Asp Ile 1280 1285 1290 Val Val Phe Asp Glu Ile Ser Met Ala Thr Asn Tyr Asp Leu Ser 1295 1300 1305Val Val Asn Ala Arg Leu Arg Ala Lys His Tyr Val Tyr Ile Gly 1310 1315 1320Asp Pro Ala Gln Leu Pro Ala Pro Arg Thr Leu Leu Thr Lys Gly 1325 1330 1335Thr Leu Glu Pro Glu Tyr Phe Asn Ser Val Cys Arg Leu Met Lys 1340 1345 1350Thr lle Gly Pro Asp Met Phe Leu Gly Thr Cys Arg Arg Cys Pro 1355 1360 1365Ala Glu Ile Val Asp Thr Val Ser Ala Leu Val Tyr Asp Asn Lys 1370 1375 1380Leu Lys Ala His Lys Asp Lys Ser Ala Gln Cys Phe Lys Met Phe 1385 1390 1395Tyr Lys Gly Val Ile Thr His Asp Val Ser Ser Ala Ile Asn Arg 1400 1405 1410Pro Gln Ile Gly Val Val Arg Glu Phe Leu Thr Arg Asn Pro Ala 1415 1420 1425Trp Arg Lys Ala Val Phe Ile Ser Pro Tyr Asn Ser Gln Asn Ala 1430 1435 1440Val Ala Ser Lys Ile Leu Gly Leu Pro Thr Gln Thr Val Asp Ser 1445 1450 1455Ser Gln Gly Ser Glu Tyr Asp Tyr Val Ile Phe Thr Gln Thr Thr 1460 1465 1470Glu Thr Ala His Ser Cys Asn Val Asn Arg Phe Asn Val Ala Ile 1475 1480 1485Thr Arg Ala Lys Ile Gly Ile Leu Cys Ile Met Ser Asp Arg Asp 1490 1495 1500Leu Tyr Asp Lys Leu Gln Phe Thr Ser Leu Glu Ile Pro Arg Arg 1505 1510 1515Asn Val Ala Thr Leu Gln Ala Glu Asn Val Thr Gly Leu Phe Lys 1520 1525 1530Asp Cys Ser Lys Ile Ile Thr Gly Leu His Pro Thr Gln Ala Pro 1535 1540 1545Thr His Leu Ser Val Asp Ile Lys Phe Lys Thr Glu Gly Leu Cys 1550 1555 1560Val Asp Ile Pro Gly Ile Pro Lys Asp Met Thr Tyr Arg Arg Leu 1565 1570 1575Ile Ser Met Met Gly Phe Lys Met Asn Tyr Gln Val Asn Gly Tyr 1580 1585 1590Pro Asn Met Phe Ile Thr Arg Glu Glu Ala Ile Arg His Val Arg 1595 1600 1605Ala Trp Ile Gly Phe Asp Val Glu Gly Cys His Ala Thr Arg Asp 1610 1615 1620Ala Val Gly Thr Asn Leu Pro Leu Gln Leu Gly Phe Ser Thr Gly 1625 1630 1635 Val Asn Leu Val Ala Val Pro Thr Gly Tyr Val Asp Thr Glu Asn 1640 1645 1650 Asn Thr Glu Phe Thr Arg Val Asn Ala Lys Pro Pro Pro Gly Asp 1655 1660 1665Gln Phe Lys His Leu Ile Pro Leu Met Tyr Lys Gly Leu Pro Trp 1670 1675 1680Asn Val Val Arg Ile Lys Ile Val Gln Met Leu Ser Asp Thr Leu 1685 1690 1695Lys Gly Leu Ser Asp Arg Val Val Phe Val Leu Trp Ala His Gly 1700 1705 1710Phe Glu Leu Thr Ser Met Lys Tyr Phe Val Lys Ile Gly Pro Glu 1715 1720 1725Arg Thr Cys Cys Leu Cys Asp Lys Arg Ala Thr Cys Phe Ser Thr 1730 1735 1740Ser Ser Asp Thr Tyr Ala Cys Trp Asn His Ser Val Gly Phe Asp 1745 1750 1755Tyr Val Tyr Asn Pro Phe Met Ile Asp Val Gin Gln Trp Gly Phe 1760 1765 1770Thr Gly Asn Leu Gln Ser Asn His Asp Gln His Cys Gln Val His 1775 1780 1785Gly Asn Ala His Val Ala Ser Cys Asp Ala Ile Met Thr Arg Cys 1790 1795 1800Leu Ala Val His Glu Cys Phe Val Lys Arg Val Asp Trp Ser Val 1805 1810 1815Glu Tyr Pro Ile Ile Gly Asp Glu Leu Arg Val Asn Ser Ala Cys 1820 1825 1830Arg Lys Val Gln His Met Val Val Lys Ser Ala Leu Leu Ala Asp 1835 1840 1845Lys Phe Pro Val Leu His Asp Ile Gly Asn Pro Lys Ala Ile Lys 1850 1855 1860Cys Val Pro Gin Ala Glu Val Glu Trp Lys Phe Tyr Asp Ala Gln 1865 1870 1875Pro Cys Ser Asp Lys Ala Tyr Lys Ile Glu Glu Leu Phe Tyr Ser 1880 1885 1890Tyr Ala Thr His His Asp Lys Phe Thr Asp Gly Val Cys Leu Phe 1895 1900 1905Trp Asn Cys Asn Val Asp Arg Tyr Pro Ala Asn Ala Ile Val Cys 1910 1915 1920Arg Phe Asp Thr Arg Val Leu Ser Asn Leu Asn Leu Pro Gly Cys 1925 1930 1935Asp Gly Gly Ser Leu Tyr Val Asn Lys His Ala Phe His Thr Pro 1940 1945 1950Ala Phe Asp Lys Ser Ala Phe Thr Asn Leu Lys Gln Leu Pro Phe 1955 1960 1965Phe Tyr Tyr Ser Asp Ser Pro Cys Glu Ser His Gly Lys Gln Val 1970 1975 1980Val Ser Asp Ile Asp Tyr Val Pro Leu Lys Ser Ala Thr Cys Ile 1985 1990 1995Thr Arg Cys Asn Leu Gly Gly Ala Val Cys Arg His His Ala Asn 2000 2005 2010Glu Tyr Arg Gln Tyr Leu Asp Ala Tyr Asn Met Met Ile Ser Ala 2015 2020 2025Gly Phe Ser Leu Trp Ile Tyr Lys Gin Phe Asp Thr Tyr Asn Leu 2030 2035 2040Trp Asn Thr Phe Thr Arg Leu Gin Ser Leu Glu Asn Val Ala Tyr 2045 2050 2055Asn Val Val Asn Lys Gly His Phe Asp Gly His Ala Gly Glu Ala 2060 2065 2070Pro Val Ser Ile Ile Asn Asn Ala Val Tyr Thr Lys Val Asp Gly 2075 2080 2085Ile Asp Val Glu Ile Phe Glu Asn Lys Thr Thr Leu Pro Val Asn 2090 2095 2100Val Ala Phe Glu Leu Trp Ala Lys Arg Asn Ile Lys Pro Val Pro 2105 2110 2115Glu Ile Lys Ile Leu Asn Asn Leu Gly Val Asp Ile Ala Asn 2120 2125 2130Thr Val Ile Trp Asp Tyr Lys Arg Glu Ala Pro Ala His Val Ser 2135 2140 2145Thr Ile Gly Val Cys Thr Met Thr Asp Ile Ala Lys Lys Pro Thr 2150 2155 2160Glu Ser Ala Cys Ser Ser Leu Thr Val Leu Phe Asp Gly Arg Val 2165 2170 2175Glu Gly Gln Val Asp Leu Phe Arg Asn Ala Arg Asn Gly Val Leu 2180 2185 2190Ile Thr Glu Gly Ser Val Lys Gly Leu Thr Pro Ser Lys Gly Pro 2195 2200 2205Ala Gln Ala Ser Val Asn Gly Val Thr Leu Ile Gly Glu Ser Val 2210 2215 2220Lys Thr Gln Phe Asn Tyr Phe Lys Lys Val Asp Gly Ile Ile Gln 2225 2230 2235Gln Leu Pro Glu Thr Tyr Phe Thr Gln Ser Arg Asp Leu Glu Asp 2240 2245 2250Phe Lys Pro Arg Ser Gln Met Glu Thr Asp Phe Leu Glu Leu Ala 2255 2260 2265Met Asp Glu Phe Ile Gln Arg Tyr Lys Leu Glu Gly Tyr Ala Phe 2270 2275 2280Glu His Ile Val Tyr Gly Asp Phe Ser His Gly Gln Leu Gly Gly 2285 2290 2295Leu His Leu Met Ile Gly Leu Ala Lys Arg Ser Gln Asp Ser Pro 2300 2305 2310Leu Lys Leu Glu Asp Phe Ile Pro Met Asp Ser Thr Val Lys Asn 2315 2320 2325Tyr Phe Ile Thr Asp Ala Gln Thr Gly Ser Ser Lys Cys Val Cys 2330 2335 2340Ser Val Ile Asp Leu Leu Leu Asp Asp Phe Val Glu Ile Ile Lys 2345 2350 2355Ser Gln Asp Leu Ser Val Ile Ser Lys Val Val Lys Val Thr Ile 2360 2365 2370Asp Tyr Ala Glu Ile Ser Phe Met Leu Trp Cys Lys Asp Gly His 2375 2380 2385Val Glu Thr Phe Tyr Pro Lys Leu Gln Ala Ser Gln Ala Trp Gln 2390 2395 2400Pro Gly Val Ala Met Pro Asn Leu Tyr Lys Met Gln Arg Met Leu 2405 2410 2415Leu Glu Lys Cys Asp Leu Gln Asn Tyr Gly Glu Asn Ala Val Ile 2420 2425 2430Pro Lys Gly Ile Met Met Asn Val Ala Lys Tyr Thr Gln Leu Cys 2435 2440 2445Gln Tyr Leu Asn Thr Leu Ala Val Pro Tyr Asn Met Arg 2450 2455 2460Val Ile His Phe Gly Ala Gly Ser Asp Lys Gly Val Ala Pro Gly 2465 2470 2475Thr Ala Val Leu Arg Gln Trp Leu Pro Thr Gly Thr Leu Leu Val 2480 2485 2490Asp Ser Asp Leu Asn Asp Phe Val Ser Asp Ala Asp Ser Thr Leu 2495 2500 25051le Gly Asp Cys Ala Thr Val His Thr Ala Asn Lys Trp Asp Leu 2510 2515 25201le Ile Ser Asp Met Tyr Asp Pro Arg Thr Lys His Val Thr Lys 2525 2530 2535Glu Asn Asp Ser Lys Glu Gly Phe Phe Thr Tyr Leu Cys Gly Phe 2540 2545 2550Ie Lys Gln Lys Leu Ala Leu Gly Gly Ser Ile Ala Val Lys Ile 2555 2560 2565Thr Glu His Ser Trp Asn Ala Asp Leu Tyr Lys Leu Met Gly His 2570 2575 2580Phe Ser Trp Trp Thr Ala Phe Val Thr Asn Val Asn Ala Ser Ser 2585 2590 2595Ser Glu Ala Phe Leu Ile Gly Ala Asn Tyr Leu Gly Lys Pro Lys 2600 2605 2610Glu Gln Ile Asp Gly Tyr Thr Met His Ala Ash Tyr Ile Phe Trp 2615 2620 2625Arg Ash Thr Ash Pro Ile Gln Leu Ser Ser Tyr Ser Leu Phe Asp 2630 2635 2640Met Ser Lys Phe Pro Leu Lys Leu Arg Gly Thr Ala Val Met Ser 2645 2650 2655Leu Lys Glu Asn Gln Ile Asn Asp Met Ile Tyr Ser Leu Leu Glu 2660 2665 2670Lys Gly Arg Leu Ile Ile Arg Glu Asn Asn Arg Val Val Val Ser 2675 2680 2685Ser Asp Ile Leu Val Asn Asn 2690 269541255PRTCoronavirus 4Met Phe Ile Phe Leu Leu Phe Leu Thr Leu Thr Ser Gly Ser Asp Leu 1 5 10 15Asp Arg Cys Thr Thr Phe Asp Asp Val Gln Ala Pro Asn Tyr Thr Gln 20 25 30His Thr Ser Ser Met Arg Gly Val Tyr Tyr Pro Asp Glu Ile Phe Arg 35 40 45Ser Asp Thr Leu Tyr Leu Thr GIn Asp Leu Phe Leu Pro Phe Tyr Ser 50 55 60Asn Val Thr Gly Phe His Thr Ile Asn His Thr Phe Gly Asn Pro Val65 70 75 80Ile Pro Phe Lys Asp Gly Ile Tyr Phe Ala Ala Thr Glu Lys Ser Asn 85 90 95Val Val Arg Gly Trp Val Phe Gly Ser Thr Met Asn Asn Lys Ser Gln 100 105 110Ser Val IIe Ile Ile Asn Asn Ser Thr Asn Val Val Ile Arg Ala Cys 115 120 125Asn Phe Glu Leu Cys Asp Asn Pro Phe Phe Ala Val Ser Lys Pro Met 130 135 140Gly Thr Gin Thr His Thr Met Ile Phe Asp Asn Ala Phe Asn Cys Thr145 150 155 160Phe Glu Tyr Ile Ser Asp Ala Phe Ser Leu Asp Val Ser Glu Lys Ser 165 170 175Gly Asn Phe Lys His Leu Arg Glu Phe Val Phe Lys Asn Lys Asp Gly 180 185 190Phe Leu Tyr Val Tyr Lys Gly Tyr Gln Pro Ile Asp Val Val Arg Asp 195 200 205Leu Pro Ser Gly Phe Asn Thr Leu Lys Pro Ile Phe Lys Leu Pro Leu 210 215 220Gly Ile Asn Ile Thr Asn Phe Arg Ala Ile Leu Thr Ala Phe Ser Pro225 230 235 240Ala Gln Asp Ile Trp Gly Thr Ser Ala Ala Ala Tyr Phe Val Gly Tyr 245 250 255Leu Lys Pro Thr Thr Phe Met Leu Lys Tyr Asp Glu Asn Gly Thr Ile 260 265 270Thr Asp Ala Val Asp Cys Ser Gln Asn Pro Leu Ala Glu Leu Lys Cys 275 280 285Ser Val Lys Ser Phe Glu Ile Asp Lys Gly Ile Tyr Gln Thr Ser Asn 290 295 300Phe Arg Val Val Pro Ser Gly Asp

Val Val Arg Phe Pro Asn lle Thr305 310 315 320Asn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Lys Phe Pro Ser 325 330 335Val Tyr Ala Trp Glu Arg Lys Lys lle Ser Asn Cys Val Ala Asp Tyr 340 345 350Ser Val Leu Tyr Asn Ser Thr Phe Phe Ser Thr Phe Lys Cys Tyr Gly 355 360 365Val Ser Ala Thr Lys Leu Asn Asp Leu Cys Phe Ser Asn Val Tyr Ala 370 375 380Asp Ser Phe Val Val Lys Gly Asp Asp Val Arg Gln Ile Ala Pro Gly385 390 395 400Gln Thr Gly Val Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe 405 410 415Met Gly Cys Val Leu Ala Trp Asn Thr Arg Asn Ile Asp Ala Thr Ser 420 425 430Thr Gly Asn Tyr Lys Tyr Arg Tyr Leu Arg His Gly Lys Leu 435 440 445Arg Pro Phe Glu Arg Asp Ile Ser Asn Val Pro Phe Ser Pro Asp Gly 450 456 460Lys Pro Cys Thr Pro Pro Ala Leu Asn Cys Tyr Pro Leu Asn Asp465 470 475 480Tyr Gly Phe Tyr Thr Thr Thr Gly Ile Gly Tyr Gln Pro Tyr Arg Val 485 490 495Val Val Leu Ser Phe Glu Leu Leu Asn Ala Pro Ala Thr Val Cys Gly 500 505 510Pro Lys Leu Ser Thr Asp Leu Ile Lys Asn Gln Cys Val Asn Phe Asn 515 520 525Phe Asn Gly Leu Thr Gly Thr Gly Val Leu Thr Pro Ser Ser Lys Arg 530 535 540Phe Gln Pro Phe Gln Gln Phe Gly Arg Asp Val Ser Asp Val Ser Asp Val Ser Thr 595 600 605Ala Ile His Ala Asp Gln Leu Thr Pro Ala Try Arg Ile Thr Pro Gly Thr Asn Ala Ser Ser 580 585 590Glu Val Ala Val Leu Tyr Gln Asp Val Asn Tyr Ser Thr 610 615 620Gly Asn Asn Val Phe Gln Thr Gln Ala Gly Cys Leu Ile Gly Ala Glu625 630 635 640His Val Ser Thr 595 600 605Ala Ile His Ala Asp Gln Leu Thr Pro Ala Try Arg Ile Tyr Ser Thr 610 615 620Gly Asn Asn Val Phe Gln Thr Gln Ala Gly Cys Leu Ile Gly Ala Glu625 630 635 640His Val Asp Thr Ser Ile 640 655Cys Ala Ser Tyr His Thr Val Ser Chr Glu Arg Gln Her Or Val Ser Mer Glu Asp Ser Ser Ile Ser Ile 690 695 700Thr Thr Glu Val Met Pro Val Ser Met Ala Lys Thr Ser Val Asp Cys705 710 715 720Asn Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Asp Ser Thr Glu Cys Ala Met Tyr Glu Ser Phe Cys Thr Glu Val Met Pro Val Ser Met Ala Lys Thr Ser Val Asp Cys705 710 715 720Asn Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Ala Met Tyr Glu Ser Phe Cys

760 765Gln Met Tyr Lys Thr Pro Thr Leu Lys Tyr Phe Gly Gly Phe Asn Phe 770 775 780Ser Gln Ile Leu Pro Asp Pro Leu Lys Pro Thr Lys Arg Ser Phe Ile785 790 795 800Glu Asp Leu Leu Phe Asn Lys Val Thr Leu Ala Asp Ala Gly Phe Met 805 810 815Lys Gln Tyr Gly Glu Cys Leu Gly Asp Ile Asn Ala Arg Asp Leu Ile 820 825 830Cys Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro Leu Leu Thr 835 840 845 Asp Asp Met Ile Ala Ala Tyr Thr Ala Ala Leu Val Ser Gly Thr Ala 850 855 860 Thr Ala Gly Trp Thr Phe Gly Ala Gly Ala Ala Leu Gln Ile Pro Phe865 870 875 880Ala Met Gln Met Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr Gln Asn 885 890 895Val Leu Tyr Glu Asn Gln Lys Gln Ile Ala Asn Gln Phe Asn Lys Ala 900 905 910Ile Ser Gln Ile Gln Glu Ser Leu Thr Thr Ser Thr Ala Leu Gly 915 920 925 Lys Leu Gln Asp Val Val Asn Gln Asn Ala Gln Asn Ala Gln Asn Thr Leu 930 935 940 Val Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile Ser Ser Val Leu Asn945 950 955 960Asp Ile Leu Ser Arg Leu Asp Lys Val Glu Ala Glu Val Gln Ile Asp 965 970 975Arg Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val Thr Gln 980 985 990Gln Leu Ile Arg Ala Ala Glu Ile Arg Ala Ser Ala Asn Leu Ala Ala 995 1000 1005Thr Lys Met Ser Glu Cys Val Leu Gly Gln Ser Lys Arg Val Asp 1010 1015 1020Phe Cys Gly Lys Gly Tyr His Leu Met Ser Phe Pro Gin Ala Ala 1025 1030 1035Pro His Gly Val Val Phe Leu His Val Thr Tyr Val Pro Ser Gin 1040 1045 1050Glu Arg Asn Phe Thr Tha Pro Ala Ile Cys His Glu Gly Lys 1055 1060 1065Ala Tyr Phe Pro Arg Glu Gly Val Val Phe Asn Gly Thr Ser 1070 1075 1080Trp Phe Ile Thr Gln Arg Asn Phe Phe Ser Pro Gln Ile Ile Thr 1085 1090 1095Thr Asp Asn Thr Phe Val Ser Gly Asn Cys Asp Val Val Ile Gly 1100 1105 1110Ile Ile Asn Asn Thr Val Tyr Asp Pro Leu Gln Pro Glu Leu Asp 1115 1120 1125Ser Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn His Thr Ser 1130 1135 1140Pro Asp Val Asp Leu Gly Asp Ile Ser Gly Ile Asn Ala Ser Val 1145 1150 1155 Val Asn Ile Gln Lys Glu Ile Asp Arg Leu Asn Glu Val Ala Lys 1160 1165 1170 Asn Leu Asn Glu Ser Leu Ile Asp Leu Gln Glu Leu Gly Lys Tyr 1175 1180 1185Glu Gln Tyr Ile Lys Trp Pro Trp Tyr Val Trp Leu Gly Phe Ile 1190 1195 1200Ala Gly Leu Ile Ala Ile Val Met Val Thr Ile Leu Leu Cys Cys 1205 1210 1215Met Thr Ser Cys Cys Ser Cys Leu Lys Gly Ala Cys Ser Cys Gly 1220 1225 1230Ser Cys Cys Lys Phe Asp Glu Asp Asp Ser Glu Pro Val Leu Lys 1235 1240 1245Gly Val Lys Leu His Tyr Thr 1250 12555274PRTCoronavirus 5Met Asp Leu Phe Met Arg Phe Phe Thr Leu Gly Ser Ile Thr Ala Gln 1 5 10 15Pro Val Lys Ile Asp Asn Ala Ser Pro Ala Ser Thr Val His Ala Thr 20 25 30Ala Thr Ile Pro Leu Gln Ala Ser Leu Pro Phe Gly Trp Leu Val Ile 35 40 45Gly Val Ala Phe Leu Ala Val Phe Gln Ser Ala Thr Lys Ile Ile Ala 50 55 60Leu Asn Lys Arg Trp Gln Leu Ala Leu Tyr Lys Gly Phe Gln Phe Ile65 70 75 80Cys Asn Leu Leu Leu Leu Phe Val Thr Ile Tyr Ser His Leu Leu 85 90 95Val Ala Ala Gly Met Glu Ala Gln Phe Leu Tyr Leu Tyr Ala Leu Ile 100 105 110Tyr Phe Leu Gln Cys Ile Asn Ala Cys Arg Ile Ile Met Arg Cys Trp 115 120 125Leu Cys Trp Lys Cys Lys Ser Lys Asn Pro Leu Leu Tyr Asp Ala Asn 130 135 140Tyr Phe Val Cys Trp His Thr His Asn Tyr Asp Tyr Cys Ile Pro Tyr 145 150 155 160Asn Ser Val Thr Asp Thr Ile Val Val Thr Glu Gly Asp Gly Ile Ser 165 170 175Thr Pro Lys Leu Lys Glu Asp Tyr Gln Ile Gly Gly Tyr Ser Glu Asp 180 185 190Arg His Ser Gly Val Lys Asp Tyr Val Val Val His Gly Tyr Phe Thr 195 200 205Glu Val Tyr Tyr Gln Leu Glu Ser Thr Gln Ile Thr Thr Asp Thr Gly 210 215 220Ile Glu Asn Ala Thr Phe Phe Ile Phe Asn Lys Leu Val Lys Asp Pro225 230 235 240Pro Asn Val Gln Ile His Thr Ile Asp Gly Ser Ser Gly Val Ala Asn 245 250 255Pro Ala Met Asp Pro Ile Tyr Asp Glu Pro Thr Thr Thr Ser Val 260 265 270Pro Leu6154PRTCoronavirus 6Met Met Pro Thr Thr Leu Phe Ala Gly Thr His Ile Thr Met Thr Thr1 5 10 15Val Tyr His Ile Thr Val Ser Gin Ile Gin Leu Ser Leu Leu Lys Val 20 25 30Thr Ala Phe Gin His Gin Asn Ser Lys Lys Thr Thr Lys Leu Val Val 35 40 45Ile Leu Arg Ile Gly Thr Gin Val Leu Lys Thr Met Ser Leu Tyr Met 50 55 60Ala lle Ser Pro Lys Phe Thr Thr Ser Leu Ser Leu His Lys Leu Leu65 70 75 80Gln Thr Leu Val Leu Lys Met Leu His Ser Ser Ser Leu Thr Ser Leu 85 90 95Leu Lys Thr His Arg Met Cys Lys Tyr Thr Gln Ser Thr Ala Leu Gln 100 105 110Glu Leu Leu Ile Gln Gln Trp Ile Gln Phe Met Met Ser Arg Arg Arg 115 120 125Leu Leu Ala Cys Lys His Lys Lys Val Ser Thr Asn Leu Cys 130 135 140Thr His Ser Phe Arg Lys Lys Gln Val Arg145 150776PRTCoronavirus 7Met Tyr Ser Phe Val Ser Glu Glu Thr Gly Thr Leu Ile Val Asn Ser I 5 10 15Val Leu Leu Ala Phe Val Val Phe Leu Leu Val Thr Leu Ala 20 25 30Ile Leu Thr Ala Leu Arg Leu Cys Ala Tyr Cys Cys Asn Ile Val Asn 35 40 45 Val Ser Leu Val Lys Pro Thr Val Tyr Val Tyr Ser Arg Val Lys Asn 50 55 60Leu Asn Ser Ser Glu Gly Val Pro Asp Leu Leu Val65 70 758221PRTCoronavirus 8Met Ala Asp Asn Gly Thr Ile Thr Val Glu Glu Leu Lys Gln Leu Leu 1 5 10 15Glu Gln Trp Asn Leu Val Ile Gly Phe Leu Phe Leu Ala Trp Ile Met 20 25 30Leu Leu Gln Phe Ala Tyr Ser Asn Arg Asn Arg Phe Leu Tyr Ile Ile 35 40 45Lys Leu Val Phe Leu Trp Leu Leu Trp Pro Val Thr Leu Ala Cys Phe 50 55 60Val Leu Ala Ala Val Tyr Arg Ile Asn Trp Val Thr Gly Gly Ile Ala65 70 75 80Ile Ala Met Ala Cys Ile Val Gly Leu Met Trp Leu Ser Tyr Phe Val 85 90 95Ala Ser Phe Arg Leu Phe Ala Arg Thr Arg Ser Met Trp Ser Phe Asn 100 105 110Pro Glu Thr Asn Ile Leu Leu Asn Val Pro Leu Arg Gly Thr Ile Val 115 120 125Thr Arg Pro Leu Met Glu Ser Glu Leu Val Ile Gly Ala Val Ile Ile 130 135 140 Arg Gly His Leu Arg Met Ala Gly His Pro Leu Gly Arg Cys Asp Ile 145 150 155 160 Lys Asp Leu Pro Lys Glu Ile Thr Val Ala Thr Ser Arg Thr Leu Ser 165 170 175Tyr Tyr Lys Leu Gly Ala Ser Gln Arg Val Gly Thr Asp Ser Gly Phe 180 185 190Ala Ala Tyr Asn Arg Tyr Arg Ile Gly Asn Tyr Lys Leu Asn Thr Asp 195 200 205His Ala Gly Ser Asn Asp Asn Ile Ala Leu Leu Val Gln 210 215 220963PRTCoronavirus 9Met Phe His Leu Val Asp Phe Gln Val Thr Ile Ala Glu Ile Leu Ilel 5 10 151le Ile Met Arg Thr Phe Arg Ile Ala Ile Trp Asn Leu Asp Val Ile 20 25 30Ile Ser Ser Ile Val Arg Gin Leu Phe Lys Pro Leu Thr Lys Lys Asn 35 40 45 Tyr Ser Glu Leu Asp Asp Glu Glu Pro Met Glu Leu Asp Tyr Pro 50 55 6010122PRTCoronavirus 10Met Lys Ile Ile Leu Phe Leu Thr Leu Ile Val Phe Thr Ser Cys Glu 1 5 10 15Leu Tyr His Tyr Gln Glu Cys Val Arg Gly Thr Thr Val Leu Lys 20 25 30Glu Pro Cys Pro Ser Gly Thr Tyr Glu Gly Asn Ser Pro Phe His Pro 35 40 45Leu Ala Asp Asn Lys Phe Ala Leu Thr Cys Thr Ser Thr His Phe Ala 50 55 60Phe Ala Cys Ala Asp Gly Thr Arg His Thr Tyr Gln Leu Arg Ala Arg65 70 75 80Ser Val Ser Pro Lys Leu Phe Ile Arg Gln Glu Glu Glu Gln Gln Gln Glu 85 90 95Leu Tyr Ser Pro Leu Phe Leu Ile Val Ala Ala Leu Val Phe Leu Ile 100 105 110Leu Cys Phe Thr Ile Lys Arg Lys Thr Glu 115 1201184PRTCoronavirus 11Met Cys Leu Lys Ile Leu Val Arg Tyr Asn Thr Arg Gly Asn Thr Tyr 1 5 10 15Ser Thr Ala Trp Leu Cys Ala Leu Gly Lys Val Leu Pro Phe His Arg 20 25 30Trp His Thr Met Val Gln Thr Cys Thr Pro Asn Val Thr Ile Asn Cys 35 40 45Gln Asp Pro Ala Gly Gly Ala Leu Ile Ala Arg Cys Trp Tyr Leu His 50 55 60Glu Gly His Gln Thr Ala Ala Phe Arg Asp Val Leu Val Val Leu Asn65 70 75 80Lys Arg Thr Asn12422PRTCoronavirus 12Met Ser Asp Asn Gly Pro Gln Ser Asn Gin Arg Ser Ala Pro Arg Ile1 5 10 13 Thr Phe Gly Gly Pro Thr Asp Ser Thr Asp Asn Asn Gli Asn Gly Gly 20 25 30 Arg Asn Gly Ala Arg Pro Lys Gln Arg Arg Pro Gln Gly Lue Pro Asn 35 40 45Asn Thr Ala Ser Trp Phe Thr Ala Leu Thr Gln His Gly Lys Glu Glu 50 55 60 Leu Arg Phe Pro Arg Gly Gln Gly Val Pro Ile Asn Thr Asn Ser Gly65 70 75 80 Pro Asp Asp Gln Ile Gly Tyr Tyr Arg Arg Ala Thr Arg Arg Val Arg 85 90 95Gly Gly Asp Gly Lys Met Lys Glu Leu Ser Pro Arg Trp Tyr Phe Tyr 100 105 110Tyr Leu Gly Thr Gly Pro Glu Ala Ser Leu Pro Tyr Gly Ala Asn Lys 115 120 125Glu Gly Ile Val Trp Val Ala Thr Glu Gly Ala Leu Asn Thr Pro Lys 130 135 140Asp His Ile Gly Thr Arg Asn Pro Asn Asn Asn Ala Ala Thr Val Leu 145 150 155 160Gln Leu Pro Gln Gly Thr Thr Leu Pro Lys Gly Phe Ara me Giu Giy Ma Edwine Edwin Thr Lys Lys Ser Ala Ala Glu Ala Ser 245 250 255Lys Lys Pro Arg Gln Lys Arg Thr Ala Thr Lys Gln Tyr Asn Val Thr 260 265 270Gln Ala Phe Gly Arg Arg Gly Pro Glu Gln Thr Gln Gly Asn Phe Gly 275 280 285Asp Gln Asp Leu Ile Arg Gln Gly Thr Asp Tyr Lys His Trp Pro Gln 290 295 300Ile Ala Gln Phe Ala Pro Ser Ala Ser Ala Phe Gly Met Ser Arg305 310 315 320Ile Gly Met Glu Val Thr Pro Ser Gly Thr Trp Leu Thr Tyr His Gly 325 330 335 Ala Ile Lys Leu Asp Asp Lys Asp Pro Gln Phe Lys Asp Asn Val Ile 340 345 350 Leu Leu Asn Lys His Ile Asp Ala Tyr Lys Thr Phe Pro Pro Thr Glu 355 360 365Pro Lys Lys Asp Lys Lys Lys Thr Asp Glu Ala Gln Pro Leu Pro 370 375 380Gln Arg Gln Lys Lys Gln Pro Thr Val Thr Leu Leu Pro Ala Ala Asp385 390 395 400Met Asp Asp Phe Ser Arg Gln Leu Gln Asn Ser Met Ser Gly Ala Ser 405 410 415Ala Asp Ser Thr Gln Ala 4201321DNAArtificial SequenceSynthetic oligonucleotide. 13ctaacatgct taggataatg g 211421DNAArtificial SequenceSynthetic oligonucleotide. 14gcctctcttg ttcttgctcg c 211521DNAArtificial SequenceSynthetic oligonucleotide. 15caggtaagcg taaaactcat c 211622DNAArtificial SequenceSynthetic oligonucleotide. 16catgtgtggc ggctcactat at 221728DNAArtificial SequenceSynthetic oligonucleotide. 17gacactatta gcataagcag ttgtagca

281827DNAArtificial SequenceSynthetic oligonucleotide. 18ttaaaccagg tggaacatca tccggtg 271922DNAArtificial SequenceSynthetic oligonucleotide. 19ggagccttga atacacccaa ag 222017DNAArtificial SequenceSynthetic oligonucleotide. 20gcacggtggc agcattg 172121DNAArtificial SequenceSynthetic oligonucleotide. 21ccacattggc acccgcaatt c 212219DNAArtificial SequenceSynthetic oligonucleotide. 22caaacattgg ccgcaaatt 192321DNAArtificial SequenceSynthetic oligonucleotide. 21cacattggc acccgcaatt c 212219DNAArtificial SequenceSynthetic oligonucleotide. 22caaacattgg ccgcaaatt 192321DNAArtificial SequenceSynthetic oligonucleotide. 23caatgegtga g 212618DNAArtificial SequenceSynthetic oligonucleotide. 25gaagtaccat ctggggetga g 212618DNAArtificial SequenceSynthetic oligonucleotide. 26ccgaagagct acccgacg 182726DNAArtificial SequenceSynthetic oligonucleotide. 27cttttcatt ttgccgtcac acccac 262824DNAArtificial SequenceSynthetic oligonucleotide. 28agetctccct agcattattc actg 242920DNAArtificial SequenceSynthetic oligonucleotide. 29caccacattt tcatcgaggc 203022DNAArtificial SequenceSynthetic oligonucleotide. 30tacctcgat cgtactccg gt 223123DNAArtificial SequenceSynthetic oligonucleotide. 31gtaggcat gattcaggtt ttg 233223DNAArtificial SequenceSynthetic oligonucleotide. 34segttgga tacccaagt gtga 243521DNAArtificial SequenceSynthetic oligonucleotide. 35tacacacaca acccacat a 213619DNAArtificial SequenceSynthetic oligonucleotide. 36gagttggac tacctaagt gtga 243521DNAArtificial SequenceSynthetic oligonucleotide. 37gagcggctg 103720DNAArtificial SequenceSynthetic oligonucleotide. 36gagttggac taccagt gtga 203022DNAArtificial SequenceSynthetic oligonucleotide. 37gagcggctg 193720DNAArtificial SequenceSynthetic oligonucleotide. 36gagttggac taccagt 203823DNAArtificial SequenceSynthetic oligonucleotide. 36gagttggac taccagg 20322DNAArtificial SequenceSynthetic oligonucleotide. 36gagttggac taccagg 20322DNAArtificial SequenceSynthetic oligonucleotide. 36gagttggac taccagg 20322DNAArtificial SequenceSynthetic oligonucleotide. 37gagcggggac taccaggt 203322DNAArtifici

* * * * *